



**The University of Toledo  
Research & Sponsored Programs  
Awards Detail, Fiscal Year 07  
07/01/2006 to 06/30/2007 \*\*\***

Proposal #	Public Title	Agency Name(s) Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Arts and Sciences, College of</b>						
<b>Biological Sciences, Department of</b>						
C-110212-02	Neurosteroid Modulation of GABA(A) Receptors	National Institute of Neurological Disorders and Stroke	09/01/2006 to 11/30/2008	36,844	16,212	\$53,056
		Bruce A Bamber Principal Investigator BIOL NA				
T-110212-05	Neurosteroid Modulation of GABA(A) Receptors	National Institute of Neurological Disorders and Stroke	09/01/2006 to 08/31/2007	59,028	25,972	\$85,000
		Bruce A Bamber Principal Investigator BIOL NA				
N-110133-01	Role of Mixed Lineage Kinase 3 in Neurofibromatosis Type 2	American Cancer Society - National	01/01/2007 to 12/31/2007	27,273	2,727	\$30,000
		Deborah N Chadee Principal Investigator BIOL NA				
C-109995-03	Role of the Serine-threonine Kinase PAK1 in Prolactin-dependent Signaling	National Institute of Diabetes, Digestive & Kidney Diseases	08/15/2006 to 05/31/2007	121,375	53,405	\$174,780
		Maria Diakonova Principal Investigator BIOL 30% AY				
T-109995-02	Role of the Serine-threonine Kinase PAK1 in Prolactin-dependent Signaling	National Institute of Diabetes, Digestive & Kidney Diseases	08/15/2006 to 05/31/2007	150,000	66,000	\$216,000
		Maria Diakonova Principal Investigator BIOL NA				
T-110198-03	Role of Adapter Proteins in Infection Diseases	National Institute of Allergy & Infectious Diseases	06/01/2004 to 05/31/2008	33,988	14,955	\$48,943
		Maria Diakonova Principal Investigator BIOL 33%				
C-107968-06	Negative Regulation of Signal Transduction by G-CSF	National Cancer Institute	09/01/2002 to 06/30/2007	139,151	58,443	\$197,594
		Fan Dong Principal Investigator BIOL NA				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
N-110257-01	Gfi-1 in the Regulation of p21Cip	Ohio Cancer Research Associates	07/01/2007 to 06/30/2009	22,727	2,273	\$25,000
		Fan Dong Principal Investigator BIOL 10% AY				
C-109729-02	NWO TEAMS	Ohio Department of Education	07/01/2006 to 06/30/2007	433,185	34,655	\$467,840
		Emilio Duran Principal Investigator BIOL NA				
N-109651-01	NWO Teach Ohio	Ohio Department of Education through Bowling Green State University	03/01/2006 to 06/30/2007	3,720	279	\$3,999
		Emilio Duran Principal Investigator BIOL NA				
N-110035-01	2007 Ohio Junior Sciences and Humanities Symposium	Army Research Office through Academy of Applied Science	10/02/2006 to 09/01/2007	20,000	0	\$20,000
		Emilio Duran Principal Investigator BIOL NA				
C-109000-03	Biomonitoring of Nutritional and Environmental Stress in Plants	U.S. Department of Agriculture	05/19/2004 to 03/14/2009	114,539	11,454	\$125,993
		John Gray Principal Investigator BIOL NA				
C-109000-04	Biomonitoring of Nutritional and Environmental Stress in Plants	U.S. Department of Agriculture	05/19/2004 to 03/14/2009	145,814	14,581	\$160,395
		John Gray Principal Investigator BIOL 20% AY				
C-106102-08	Regulation of Pharyngeal Pumping in Parasitic Nematodes	National Institute of Allergy & Infectious Diseases	01/15/2000 to 01/31/2008	156,240	68,746	\$224,986
		Richard Komuniecki Principal Investigator BIOL NA				
S-106102-08-S1	Regulation of Pharyngeal Pumping in Parasitic Nematodes	National Institute of Allergy & Infectious Diseases	01/15/2000 to 01/31/2008	33,396	14,694	\$48,090
		Richard Komuniecki Principal Investigator BIOL NA				
N-109224-01	Impact of the Interferon Regulated Proteins XAF1 and ZNF313 on Innate Immunity	National Institute of Allergy & Infectious Diseases	04/01/2006 to 03/31/2007	150,000	66,000	\$216,000
		Douglas Leaman Principal Investigator BIOL NA				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award			
				Direct Cost	F&A Cost**	Total Cost	
<b>Biological Sciences, Department of</b>							
N-110092-01	The Role of T Cell Repertoire Selection in the NOD mouse model of MOG-Induced EAE	National Institute of Allergy & Infectious Diseases	06/01/2007 to 05/31/2008	75,000	33,000	\$108,000	
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)					
		Anthony Quinn	Principal Investigator	BIOL	25%		
<b>Totals for Biological Sciences, Department of</b>			<b>17</b>	<b>1,722,280</b>	<b>483,396</b>	<b>\$2,205,676</b>	
<b>Chemistry, Department of</b>							
C-108692-03	Development of New Carbohydrate Synthesis Methodologies	National Institute of General Medical Sciences	03/01/2005 to 02/29/2008	157,388	64,851	\$222,239	
		Xuefei Huang			Principal Investigator	CHEM	NA
C-109471-02	CAREER: Synthetic Studies of Hyaluronan Oligosaccharides as Biological Probes	National Science Foundation	06/01/2006 to 05/31/2011	103,473	45,527	\$149,000	
		Xuefei Huang			Principal Investigator	CHEM	NA
S-108692-03-S1	Development of New Carbohydrate Synthesis Methodologies	National Institute of General Medical Sciences	03/01/2005 to 02/29/2008	23,424	10,307	\$33,731	
		Xuefei Huang			Principal Investigator	CHEM	NA
N-109904-01-A1	Novel Sensors for Chemical and Bio-Defense	Department of Defense	12/12/2006 to 08/11/2008	730,139	239,861	\$970,000	
		Jon R. Kirchhoff			Principal Investigator	CHEM	NA
N-110245-01	NIST-Summer Undergraduate Research Fellowship Program for Rebecca Teague	National Institute of Standards and Technology	05/01/2007 to 09/30/2007	7,420	0	\$7,420	
		Cora Lind			Principal Investigator	CHEM	NA
C-108426-04	CAREER: Structural Analysis of Branched DNA Recognition	National Science Foundation	03/01/2004 to 02/28/2009	95,070	39,930	\$135,000	
		Timothy Mueser			Principal Investigator	CHEM	11%
C-108072-04	Energetic Materials - An Advanced Crystallographic Study	Office of Naval Research	11/28/2001 to 10/31/2006	11,276	4,961	\$16,237	
		A. Alan Pinkerton			Principal Investigator	CHEM	NA

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Chemistry, Department of</b>						
N-110083-01	Intermolecular Interactions in Energetic Materials	Office of Naval Research	11/26/2006 to 12/31/2007	104,775	46,101	\$150,876
		A. Alan Pinkerton	Principal Investigator	CHEM	NA	
N-109938-01	An Orthogonal Ligation Strategy for the Synthesis of Multi-Epitope Tumor-Associated MUC1 Glycopeptides	Elsa U. Pardee Foundation	01/01/2007 to 12/31/2008	107,537	26,884	\$134,421
		Steven Joseph Sucheck	Principal Investigator	CHEM	NA	
C-108867-03	Probing the Enzymatic Basis of Canavan Disease	National Institute of Neurological Disorders and Stroke	02/15/2005 to 01/31/2008	126,456	55,641	\$182,097
		Ronald Viola	Principal Investigator	CHEM	NA	
S-108867-03-S1	Probing the Enzymatic Basis of Canavan Disease	National Institute of Neurological Disorders and Stroke	02/15/2005 to 01/31/2008	27,031	11,893	\$38,924
		Ronald Viola	Principal Investigator	CHEM	NA	
<b>Totals for Chemistry, Department of</b>			<b>11</b>	<b>1,493,989</b>	<b>545,956</b>	<b>\$2,039,945</b>
<b>English, Department of</b>						
N-110153-01	OhioWINS	Ohio Board of Regents	07/01/2006 to 06/30/2007	46,000	0	\$46,000
		Barbara J. Schneider	Principal Investigator	ENGL	NA	
<b>Totals for English, Department of</b>			<b>1</b>	<b>46,000</b>	<b>0</b>	<b>\$46,000</b>
<b>Environmental Sciences, Department of</b>						
N-109845-01	Evaluating the Economic Costs and Benefits of Slowing the Spread of the Emerald Ash Borer in Ohio and Michigan	U.S. Department of Agriculture	09/13/2006 to 12/31/2008	192,230	57,770	\$250,000
		Jonathan Bossenbroek	Principal Investigator	ENVS	NA	
N-109260-01-A1	Temporal Resolution of the Maumee River Plume	National Oceanic and Atmospheric Administration through University of Michigan	07/01/2005 to 06/30/2008	6,951	3,058	\$10,009
		Thomas B. Bridgeman	Principal Investigator	ENVS	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Environmental Sciences, Department of</b>						
C-109138-02	Effects of Land Use Change on the Energy and Water Balance of the Semi-Arid Region of Inner Mongolia	NASA Goddard Space Flight Center	11/01/2005 to 10/31/2008	152,024	52,514	\$204,538
		Jiquan Chen	Principal Investigator	ENVS	NA	
N-109632-01	Maumee Bay State Park Shoreline and Wetland Restoration Plan	Toledo Metropolitan Area Council of Governments	07/01/2006 to 09/30/2007	14,342	307	\$14,649
		Daryl Dwyer	Principal Investigator	ENVS	NA	
R-109357-03	Berger Ditch Stream Gauge	U.S. Geological Survey	05/01/2005 to 09/30/2007	7,000	0	\$7,000
		Daryl Dwyer	Principal Investigator	ENVS	0%	
N-109467-01	Collaborative Research: Deglaciation Chronology of the Des Moines Lobe-Implications for Ice Sheet Dynamics and Climate Change	National Science Foundation	08/01/2006 to 07/31/2007	20,826	9,163	\$29,989
		Timothy G. Fisher	Principal Investigator	ENVS	NA	
N-110284-01	Thunder Bay Boulder Sampling	Comer Science & Education Foundation	03/09/2007 to 06/30/2007	22,000	0	\$22,000
		Timothy G. Fisher	Principal Investigator	ENVS	NA	
N-110287-01	Status and Distribution of Native Unionid Mussels (Unionidae) in the Coastal Wetlands of the Winous Point Marsh Conservancy	Winous Point	05/14/2007 to 12/01/2007	4,545	455	\$5,000
		Johan F. Gottgens	Principal Investigator	ENVS	NA	
N-109977-01	Geomorphic and Hydrogeomorphic Maps for Assateague Island National Seashore	National Park Service	08/15/2006 to 06/30/2008	66,663	11,666	\$78,329
		David E. Krantz	Principal Investigator	ENVS	NA	
N-109633-01	Surficial Geology of the Oak Openings Region, Whitehouse Quadrangle, Lucas County, Ohio	U.S. Geological Survey	08/21/2006 to 08/20/2007	9,492	1,708	\$11,200
		James M. Martin-Hayden	Principal Investigator	ENVS	NA	
N-109889-01	Experimental and Spatial Modeling of Environmental Factors Affecting Foraging Success of Age-0 Yellow Perch	Great Lakes Fishery Commission	01/01/2007 to 12/31/2009	139,657	6,983	\$146,640
		Christine Marie Mayer	Principal Investigator	ENVS	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Environmental Sciences, Department of</b>						
N-110175-01	Yellow Perch Foraging on Hexagenia spp.: Effects of Hypoxia and Dreissena spp.	Ohio Lake Erie Commission	01/16/2007 to 06/30/2007	8,992	899	\$9,891
		Christine Marie Mayer	Principal Investigator	ENVS	NA	
N-109925-01	Effects of Coleopteran-Active B+ Corn on Multiple Trophic Levels in Soil Communities	U.S. Department of Agriculture through University of Vermont	05/16/2005 to 05/16/2006	8,481	1,989	\$10,470
		Daryl Lee Moorhead	Principal Investigator	ENVS	NA	
N-109966-01	Community Molecular Fingerprinting to Identify the Spatial Origins of Microbial Contamination in Cuyahoga County within the Rocky River Watershed II	Cuyahoga County Board of Health	07/15/2006 to 12/31/2006	6,957	1,043	\$8,000
		William Von Sigler	Principal Investigator	ENVS	NA	
<b>Totals for Environmental Sciences, Department of</b>			<b>14</b>	<b>660,160</b>	<b>147,555</b>	<b>\$807,715</b>
<b>Foreign Languages, Department of</b>						
N-119920-01	Student Teacher Assistants	Japanese School of Toledo	04/01/2007 to 03/31/2008	18,000	1,800	\$19,800
		Joseph Hara	Principal Investigator	FORL	NA	
<b>Totals for Foreign Languages, Department of</b>			<b>1</b>	<b>18,000</b>	<b>1,800</b>	<b>\$19,800</b>
<b>Geography and Planning, Department of</b>						
N-110308-01	SATELLITES: Using Geospatial Technology to Teach Science in Cleveland Municipal Schools	Ohio Space Grant Consortium	06/01/2007 to 05/31/2008	10,000	0	\$10,000
		Kevin Paul Czajkowski	Principal Investigator	GEOG	NA	
N-119883-01	Implementation of Earth System Science Education Alliance in the Great Lakes Region	National Science Foundation through Institute for Global Environmental Strategies	06/01/2007 to 05/31/2010	9,444	556	\$10,000
		Kevin Paul Czajkowski	Principal Investigator	GEOG	NA	
N-110189-01	Perrysburg Township Planning Internship	Perrysburg Township	01/08/2007 to 04/27/2007	3,799	393	\$4,192
		Daniel J Hammel	Principal Investigator	GEOG	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Geography and Planning, Department of</b>						
N-109957-01	Assessment of BUIs for Ohio Areas of Concern	Ohio Environmental Protection Agency	09/01/2006 to 04/20/2007	9,790	4,308	\$14,098
		Patrick L. Lawrence	Principal Investigator	GEOG	NA	
R-109814-02	Expanding Regional Freight Information Resources for the Upper Midwest: The Great Lakes Maritime Information Delivery System	U.S. Department of Transportation through Great Lakes Maritime Research Institute	10/01/2006 to 09/30/2007	76,389	33,611	\$110,000
		Peter S. Lindquist	Principal Investigator	GEOG	NA	
C-108831-03	Greenhouse Nurseries	U.S. Department of Agriculture through Ohio State University Research Foundation	10/01/2006 to 09/14/2008	342,269	85,567	\$427,836
		Neil Reid	Principal Investigator	URB	NA	
<b>Totals for Geography and Planning, Department of Instrumentation Center</b>			<b>6</b>	<b>451,691</b>	<b>124,435</b>	<b>\$576,126</b>
<b>Instrumentation Center</b>						
N-108904-03	Solvent Structure and Function in Macromolecules	National Science Foundation	03/15/2005 to 02/29/2008	155,637	68,480	\$224,117
		Bryant L. Hanson	Principal Investigator	INSC	NA	
<b>Totals for Instrumentation Center</b>			<b>1</b>	<b>155,637</b>	<b>68,480</b>	<b>\$224,117</b>
<b>Lake Erie Soil and Water Research and Education Center</b>						
N-109516-01	Walleye and Yellow Perch Stock Structure in the Great Lakes: A High-resolution DNA Data Base for Fishery Management	National Oceanic and Atmospheric Administration through Ohio State University Research Foundation	09/01/2004 to 07/31/2007	48,006	11,969	\$59,975
		Carol Stepien	Principal Investigator	LERC	NA	
N-109789-01	Planning Proposal for the Lake Erie Center	National Science Foundation	10/01/2006 to 09/30/2008	18,750	6,138	\$24,888
		Carol Stepien	Principal Investigator	LERC	NA	
N-110243-01	Planning Proposal for the Lake Erie Center	National Science Foundation	06/01/2007 to 05/01/2008	8,500	1,500	\$10,000
		Carol Stepien	Principal Investigator	LERC	2%	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Lake Erie Soil and Water Research and Education Center</b>						
N-110309-01	Molecular Systematics, Biogeography and Invasion Identity of Neogobiin Fishes	National Science Foundation	06/01/2007 to 04/30/2008	5,086	914	\$6,000
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				
		Carol Stepien	Principal Investigator	LERC	NA	
<b>Totals for Lake Erie Soil and Water Research and Education Center</b>			<b>4</b>	<b>80,342</b>	<b>20,521</b>	<b>\$100,863</b>
<b>Mathematics, Department of</b>						
N-109573-01	Cohomology and Representation Theory	National Science Foundation	10/01/2006 to 11/09/2007	21,581	9,496	\$31,077
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				
		David Hemmer	Principal Investigator	MATH	NA	
<b>Totals for Mathematics, Department of</b>			<b>1</b>	<b>21,581</b>	<b>9,496</b>	<b>\$31,077</b>
<b>Physics and Astronomy, Department of</b>						
N-109624-01	Simulating Extended Time and Length Scales Using Parallel Accelerated Dynamics	National Science Foundation	08/15/2006 to 07/31/2007	75,695	33,305	\$109,000
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				
		Jacques G. Amar	Principal Investigator	PHYS	NA	
N-109865-01	Be Stars and Circumstellar Disks in NGC 346	Space Telescope Science Institute	09/01/2006 to 08/31/2008	32,915	14,482	\$47,397
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				
		Karen B. Bjorkman	Principal Investigator	PHYS	NA	
A-109975-01	Wright Center for Photovoltaic Innovation and Commercialization (PVIC)	Ohio Department of Development	02/26/2007 to 02/25/2010	11,042,000	0	\$11,042,000
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				
		Robert W. Collins	Principal Investigator	PHYS	NA	
		Alvin D. Compaan	Co-Investigator	PHYS	NA	
		Xunming Deng	Co-Investigator	PHYS	NA	
		Dean M. Giolando	Co-Investigator	CHEM	NA	
		Roger J. King	Co-Investigator	EECS	NA	
		Thomas A. Stuart	Co-Investigator	EECS	NA	
		Jacques G. Amar	Co-Investigator	PHYS	NA	
		Rosa A. Lukaszew	Co-Investigator	PHYS	NA	
		Sanjay Khare	Co-Investigator	PHYS	NA	
		Sylvain Marsillac	Co-Investigator	PHYS	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Physics and Astronomy, Department of</b>						
N-109613-01	Monolithic Silicon Microbolometer Materials for Uncooled Infrared Detectors	U.S. Department of the Army through Pennsylvania State University	05/01/2006 to 10/31/2006	14,741	33,504	\$48,245
		Robert W. Collins	Principal Investigator	PHYS	NA	
N-109975-01	Wright Center for Photovoltaic Innovation and Commercialization (PVIC)	Ohio Department of Development	02/26/2007 to 02/25/2010	6,902,944	690,294	\$7,593,238
		Robert W. Collins	Principal Investigator	PHYS	10%	
		Alvin D. Compaan	Co-Investigator	PHYS	10%	
		Xunming Deng	Co-Investigator	PHYS	10%	
		Dean M. Giolando	Co-Investigator	CHEM	10%	
		Roger J. King	Co-Investigator	EECS	10%	
		Thomas A. Stuart	Co-Investigator	EECS	10%	
		Jacques G. Amar	Co-Investigator	PHYS	10%	
		Rosa A. Lukaszew	Co-Investigator	PHYS	10%	
		Sanjay Khare	Co-Investigator	PHYS	10%	
		Sylvain Marsillac	Co-Investigator	PHYS	10%	
S-109613-02-S1	Monolithic Silicon Microbolometer Materials for Uncooled Infrared Detectors	U.S. Department of the Army through Pennsylvania State University	05/01/2006 to 10/31/2006	69,582	30,615	\$100,197
		Robert W. Collins	Principal Investigator	PHYS	NA	
C-107834-02-I	Flexible and Lightweight Thin-Film Solar Cells Based on a Si and CdTe	Air Force Research Lab-Kirtland	11/20/2002 to 09/17/2007	84,699	37,268	\$121,967
		Alvin D. Compaan	Principal Investigator	PHYS	NA	
C-107834-04	Flexible and Lightweight Thin-Film Solar Cells Based on a Si and CdTe	Air Force Research Lab-Kirtland	11/20/2002 to 09/17/2007	604,861	266,139	\$871,000
		Alvin D. Compaan	Principal Investigator	PHYS	NA	
C-108224-03-S1	Sputtered II-VI Alloys and Structures for Tandem PV	National Renewable Energy Laboratory	12/09/2003 to 02/09/2007	78,240	34,426	\$112,666
		Alvin D. Compaan	Principal Investigator	PHYS	NA	
C-108901-02-I01	Fabrication and Physics of CdTe Devices by Sputtering	National Renewable Energy Laboratory	03/01/2005 to 03/31/2007	96,542	42,478	\$139,020
		Alvin D. Compaan	Principal Investigator	PHYS	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																																					
				Direct Cost	F&A Cost**	Total Cost																																			
<b>Physics and Astronomy, Department of</b>																																									
C-108901-02-I02	Fabrication and Physics of CdTe Devices by Sputtering	National Renewable Energy Laboratory	03/01/2005 to 05/31/2008	41,667	18,333	\$60,000																																			
		<table border="1"> <tr> <td>Alvin D. Compaan</td> <td>Principal Investigator</td> <td>PHYS</td> <td>8%</td> </tr> <tr> <td>Victor G. Karpov</td> <td>Co-Investigator</td> <td>PHYS</td> <td>8%</td> </tr> <tr> <td>Robert W. Collins</td> <td>Co-Investigator</td> <td>PHYS</td> <td>8%</td> </tr> <tr> <td>Dean M. Giolando</td> <td>Co-Investigator</td> <td>CHEM</td> <td>8%</td> </tr> <tr> <td>Dean M. Giolando</td> <td>Co-Investigator</td> <td>CHEM</td> <td>11%</td> </tr> <tr> <td>Robert W. Collins</td> <td>Co-Investigator</td> <td>PHYS</td> <td>11%</td> </tr> <tr> <td>Victor G. Karpov</td> <td>Co-Investigator</td> <td>PHYS</td> <td>22%</td> </tr> </table>			Alvin D. Compaan	Principal Investigator	PHYS	8%	Victor G. Karpov	Co-Investigator	PHYS	8%	Robert W. Collins	Co-Investigator	PHYS	8%	Dean M. Giolando	Co-Investigator	CHEM	8%	Dean M. Giolando	Co-Investigator	CHEM	11%	Robert W. Collins	Co-Investigator	PHYS	11%	Victor G. Karpov	Co-Investigator	PHYS	22%									
Alvin D. Compaan	Principal Investigator	PHYS	8%																																						
Victor G. Karpov	Co-Investigator	PHYS	8%																																						
Robert W. Collins	Co-Investigator	PHYS	8%																																						
Dean M. Giolando	Co-Investigator	CHEM	8%																																						
Dean M. Giolando	Co-Investigator	CHEM	11%																																						
Robert W. Collins	Co-Investigator	PHYS	11%																																						
Victor G. Karpov	Co-Investigator	PHYS	22%																																						
C-108901-03-I01	Fabrication and Physics of CdTe Devices by Sputtering	National Renewable Energy Laboratory	03/01/2005 to 05/31/2008	89,444	39,356	\$128,800																																			
		<table border="1"> <tr> <td>Alvin D. Compaan</td> <td>Principal Investigator</td> <td>PHYS</td> <td>8%</td> <td>CY</td> </tr> <tr> <td>Dean M. Giolando</td> <td>Co-Investigator</td> <td>CHEM</td> <td>8%</td> <td>AY</td> </tr> <tr> <td>Dean M. Giolando</td> <td>Co-Investigator</td> <td>CHEM</td> <td>11%</td> <td>ST</td> </tr> <tr> <td>Robert W. Collins</td> <td>Co-Investigator</td> <td>PHYS</td> <td>8%</td> <td>AY</td> </tr> <tr> <td>Robert W. Collins</td> <td>Co-Investigator</td> <td>PHYS</td> <td>11%</td> <td>ST</td> </tr> <tr> <td>Victor G. Karpov</td> <td>Co-Investigator</td> <td>PHYS</td> <td>8%</td> <td>AY</td> </tr> <tr> <td>Victor G. Karpov</td> <td>Co-Investigator</td> <td>PHYS</td> <td>22%</td> <td>ST</td> </tr> </table>			Alvin D. Compaan	Principal Investigator	PHYS	8%	CY	Dean M. Giolando	Co-Investigator	CHEM	8%	AY	Dean M. Giolando	Co-Investigator	CHEM	11%	ST	Robert W. Collins	Co-Investigator	PHYS	8%	AY	Robert W. Collins	Co-Investigator	PHYS	11%	ST	Victor G. Karpov	Co-Investigator	PHYS	8%	AY	Victor G. Karpov	Co-Investigator	PHYS	22%	ST		
Alvin D. Compaan	Principal Investigator	PHYS	8%	CY																																					
Dean M. Giolando	Co-Investigator	CHEM	8%	AY																																					
Dean M. Giolando	Co-Investigator	CHEM	11%	ST																																					
Robert W. Collins	Co-Investigator	PHYS	8%	AY																																					
Robert W. Collins	Co-Investigator	PHYS	11%	ST																																					
Victor G. Karpov	Co-Investigator	PHYS	8%	AY																																					
Victor G. Karpov	Co-Investigator	PHYS	22%	ST																																					
N-109978-01	Coatings for Fully Integrated Solar-Powered Interior Lighting Technology	Air Force Office of Scientific Research through Bowling Green State University	09/01/2006 to 08/31/2007	34,722	15,278	\$50,000																																			
		<table border="1"> <tr> <td>Alvin D. Compaan</td> <td>Principal Investigator</td> <td>PHYS</td> <td>NA</td> </tr> </table>			Alvin D. Compaan	Principal Investigator	PHYS	NA																																	
Alvin D. Compaan	Principal Investigator	PHYS	NA																																						
C-108900-02-I01	Fabrication and Characterization of Advance Triple-Junction Amorphous Silicon Based Solar Cells	National Renewable Energy Laboratory	03/07/2005 to 03/31/2007	107,066	47,109	\$154,175																																			
		<table border="1"> <tr> <td>Xunming Deng</td> <td>Principal Investigator</td> <td>PHYS</td> <td>NA</td> </tr> </table>			Xunming Deng	Principal Investigator	PHYS	NA																																	
Xunming Deng	Principal Investigator	PHYS	NA																																						
C-108900-02-I02	Fabrication and Characterization of Advance Triple-Junction Amorphous Silicon Based Solar Cells	National Renewable Energy Laboratory	03/07/2005 to 03/31/2008	45,833	20,167	\$66,000																																			
		<table border="1"> <tr> <td>Xunming Deng</td> <td>Principal Investigator</td> <td>PHYS</td> <td>25%</td> </tr> <tr> <td>Robert W. Collins</td> <td>Co-Investigator</td> <td>PHYS</td> <td>15%</td> </tr> <tr> <td>Robert W. Collins</td> <td>Co-Investigator</td> <td>PHYS</td> <td>15%</td> </tr> </table>			Xunming Deng	Principal Investigator	PHYS	25%	Robert W. Collins	Co-Investigator	PHYS	15%	Robert W. Collins	Co-Investigator	PHYS	15%																									
Xunming Deng	Principal Investigator	PHYS	25%																																						
Robert W. Collins	Co-Investigator	PHYS	15%																																						
Robert W. Collins	Co-Investigator	PHYS	15%																																						
C-108900-03-I01	Fabrication and Characterization of Advance Triple-Junction Amorphous Silicon Based Solar Cells	National Renewable Energy Laboratory	03/07/2005 to 03/31/2008	93,750	41,250	\$135,000																																			
		<table border="1"> <tr> <td>Xunming Deng</td> <td>Principal Investigator</td> <td>PHYS</td> <td>25%</td> <td>AY</td> </tr> <tr> <td>Robert W. Collins</td> <td>Co-Investigator</td> <td>PHYS</td> <td>15%</td> <td>ST</td> </tr> </table>			Xunming Deng	Principal Investigator	PHYS	25%	AY	Robert W. Collins	Co-Investigator	PHYS	15%	ST																											
Xunming Deng	Principal Investigator	PHYS	25%	AY																																					
Robert W. Collins	Co-Investigator	PHYS	15%	ST																																					

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Physics and Astronomy, Department of</b>						
C-109330-02	Oscillator Strengths for Ultraviolet Atomic and Molecular Transitions	NASA Goddard Space Flight Center	02/01/2006 to 01/31/2007	59,062	25,991	85,053
		Steven R. Federman	Principal Investigator	PHYS	NA	
N-110005-01	REU Site: Research Experiences for Undergraduates in Physics and Astronomy	National Science Foundation	04/01/2007 to 03/31/2008	72,300	10,000	82,300
		Richard E. Irving	Principal Investigator	PHYS	NA	
C-108517-03-I01	Mars Water Ice Clouds	NASA Goddard Space Flight Center	11/01/2004 to 10/31/2007	9,951	7,206	17,157
		Philip B. James	Principal Investigator	PHYS	NA	
N-119927-01	Physical Mechanisms of Set-Reset-Set Transitions in PCM	Intel Corporation	06/27/2007 to 07/31/2008	55,556	24,444	80,000
		Victor G. Karpov	Principal Investigator	PHYS	25%	
N-110118-01	Collaborative Research: Using Nanoscale Patterning to Reveal the Atomic-scale Effects which Drive Unstable Growth on GaAs (001)	National Science Foundation	06/01/2007 to 05/31/2010	41,311	18,177	59,488
		Sanjay Khare	Principal Investigator	PHYS	5% AY	
N-110285-01	AB Initio Modeling of Slippery Hexagonal Solids	Universal Technology Corporation	04/18/2007 to 03/17/2008	30,139	13,261	43,400
		Sanjay Khare	Principal Investigator	PHYS	19%	
N-109606-01	Ultrafast Laser Study and Permanent Modification of Anisotropy in Ferromagnetic Thin Films	National Science Foundation through College of William & Mary	07/01/2006 to 06/30/2007	37,575	16,533	54,108
		Rosa A. Lukaszew	Principal Investigator	PHYS	NA	
N-110157-01	Magnetic Nano-Structures	American Chemical Society	05/01/2007 to 08/31/2007	8,000	0	8,000
		Rosa A. Lukaszew	Principal Investigator	PHYS	NA	
N-119859-01	Study of CIGS Solar Cells Back Contact	Guardian Industries Corporation	05/07/2007 to 05/06/2008	26,000	11,440	37,440
		Sylvain Marsillac	Principal Investigator	PHYS	2%	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Physics and Astronomy, Department of</b>						
N-109941-01	Searching for Protostars in a Quiescent Giant Molecular Cloud	Jet Propulsion Laboratory	05/30/2006 to 05/31/2008	43,750	19,250	\$63,000
		Samuel Thomas Megeath	Principal Investigator	PHYS	NA	
N-110048-01	An IRS Survey Of Spitzer Identified Protostars In The Orion A Cloud	Jet Propulsion Laboratory	09/18/2006 to 09/30/2008	76,432	60,052	\$136,484
		Samuel Thomas Megeath	Principal Investigator	PHYS	NA	
C-108168-04-S1	The Ohio Science and Engineering Alliance	National Science Foundation through Ohio State University Research Foundation	11/01/2003 to 10/31/2007	12,000	0	\$12,000
		Constantine E. Theodosiou	Principal Investigator	PHYS	NA	
R-107964-04	The Smallest Interstellar Grains: Optical/ Near-IR Emission from Nanoparticles	National Science Foundation	08/01/2003 to 07/31/2007	66,638	29,321	\$95,959
		Adolf N. Witt	Principal Investigator	PHYS	NA	
<b>Totals for Physics and Astronomy, Department of</b>			<b>29</b>	<b>19,953,415</b>	<b>1,599,679</b>	<b>\$21,553,094</b>
<b>Political Science and Public Administration, Department of</b>						
N-110112-01	Lesotho's Difficult Options Within South Africa: Abstract	U.S. Department of Education	04/01/2007 to 03/31/2009	75,000	0	\$75,000
		Mark E. Denham	Principal Investigator	POLS	NA	
<b>Totals for Political Science and Public Administration, Department of</b>			<b>1</b>	<b>75,000</b>	<b>0</b>	<b>\$75,000</b>
<b>Psychology, Department of</b>						
N-109998-01	Clinical Training Grant: Integration of Academic Clinical Training with Public Mental Health Service	Ohio Department of Mental Health	07/01/2006 to 06/30/2007	22,048	1,102	\$23,150
		Wesley A Bullock	Principal Investigator	PSYC	NA	
N-110097-01	Community Externship	Toledo Hospital	08/21/2006 to 05/04/2007	11,209	109	\$11,318
		Jeanne B Funk	Principal Investigator	PSYC	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s) Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Psychology, Department of</b>						
C-109190-02	A Neural Correlate of Tinnitus	Tinnitus Research Consortium through University of Kansas Medical Center	07/01/2005 to 06/30/2007	39,633	0	\$39,633
		Henry E Heffner Principal Investigator PSYC NA				
C-109234-02	Developing Techniques for Studying Tinnitus in Animals	National Institute of Deafness & Other Communication Disorders	12/07/2005 to 11/30/2007	120,000	52,800	\$172,800
		Henry E Heffner Principal Investigator PSYC NA				
C-109234-02-S1	Developing Techniques for Studying Tinnitus in Animals	National Institute of Deafness & Other Communication Disorders	12/07/2005 to 11/30/2008	25,650	11,286	\$36,936
		Henry E Heffner Principal Investigator PSYC NA				
N-110188-01	Externship Agreement	University of Toledo, Health Science Campus	05/15/2006 to 05/09/2007	13,451	673	\$14,124
		Joseph David Hovey Principal Investigator PSYC NA				
N-110191-01	Externship Contract	Partners for Success & Innovation	08/21/2006 to 05/04/2007	25,220	1,261	\$26,481
		Joseph David Hovey Principal Investigator PSYC NA				
N-109993-01	Handedness Differences in Risk Perception & Risk Taking: The Role of Handedness and Interhemispheric Interaction	National Science Foundation	09/01/2006 to 08/31/2009	174,528	75,472	\$250,000
		John D. Jasper Principal Investigator PSYC NA				
<b>Totals for Psychology, Department of</b>			<b>8</b>	<b>431,739</b>	<b>142,703</b>	<b>\$574,442</b>
<b>Totals for Arts and Sciences, College of</b>			<b>94</b>	<b>25,109,834</b>	<b>3,144,021</b>	<b>\$28,253,855</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Business Administration, College of</b>						
<b>Finance and Business Economics, Department of</b>						
N-109922-01	Earnest Money	Ohio Department of Commerce	09/01/2006 to 01/31/2007	18,000	2,000	\$20,000
		Gary S. Moore	Principal Investigator	FIBE	NA	
N-109923-01	Liability Limitation	Ohio Department of Commerce	09/01/2006 to 08/30/2007	66,343	7,371	\$73,714
		Gary S. Moore	Principal Investigator	FIBE	NA	
<b>Totals for Finance and Business Economics, Department of</b>			<b>2</b>	<b>84,343</b>	<b>9,371</b>	<b>\$93,714</b>
<b>Information Operations and Technology Management</b>						
N-110203-01	Developing a Global Supply Chain Management/Transportation System Efficiency Graduate Degree Program	U.S. Department of Transportation through Michigan-Ohio University Transportation Center	11/22/2006 to 11/21/2007	6,945	3,055	\$10,000
		S. Subba Rao	Principal Investigator	IOTM	3%	
A-106886-06-S2	Strategies and Innovative Procedures for Dynamic Partnering for the Forging Supply Chain	Department of Defense through Advanced Technology Institute	02/19/2001 to 02/08/2008	31,583	13,897	\$45,480
		Mark A. Vonderembse	Principal Investigator	IOTM	NA	
<b>Totals for Information Operations and Technology Management</b>			<b>2</b>	<b>38,528</b>	<b>16,952</b>	<b>\$55,480</b>
<b>Northwest Ohio Center for Labor-Management Cooperation</b>						
C-104900-02	Toledo Labor-Management-Citizens Committee	City of Toledo	01/01/1996 to 12/31/2007	107,698	5,616	\$113,314
		Martin R. Fitts	Principal Investigator	LMC	NA	
R-108071-04	Toledo Labor-Management-Citizens Committee	City of Toledo	01/01/2003 to 12/31/2006	125,271	6,533	\$131,804
		Martin R. Fitts	Principal Investigator	LMC	NA	
<b>Totals for Northwest Ohio Center for Labor-Management Cooperation</b>			<b>2</b>	<b>232,969</b>	<b>12,149</b>	<b>\$245,118</b>
<b>Totals for Business Administration, College of</b>			<b>6</b>	<b>355,840</b>	<b>38,472</b>	<b>\$394,312</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Education, College of</b>						
<b>Administration, College of Education</b>						
R-108836-03	Camp Adventure Youth Services	University of Northern Iowa	07/01/2004 to 08/31/2007	36,000	0	\$36,000
		Thomas J. Switzer	Principal Investigator	AEDU	NA	
S-108836-02-S1	Camp Adventure Youth Services	University of Northern Iowa	07/01/2004 to 08/31/2006	6,000	0	\$6,000
		Thomas J. Switzer	Principal Investigator	AEDU	NA	
<b>Totals for Administration, College of Education</b>			<b>2</b>	<b>42,000</b>	<b>0</b>	<b>\$42,000</b>
<b>Curriculum and Instruction, Department of</b>						
C-108733-04	Literacy Education Partnership Field Faculty Network Structure	Ohio Department of Education through John Carroll University	12/16/2003 to 06/30/2007	85,129	6,810	\$91,939
		Eileen M. Carr	Principal Investigator	CURI	NA	
C-108781-03	Utoledo, Uteach, Utouch the Future (UT3)	U.S. Department of Education	10/01/2004 to 09/30/2007	1,075,697	59,823	\$1,135,520
		Charlene M. Czerniak	Principal Investigator	CURI	NA	
C-106314-08	Capacity-Building Faculty Support Grant	Ohio Department of Education	07/01/1999 to 06/30/2007	78,704	6,296	\$85,000
		Paul Hubaker	Principal Investigator	CURI	NA	
N-110122-01	K-5 Algebraic Thinking Initiative	U.S. Department of Education through Ohio Board of Regents	01/19/2007 to 05/01/2008	76,738	6,140	\$82,878
		Debra Johannning	Principal Investigator	CURI	18%	
N-110321-01	Toledo Urban Mathematics and Science Alliance (TUMSA)	Ohio Board of Regents through Ohio Board of Regents	02/01/2007 to 06/30/2008	340,019	0	\$340,019
		Carla Johnson	Principal Investigator	CURI	NA	
N-109961-01	College Tech Prep Technical Services	Ohio Department of Education	07/01/2006 to 06/30/2007	270,833	21,667	\$292,500
		James W. Piper	Principal Investigator	CURI	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Curriculum and Instruction, Department of</b>						
R-109438-02	Tech Prep Technical Services Perkins Leadership	Ohio Department of Education	07/01/2005 to 06/30/2007	90,277	7,223	\$97,500
		James W. Piper	Principal Investigator	CURI	NA	
C-107283-04	Middle School Science Curriculum Materials:Meeting Standards and Fostering Inquiry through Project-Based Inquiry Science Units	National Science Foundation through Georgia Institute of Technology	12/12/2002 to 11/30/2007	13,839	6,089	\$19,928
		Rebecca M. Schneider	Principal Investigator	CURI	NA	
N-110205-01	Middle School Science Curriculum Materials	National Science Foundation through Georgia Institute of Technology	02/01/2007 to 11/30/2007	12,364	5,440	\$17,804
		Rebecca M. Schneider	Principal Investigator	CURI	NA	
<b>Totals for Curriculum and Instruction, Department of</b>			<b>9</b>	<b>2,043,600</b>	<b>119,488</b>	<b>\$2,163,088</b>
<b>Department of Special Education Services</b>						
N-109956-01	The UT Vision Program Expansion Project	Ohio Department of Education	08/31/2006 to 09/01/2007	171,297	13,703	\$185,000
		Sakui W. G. Malakpa	Principal Investigator	SPCE	NA	
<b>Totals for Department of Special Education Services</b>			<b>1</b>	<b>171,297</b>	<b>13,703</b>	<b>\$185,000</b>
<b>Early Childhood, Physical, and Special Education</b>						
C-108336-03	Accelerating Achievement in Math & Science in Urban Schools	U.S. Department of Education	07/01/2004 to 06/30/2007	337,407	64,859	\$402,266
		Laurence J. Coleman	Principal Investigator	ECPS	NA	
C-109409-02	Securing Career Opportunities at UT	Ability Center of Greater Toledo	10/01/2005 to 09/30/2007	45,749	4,575	\$50,324
		Patricia Devlin	Principal Investigator	ECPS	NA	
N-109926-01	Student Internship	Central Catholic High School	08/21/2006 to 05/04/2007	24,956	2,496	\$27,452
		Patricia Devlin	Principal Investigator	ECPS	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Early Childhood, Physical, and Special Education</b>						
N-110172-01	OISM and UT: Continuous Improvement of Educator Preparation and Partnerships in NW Ohio	Ohio Department of Education	02/01/2007 to 09/30/2007	27,778	2,222	\$30,000
		Patricia Devlin Principal Investigator ECPS NA				
N-119912-01	Career Exploration Program	Lott Industries, Inc.	06/08/2007 to 08/10/2007	4,645	465	\$5,110
		Patricia Devlin Principal Investigator ECPS NA				
C-109727-03	Itinerant ECSE Service Delivery in Ohio	Ohio Department of Education	08/24/2004 to 06/30/2007	147,223	11,778	\$159,001
		Laurie A. Dinnebeil Principal Investigator ECPS NA				
N-110101-01	Internship in Early Childhood Special Education	Northwest Ohio Special Education Regional Resource Center (NWO SERRC)	01/08/2007 to 05/04/2007	3,413	341	\$3,754
		Laurie A. Dinnebeil Principal Investigator ECPS NA				
N-110142-01	UT-CCAMPIS Student Parents	U.S. Department of Education	10/01/2006 to 09/30/2007	124,626	2,000	\$126,626
		Laurie A. Dinnebeil Principal Investigator ECPS NA				
N-119938-01	Infant/Toddler Teacher Training in Lucas County	Stranahan Foundation	03/01/2007 to 02/28/2008	41,667	3,333	\$45,000
		Laurie A. Dinnebeil Principal Investigator ECPS 5% CY				
C-109060-03	Print Referencing Efficacy	U.S. Department of Education through University of Virginia	06/01/2005 to 08/31/2007	168,669	51,444	\$220,113
		Joan N. Kaderavek Principal Investigator ECPS NA				
C-108762-02	Fitness Programs Testing & Data Interpretation	Toledo Public Schools	01/01/2005 to 06/30/2007	18,033	1,443	\$19,476
		Celia L. Regimbal Principal Investigator ECPS NA				
C-108762-03	Fitness Programs Testing & Data Interpretation	Toledo Public Schools	01/01/2005 to 06/30/2007	38,116	3,049	\$41,165
		Celia L. Regimbal Principal Investigator ECPS NA				
<b>Totals for Early Childhood, Physical, and Special Education</b>			<b>12</b>	<b>982,282</b>	<b>148,005</b>	<b>\$1,130,287</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Educational Leadership, Department of</b>						
N-110046-01	Lorain County Community College Presidential File	Lorain County Community College	08/21/2006 to 08/03/2007	11,185	1,119	12,304
		Ronald D. Opp	Principal Investigator	EDLE	NA	
N-110071-01	Owens Community College Presidential Fellow	Owens Community College	08/21/2006 to 08/03/2007	21,375	2,138	23,513
		Ronald D. Opp	Principal Investigator	EDLE	NA	
N-110116-01	Wayne County Community College District Presidential Fellow	Wayne County Community College	08/21/2006 to 08/03/2007	21,375	2,138	23,513
		Ronald D. Opp	Principal Investigator	EDLE	NA	
N-110319-01	Northwest State Community College Presidential Fellow	Northwest State Community College	08/21/2006 to 08/03/2007	11,185	1,119	12,304
		Ronald D. Opp	Principal Investigator	EDLE	NA	
N-110631-01	Owens Community College Presidential Fellow	Owens Community College	08/21/2006 to 08/03/2007	11,185	1,119	12,304
		Ronald D. Opp	Principal Investigator	EDLE	NA	
<b>Totals for Educational Leadership, Department of</b>			<b>5</b>	<b>76,305</b>	<b>7,633</b>	<b>\$83,938</b>
<b>Foundations of Education Department</b>						
R-106939-07	Midwest Educational Research Consortium/East Toledo Gearup Initiative (Gearup)	U.S. Department of Education through Bowling Green State University	09/15/2000 to 09/14/2007	37,037	2,963	40,000
		Dale Snauwaert	Principal Investigator	FDED	3% CY	
		Christine Fox	Co-Investigator	FDED	8% AY	
		Christine Fox	Co-Investigator	FDED	52% ST	
		Svetlana Beltyukova	Co-Investigator	FDED	8% AY	
		Svetlana Beltyukova	Co-Investigator	FDED	52% ST	
R-109798-02	MERC GEAR-UP Learning Centers II	U.S. Department of Education through Bowling Green State University	09/01/2005 to 08/31/2007	32,407	2,593	35,000

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Foundations of Education Department</b>						
		<b>Key Personnel:</b> (Name, Project Role, Department/Institution, Committed Effort, Appt.)				
		Dale Snauwaert	Principal Investigator	FDED	2%	CY
		Christine Fox	Co-Investigator	FDED	8%	AY
		Svetlana Belyukova	Co-Investigator	FDED	8%	AY
		Christine Fox	Co-Investigator	FDED	47%	ST
		Svetlana Belyukova	Co-Investigator	FDED	47%	ST
<b>Totals for Foundations of Education Department</b>				<b>2</b>	<b>69,444</b>	<b>5,556</b>
<b>Totals for Education, College of</b>				<b>31</b>	<b>3,384,928</b>	<b>294,385</b>
						<b>\$75,000</b>
						<b>\$3,679,313</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
N-110315-01	System Implementation and Demonstration of SWARM Communication	Bluetronix, Inc.	03/19/2007 to 08/17/2007	10,062	4,427	\$14,489
		Brent D. Cameron	Principal Investigator	BIOE	NA	
C-109333-02	Development of Wear Growth Model in Artificial Disc	Depuy Spine, Inc.	01/20/2005 to 12/31/2007	9,090	1,010	\$10,100
		Vijay K Goel	Principal Investigator	SPNR	NA	
C-109759-03	FEA of Various Devices	Facet Solutions	01/01/2006 to 11/30/2007	13,044	1,956	\$15,000
		Vijay K Goel	Principal Investigator	BIOE	NA	
C-109864-02	FEA of Various Devices	Disc Motion Technologies, Inc.	06/01/2006 to 12/05/2007	21,740	3,260	\$25,000
		Vijay K Goel	Principal Investigator	BIOE	NA	
N-109996-01	Cadaver Testing of Dynamic System	Medicine Lodge, Inc.	08/01/2006 to 07/31/2007	9,391	1,409	\$10,800
		Vijay K Goel	Principal Investigator	BIOE	NA	
N-109997-01	Consultation with FE Modeling of a Cervical Plate	Precision Surgery, Inc.	08/01/2006 to 07/31/2008	3,478	522	\$4,000
		Vijay K Goel	Principal Investigator	BIOE	NA	
N-110075-01	Consulting	Graham Medical Technologies, Inc.	10/01/2006 to 09/30/2007	1,597	415	\$2,012
		Vijay K Goel	Principal Investigator	BIOE	NA	
N-110102-01	Experimental Analyses of a Dynamic System	Medicine Lodge, Inc.	10/27/2006 to 10/26/2007	20,374	3,056	\$23,430
		Vijay K Goel	Principal Investigator	BIOE	NA	
N-110103-01	Experimental Analysis of a Cervical Rod System	Altiva, Inc.	10/27/2006 to 10/26/2007	10,435	1,565	\$12,000
		Vijay K Goel	Principal Investigator	BIOE	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Bioengineering, Department of</b>						
N-110106-01	Evaluation of Cement for Vertebroplasty	Calcitec, Inc.	11/07/2006 to 11/06/2007	10,435	1,565	\$12,000
		Vijay K Goel Principal Investigator BIOE NA				
N-110111-01	Testing of a Spinal Implant	Orthokinetic Technologies LLC	11/24/2006 to 11/23/2007	22,338	3,351	\$25,689
		Vijay K Goel Principal Investigator BIOE NA				
N-110138-01	Nucleus Testing	BioCure	12/01/2006 to 11/30/2007	14,110	0	\$14,110
		Vijay K Goel Principal Investigator BIOE NA				
N-110148-01	MR Imaging of Cervical Spines with Disc Replacement	Depuy Spine, Inc. through Depuy Spine, Inc.	01/01/2007 to 12/31/2007	13,709	3,427	\$17,136
		Vijay K Goel Principal Investigator BIOE NA				
N-110208-01	MR Imaging of Cervical Spines with Disc Replacement	Depuy Spine, Inc.	01/01/2007 to 12/31/2007	24,480	6,120	\$30,600
		Vijay K Goel Principal Investigator BIOE NA				
N-110236-01	Mechanical Testing of a Plate	Madhavan Pisharodi, M.D.	02/01/2007 to 03/15/2007	8,695	1,305	\$10,000
		Vijay K Goel Principal Investigator BIOE NA				
N-110240-01	Finite Element Analysis of Anterior Cervical Static and Dynamic Plates	Medtronic Sofamor Danet USA, Inc,	02/01/2007 to 01/31/2008	12,720	3,180	\$15,900
		Vijay K Goel Principal Investigator BIOE NA				
N-110254-01	FEA of Lumbar Disc	Orthokinetic Technologies LLC	02/28/2007 to 02/27/2008	11,423	2,856	\$14,279
		Vijay K Goel Principal Investigator BIOE NA				
N-110305-01	Biomechanics of Staple Device for Stabilization	Medtronic Sofamor Danet USA, Inc,	03/01/2007 to 02/28/2008	23,039	5,760	\$28,799
		Vijay K Goel Principal Investigator BIOE NA				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Bioengineering, Department of</b>						
N-110329-01	Development of the Head and Neck Finite Element Model for Chiropractic Research	National Upper Cervical Chiropractic Research Association	05/01/2007 to 04/30/2009	50,909	5,091	\$56,000*
		Vijay K Goel Principal Investigator BIOE	NA			
N-117641-01	Testing of a Nucleus Replacement Device	Orthokinetic Technologies LLC	04/29/2007 to 04/19/2008	2,065	310	\$2,375
		Vijay K Goel Principal Investigator BIOE	NA			
N-117643-01	Finite Element Analysis of an Artificial Disc	Orthokinetic Technologies LLC	04/20/2007 to 04/19/2008	8,355	1,253	\$9,608
		Vijay K Goel Principal Investigator BIOE	NA			
N-119870-01	Effect of Growth Factors and Dynamic Loading on the Intervertebral Disc Cells	Medtronic Sofamor Danet USA, Inc,	05/18/2007 to 09/30/2009	21,080	4,216	\$25,296
		Vijay K Goel Principal Investigator BIOL	NA			
N-119899-01	Cage Type Device Testing	Orthokinetic Technologies LLC	06/15/2007 to 06/14/2008	9,120	2,280	\$11,400*
		Vijay K Goel Principal Investigator Ortho Surg	1%			
N-119900-01	Altive Study	Orthokinetic Technologies LLC	06/01/2007 to 05/31/2008	11,836	2,367	\$14,203*
		Vijay K Goel Principal Investigator BIOE	1%			
N-119905-01	Biomechanical Comparison Between Artificial Cervical Disc	Medtronic Sofamor Danet USA, Inc,	06/05/2007 to 05/30/2008	18,840	4,710	\$23,550*
		Vijay K Goel Principal Investigator BIOE	NA			
N-119945-01	Biomechanical Testing of Nucleus Augmentation	Orthokinetic Technologies LLC	05/27/2007 to 05/26/2008	3,800	950	\$4,750
		Vijay K Goel Principal Investigator BIOE	NA			
N-119946-01	Testing of a Nucleus Replacment Device	Orthokinetic Technologies LLC	05/27/2007 to 05/26/2008	1,900	475	\$2,375
		Vijay K Goel Principal Investigator BIOE	NA			

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Bioengineering, Department of</b>						
N-119948-01	SMA Staple Graft Containment Study Protocol Phase II: Final Testing	Medtronic Sofamor Danet USA, Inc.	06/01/2007 to 05/30/2008	11,520	2,880	\$14,400
		Vijay K Goel	Principal Investigator	BIOE	1%	
N-119993-01	Biomechanical Evaluation of the DePuy Spine Cervical Disc Replacement Using In Vitro and Analytical Protocols: Motion-Sparing Versus Fusion in the Cervical Spine	Depuy Spine, Inc.	07/01/2007 to 07/30/2008	28,320	7,080	\$35,400*
		Vijay K Goel	Principal Investigator	BIOE	1% AY	
R-108753-02	Effect of MP-52 on Intervertebral Disc Degeneration and Regeneration	Depuy Spine, Inc.	12/06/2006 to 12/05/2007	10,000	1,000	\$11,000
		Vijay K Goel	Principal Investigator	BIOE	NA	
<b>Totals for Bioengineering, Department of</b>			<b>30</b>	<b>417,905</b>	<b>77,796</b>	<b>\$495,701</b>
<b>Chemical and Environmental Engineering, Department of</b>						
N-109616-01	Scalable Steam Methane Reformer System for Distributed Hydrogen Production	Department of Energy through Catacel, Inc.	03/01/2006 to 02/28/2007	13,897	6,115	\$20,012
		Martin Abraham	Principal Investigator	CHME	NA	
N-109863-01-A1	Development of Clean Sources of Hydrogen for Fuel Cells	U.S. Department of the Army	07/28/2006 to 12/31/2007	658,738	191,262	\$850,000
		Martin Abraham	Principal Investigator	CHME	NA	
N-110026-01	Improved Oxidative Stability of Biodiesel Fuels: Antioxidant Research and Development	U.S. Department of Transportation through Michigan-Ohio University Transportation Center	11/22/2006 to 12/31/2007	5,556	4,135	\$9,691
		Martin Abraham	Principal Investigator	CHME	NA	
N-110077-01	Utility Vehicles for Hydrogen Economy	Ohio Department of Development	03/01/2007 to 02/28/2009	228,022	0	\$228,022
		Martin Abraham	Principal Investigator	CHME	NA	
N-110168-01	Environmental Progress Office Operations	American Institute of Chemical Engineers	04/01/2007 to 12/31/2007	20,779	0	\$20,779
		Martin Abraham	Principal Investigator	CHME	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Chemical and Environmental Engineering, Department of</b>						
N-109991-01	Hydrogen Generation via Metal-Steam Reforming	Edison Materials Technology Center	02/01/2007 to 02/02/2008	25,000	5,000	\$30,000
		Abdul-Majeed Azad Principal Investigator CHME NA				
N-110119-01	A Novel Desulfurizer-embedded Processor for Sulfur-laden Logistic Fuels	Ohio Department of Development through Catacel, Inc.	04/01/2007 to 05/06/2009	211,448	85,997	\$297,445
		Abdul-Majeed Azad Principal Investigator CHME NA				
N-109866-01	Novel Ionic Liquid/Polyimide Membranes for Separation of H2 from Gasified Coal	Ohio Coal Development Office through Ohio University	09/01/2006 to 09/30/2007	63,187	16,429	\$79,616
		Maria R. Coleman Principal Investigator CHME NA				
N-110183-01	Characterization of Composites for PolyOne Corporation	PolyOne Corporation	01/18/2007 to 12/17/2007	87,554	22,764	\$110,318
		Maria R. Coleman Principal Investigator CHME NA				
C-108446-04	Modeling of Advanced High Temperature Composite Behavior	NASA John H. Glenn Research Center at Lewis Field	11/01/2003 to 10/31/2008	74,700	15,300	\$90,000
		Kenneth DeWitt Principal Investigator CHME NA				
N-109987-01	Ohio Space Grant Consortium (OSGC) Scholarships and Fellowships for 2006-2007 to University of Toledo	National Aeronautics and Space Administration through Ohio Space Grant Consortium	08/22/2006 to 08/21/2007	27,500	0	\$27,500
		Kenneth DeWitt Principal Investigator CHME NA				
N-109990-01	Application of the ARI Methodology For Accelerating Innovation in Health	University of Leeds	08/01/2006 to 01/31/2009	256,978	111,531	\$368,509
		John P. Dismukes Principal Investigator CHME NA				
C-109648-02-S1	Development of Bacterial-Sensing Ultrafiltration Membranes with Improved Permeability, Selectivity and Fouling Control	National Science Foundation	05/01/2006 to 04/30/2008	10,190	2,548	\$12,738
		Isabel C. Escobar Principal Investigator CHME NA				
N-110033-01	Student Travel Support for the 2007 North American Membrane Society Meeting	National Science Foundation	10/01/2006 to 09/30/2007	5,000	0	\$5,000
		Isabel C. Escobar Principal Investigator CHME NA				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Chemical and Environmental Engineering, Department of</b>						
N-110034-01	North American Membrane Society (NAMS) 2007 Conference	Office of Naval Research	09/22/2006 to 12/31/2007	5,000	0	\$5,000
		Isabel C. Escobar Principal Investigator CHME NA				
N-110151-01	Development of Silver/Copper Coated Membrane Feed Spacers for Biofouling Control	National Science Foundation	05/15/2007 to 04/30/2008	34,722	15,278	\$50,000
		Isabel C. Escobar Principal Investigator CHME NA				
R-108982-06	Special Funding for Engineering for Migrant Students	U.S. Department of Education through Ohio Department of Education	04/23/2002 to 06/30/2007	52,381	2,619	\$55,000
		Isabel C. Escobar Principal Investigator CHME NA				
S-109786-01-S1	REU Supplement: A Novel Approach to Antibiotic and Anti-biofouling Activities of Natural Phenols	National Science Foundation	09/01/2006 to 08/31/2009	3,324	750	\$4,074
		Dong Shik Kim Principal Investigator CHME NA				
N-109772-01	Support of the 2006 "Membranes: Materials & Processes" Gordon Research Conference	National Science Foundation	08/01/2006 to 07/31/2007	7,500	0	\$7,500
		Glenn Lipscomb Principal Investigator CHME NA				
N-109821-01	Defining the Role of Caustic in the Tomato Lye Peeling Process	Center for Innovative Food Technology	06/15/2006 to 05/16/2008	20,833	4,167	\$25,000
		Constance Ann Schall Principal Investigator CHME NA				
N-109815-01	Solvent Screening in Mitigation of the Tomato Lye Peeling Process	Center for Innovative Food Technology	06/15/2006 to 05/16/2008	20,833	4,167	\$25,000
		Sasidhar Varanasi Principal Investigator CHME NA				
N-109944-01	Ionic Liquid Pretreatment of Lignocellulosic Feed Stocks for Producing Ethanol	Suganit Systems, Inc.	08/01/2006 to 04/30/2007	29,359	7,633	\$36,992
		Sasidhar Varanasi Principal Investigator CHME NA				
N-119904-01-A1	An Efficient Approach for Saccharification of Cellulose from Biomass for Fuel/ Chemical Production	Suganit Systems, Inc.	05/07/2007 to 08/31/2008	20,000	0	\$20,000
		Sasidhar Varanasi Principal Investigator CHME 2%				
<b>Totals for Chemical and Environmental Engineering, Department of</b>			<b>23</b>	<b>1,882,501</b>	<b>495,695</b>	<b>\$2,378,196</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Civil Engineering, Department of</b>						
N-119924-01	Telecommunity Education - Math/Science Curriculum	Toledo Public Schools	05/03/2007 to 12/31/2007	27,592	12,141	\$39,733
		Defne Apul	Principal Investigator	CVLE	NA	
C-108261-03	Addendum to the Project "Pavement Forecasting Models"	Ohio Department of Transportation	11/01/2003 to 12/31/2007	39,605	11,883	\$51,488
		Eddie Yein-Juin Chou	Principal Investigator	CVLE	NA	
N-109985-01	GIS Internship for Vinod Vishwanatha	GVM, LLC	06/01/2006 to 08/24/2006	4,798	480	\$5,278
		Eddie Yein-Juin Chou	Principal Investigator	CVLE	NA	
R-108854-02	A Roadway Management Information System for the City of Perrysburg	City of Perrysburg	05/01/2004 to 04/30/2007	14,156	1,415	\$15,571
		Eddie Yein-Juin Chou	Principal Investigator	CVLE	NA	
C-108891-03	Integrating Uncertainty Analysis in the Risk Characterization of In-Place Remedial Strategies for Contaminated Sediments	Department of Defense through University of Michigan	09/23/2004 to 09/22/2008	7,745	3,253	\$10,998
		Cyndee Gruden	Principal Investigator	CVLE	NA	
N-109969-01	Developing GIS Data Base	GVM, LLC	06/01/2006 to 08/24/2006	4,798	480	\$5,278
		Jiwan D. Gupta	Principal Investigator	CVLE	NA	
N-109962-01	Development of Water Resources Models for the Old Woman Creek Watershed	Ohio Lake Erie Commission	11/06/2006 to 12/31/2007	9,091	909	\$10,000
		Andrew G. Heydinger	Principal Investigator	CVLE	NA	
C-105227-11	Radon Web Site	U.S. Environmental Protection Agency through Ohio Department of Health	02/01/1997 to 09/30/2007	24,300	0	\$24,300
		Ashok Kumar	Principal Investigator	CVLE	NA	
C-105227-12	Radon Web Site	U.S. Environmental Protection Agency through Ohio Department of Health	02/01/1997 to 09/30/2007	26,000	0	\$26,000
		Ashok Kumar	Principal Investigator	CVLE	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Civil Engineering, Department of</b>						
C-106736-07	University of Toledo Pollution Prevention Incentives for States Grant Proposal	U.S. Environmental Protection Agency	10/01/2003 to 09/30/2007	55,832	15,704	\$71,536
		Ashok Kumar Principal Investigator CVLE NA				
C-107878-05	Grant 530047 University Research Team MRC Phase I Supplement 4 (Strain Concentration)	Ohio Department of Transportation through HNTB Ohio, Inc.	07/01/2002 to 12/31/2007	34,628	2,990	\$37,618
		Douglas K. Nims Principal Investigator CVLE NA				
C-108462-03-A1	Internation US-Turkey Coopertive Research: Seismic Retrofitting of Reinforced Concrete Structural Members by Composite Materials	National Science Foundation	08/01/2004 to 07/31/2008	11,809	691	\$12,500
		Azadeh Parvin Principal Investigator CVLE NA				
N-109699-01	A National Model for Engineering Mathematics Education	National Science Foundation through Wright State University	08/15/2006 to 07/31/2009	74,643	25,360	\$100,003
		Brian W. Randolph Principal Investigator CVLE NA				
<b>Totals for Civil Engineering, Department of</b>			<b>13</b>	<b>334,997</b>	<b>75,306</b>	<b>\$410,303</b>
<b>Electrical Engineering and Computer Science, Department of</b>						
C-108879-03	Technical Enhancements to the CAE Tool for Efficient Selection of Laser Welding Parameters	DaimlerChrysler AG	08/28/2004 to 08/31/2007	41,667	18,333	\$60,000
		Devinder Kaur Principal Investigator EECS NA				
N-110011-01	SGER: Theoretical Foundations and Advanced Analysis in Real-Time, Hybrid, and Embedded Systems	National Science Foundation	09/15/2006 to 08/31/2008	129,444	56,955	\$186,399
		Wei Li Principal Investigator EECS NA				
N-109846-01	A Lithium Ion Battery Management System for Autonomous Undersea Vehicles	U.S. Naval Oceanographic Office	07/31/2006 to 01/30/2007	83,245	36,628	\$119,873
		Thomas A. Stuart Principal Investigator EECS NA				
N-110162-01-A1	A Lithium Ion Battery Management System for Autonomous Undersea Vehicles (Supplement #1)	U.S. Naval Oceanographic Office	12/28/2006 to 09/30/2008	33,113	11,930	\$45,043
		Thomas A. Stuart Principal Investigator EECS NA				
<b>Totals for Electrical Engineering and Computer Science, Department of</b>			<b>4</b>	<b>287,469</b>	<b>123,846</b>	<b>\$411,315</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Mechanical, Industrial, and Manufacturing Engineering, Department of</b>						
C-107184-07-I01	Technology Validation and Risk Reduction Research for Flywheel Technology	NASA John H. Glenn Research Center at Lewis Field	08/07/2001 to 06/30/2007	51,000	0	51,000
		Abdollah Aliakbarkhan Afjeh Principal Investigator	MIME	NA	CY	
C-107343-06-I03	Research in Controls for Flywheel Technology Applications	NASA John H. Glenn Research Center at Lewis Field	12/01/2001 to 08/31/2007	60,643	12,421	73,064
		Abdollah Aliakbarkhan Afjeh Principal Investigator	MIME	NA	CY	
C-108730-04-I03	Computed Tomography and Digital Radiography Based Research for Aerospace Materials	NASA John H. Glenn Research Center at Lewis Field	05/01/2004 to 08/31/2007	14,878	3,059	17,937
		Abdollah Aliakbarkhan Afjeh Principal Investigator	MIME	NA	CY	
C-109030-03-I01	NASA-GRC Solid Oxide Fuel Cell Technology for Aeronautic Applications	NASA John H. Glenn Research Center at Lewis Field	12/01/2004 to 06/30/2007	83,000	17,000	100,000
		Abdollah Aliakbarkhan Afjeh Principal Investigator	MIME	1%	CY	
		Kenneth DeWitt Co-Investigator	MIME	NA		
C-109030-03-I02	NASA-GRC Solid Oxide Fuel Cell Technology for Aeronautic Applications	NASA John H. Glenn Research Center at Lewis Field	06/26/2007 to 08/31/2007	48,472	9,928	58,400
		Abdollah Aliakbarkhan Afjeh Principal Investigator	MIME	NA		
		Kenneth DeWitt Co-Investigator	MIME	NA		
C-109111-02-I02	Particulates Measurements and Measurement-System Development for Aircraft Engines	NASA John H. Glenn Research Center at Lewis Field	01/03/2005 to 12/31/2008	33,871	8,129	42,000
		Abdollah Aliakbarkhan Afjeh Principal Investigator	MIME	NA	CY	
C-109139-04-I05	Evaluation of Several Space Lubricants Using the Spiral Orbit Tribometer	NASA John H. Glenn Research Center at Lewis Field	03/15/2005 to 08/31/2007	8,300	1,700	10,000
		Abdollah Aliakbarkhan Afjeh Principal Investigator	MIME	NA		
C-109140-02-I04	Component Development for Structural Seals	NASA John H. Glenn Research Center at Lewis Field	04/01/2005 to 08/31/2008	66,400	13,600	80,000
		Abdollah Aliakbarkhan Afjeh Principal Investigator	MIME	NA	CY	
C-109285-02-I03	CFD Simulation of Turbomachinery	NASA John H. Glenn Research Center at Lewis Field	03/01/2007 to 09/30/2008	39,010	7,990	47,000
				NA		

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Mechanical, Industrial, and Manufacturing Engineering, Department of</b>						
C-109310-02-I02	Development and Investigation of Multiple Phenomena in Turbomachinery and Propeller Aeroelasticity	NASA John H. Glenn Research Center at Lewis Field	10/01/2005 to 10/31/2007	37,350	7,650	45,000
		Abdollah Aliakbarkhan Afjeh	Principal Investigator	AENG	0% CY	
C-109571-01-I02	Development of an Information Exchange Mechanism Within a Virtual Engine Test Cell	NASA John H. Glenn Research Center at Lewis Field	10/01/2006 to 08/31/2007	23,240	4,760	28,000
		Abdollah Aliakbarkhan Afjeh	Principal Investigator	AENG	0% CY	
C-109594-01	Development of Foundation Technology for Code Coupling in Integrated Inlet/Fan Simulations	NASA John H. Glenn Research Center at Lewis Field	10/01/2006 to 09/30/2009	48,387	11,613	60,000
		Abdollah Aliakbarkhan Afjeh	Principal Investigator	AENG	0%	
C-109594-02-I02	Development of Foundation Technology for Code Coupling in Integrated Inlet/Fan Simulations	NASA John H. Glenn Research Center at Lewis Field	10/01/2006 to 08/31/2007	23,240	4,760	28,000
		Abdollah Aliakbarkhan Afjeh	Principal Investigator		0% CY	
C-109875-02	Damping Concepts for Rotating Blades and Rotordynamics	NASA John H. Glenn Research Center at Lewis Field	03/07/2007 to 08/31/2007	18,260	3,740	22,000
		Abdollah Aliakbarkhan Afjeh	Principal Investigator	MIME	NA	
N-110115-01	Small Turbine Institute	Teledyne	10/09/2006 to 12/30/2006	23,697	6,824	30,521
		Abdollah Aliakbarkhan Afjeh	Principal Investigator	MIME	NA	
N-110177-01	Numerical Propulsion System Simulation Model for the Revolutionary Innovative Turbine Engine	Air Force Research Lab-Kirtland through Universal Technology Corporation	12/18/2006 to 01/31/2007	12,029	3,128	15,157
		Abdollah Aliakbarkhan Afjeh	Principal Investigator	MIME	NA	
N-110304-01	Zooming Methodologies for Gas Turbine Engine Simulations	Advanced Virtual Engine Test Cell, Inc.	01/01/2007 to 12/31/2007	106,796	33,204	140,000
		Abdollah Aliakbarkhan Afjeh	Principal Investigator	MIME	NA	
N-119913-01	Small Turbine Institute	Teledyne Continental Motors	02/09/2007 to 02/08/2008	348,856	115,144	464,000
		Abdollah Aliakbarkhan Afjeh	Principal Investigator	MIME	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Mechanical, Industrial, and Manufacturing Engineering, Department of</b>						
N-110241-01	Toward Negative Poisson's Ratio Composites - Numerical and Experimental Study	National Science Foundation	06/15/2007 to 05/31/2010	156,277	59,962	\$216,239
		Lesley Berhan	Principal Investigator	MIME	2%	
C-105907-10	Computational Fluid Dynamics Related to Phonation	National Institute of Dental and Craniofacial Research through University of Cincinnati	09/01/2005 to 06/30/2006	33,242	13,962	\$47,204
		Kenneth DeWitt	Principal Investigator	MIME	NA	
C-107343-06-I01	Research in Controls for Flywheel Technology Applications	NASA John H. Glenn Research Center at Lewis Field	12/01/2001 to 10/31/2007	19,920	4,080	\$24,000
		Kenneth DeWitt	Principal Investigator	MIME	NA	
C-107343-06-I02	Research in Controls for Flywheel Technology Applications	NASA John H. Glenn Research Center at Lewis Field	12/01/2001 to 10/31/2007	20,750	4,250	\$25,000
		Kenneth DeWitt	Principal Investigator	MIME	NA	
C-108465-03-I03	Ignition Characteristics of Aviation Fuels	NASA John H. Glenn Research Center at Lewis Field	11/24/2003 to 06/30/2007	34,860	7,140	\$42,000
		Kenneth DeWitt	Principal Investigator	MIME	NA	
C-108730-04-I01	Computed Tomography and Digital Radiography Based Research for Aerospace Materials	NASA John H. Glenn Research Center at Lewis Field	05/01/2004 to 12/31/2008	70,550	14,450	\$85,000
		Kenneth DeWitt	Principal Investigator	MIME	NA	
C-108730-04-I02	Computed Tomography and Digital Radiography Based Research for Aerospace Materials	NASA John H. Glenn Research Center at Lewis Field	05/01/2004 to 12/31/2008	3,735	765	\$4,500
		Kenneth DeWitt	Principal Investigator	MIME	NA	
C-108974-02-I05	Life Prediction Modeling and Structural Analysis of Ceramic Matrix	NASA John H. Glenn Research Center at Lewis Field	11/01/2004 to 03/31/2007	132,800	27,200	\$160,000
		Kenneth DeWitt	Principal Investigator	MIME	NA	
C-109110-03-I02	Extended Durability of Materials I Advanced Power Systems for Space Exploration	NASA John H. Glenn Research Center at Lewis Field	01/01/2005 to 06/30/2007	31,872	6,528	\$38,400
		Kenneth DeWitt	Principal Investigator	MIME	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Mechanical, Industrial, and Manufacturing Engineering, Department of</b>						
C-109139-04-I03	Evaluation of Several Space Lubricants Using the Spiral Orbit Tribometer	NASA John H. Glenn Research Center at Lewis Field	03/15/2005 to 06/28/2008	19,871	5,229	\$25,100
		Kenneth DeWitt	Principal Investigator	MIME	NA	
C-109139-04-I04	Evaluation of Several Space Lubricants Using the Spiral Orbit Tribometer	NASA John H. Glenn Research Center at Lewis Field	03/15/2005 to 06/28/2008	33,200	6,800	\$40,000
		Kenneth DeWitt	Principal Investigator	MIME	NA	
C-109285-02-I02	CFD Simulation of Turbomachinery	NASA John H. Glenn Research Center at Lewis Field	10/01/2005 to 09/30/2008	5,647	1,157	\$6,804
		Kenneth DeWitt	Principal Investigator	MIME	NA	
N-109949-01	Numerical Simulation of Convective and Radiative Heat Transfer in a Combustion Chamber	American Water Heater Company	10/04/2006 to 04/03/2007	13,349	3,833	\$17,182
		Kenneth DeWitt	Principal Investigator	MIME	NA	
N-110045-01	Scholarships and Fellowships for 2006-2007 to the University of Toledo	Ohio Space Grant Consortium	08/22/2006 to 08/21/2007	2,500	0	\$2,500
		Kenneth DeWitt	Principal Investigator	MIME	NA	
N-109970-01	Multipurpose Educational Modules to Teach Hydraulic Hybrid Vehicle Technologies	U.S. Department of Transportation through Michigan-Ohio University Transportation Center	01/01/2007 to 12/31/2007	23,825	6,175	\$30,000
		Mohammad Elahinia	Principal Investigator	MIME	NA	
N-110224-01	Reducing Noise and Vibration of Hydraulic Hybrid and Plug-In Hybrid Electric Vehicles	U.S. Department of Transportation through Michigan-Ohio University Transportation Center	07/01/2007 to 08/31/2007	23,825	6,175	\$30,000
		Mohammad Elahinia	Principal Investigator	MIME	8%	
		Walter W. Olson	Co-Investigator	MIME	0%	
N-110179-01	Torsional Fatigue of Case-Hardened Specimens	MacSteel Company	09/01/2006 to 08/31/2007	42,827	18,844	\$61,671
		Ali Fatemi	Principal Investigator	MIME	NA	
N-110180-01	Metallic Materials Classification for Multiaxial Fatigue Damage Accumulation for Variable Amplitude Loading	Electricite de France	10/15/2006 to 10/15/2008	97,377	42,845	\$140,222
		Ali Fatemi	Principal Investigator	MIME	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Mechanical, Industrial, and Manufacturing Engineering, Department of</b>						
R-106718-05	Strain-Controlled Fatigue Performance for Design Optimization	American Iron and Steel Institute	01/01/1999 to 05/01/2008	61,280	15,320	\$76,600
		Ali Fatemi Principal Investigator MIME 8%				
C-109527-02-I01	Application of the BASS Computational Aeroacoustics Code to 3D Fan Noise Prediction	NASA John H. Glenn Research Center at Lewis Field	10/01/2005 to 09/30/2008	61,420	12,580	\$74,000
		Duane Hixon Principal Investigator MIME NA				
C-109527-02-I02	Application of the BASS Computational Aeroacoustics Code to 3D Fan Noise Prediction	NASA John H. Glenn Research Center at Lewis Field	10/01/2005 to 08/31/2007	27,150	9,850	\$37,000
		Duane Hixon Principal Investigator MIME NA				
N-119911-01	Turbomachinery Computational AeroAcoustics (CAA)	NASA John H. Glenn Research Center at Lewis Field through ASRC Aerospace Corporation	06/25/2007 to 08/31/2008	106,592	37,036	\$143,628
		Duane Hixon Principal Investigator MIME NA				
R-109307-05	An REU Supplement is Requested in Support of NSF Award 0401690 (CAREER : Micromachined Surface Conduction Tunneling Gas Sensors)	National Science Foundation	08/18/2003 to 08/15/2007	5,000	1,000	\$6,000
		Ahalapitiya H Jayatissa Principal Investigator MIME NA				
C-108446-04-I01	Modeling of Advanced High Temperature Composite Behavior	NASA John H. Glenn Research Center at Lewis Field	07/01/2004 to 08/31/2007	37,350	7,650	\$45,000
		Theo G. Keith Principal Investigator MIME NA				
C-109291-02-I01	Investigation of a Heavy Loaded Journal Bearing for Aero Application	NASA John H. Glenn Research Center at Lewis Field	01/01/2006 to 12/31/2008	34,437	7,053	\$41,490
		Theo G. Keith Principal Investigator MIME NA				
C-109364-02-I03	Microstructural Analysis of Advanced Space and Turbine Materials	NASA John H. Glenn Research Center at Lewis Field	11/01/2005 to 06/30/2007	58,100	11,900	\$70,000
		Theo G. Keith Principal Investigator MIME NA				
C-109427-01-I04	Advanced Structural Seal Development	NASA John H. Glenn Research Center at Lewis Field	09/14/2005 to 06/30/2007	46,473	9,519	\$55,992
		Theo G. Keith Principal Investigator MIME NA				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Mechanical, Industrial, and Manufacturing Engineering, Department of</b>						
N-110136-01	DAK06A0439 - Life Prediction and Durability of Aerospace Materials FA8650-04-C-5212	General Dynamics	11/01/2006 to 12/31/2007	19,841	5,159	\$25,000
		Theo G. Keith	Principal Investigator	MIME	NA	
N-110226-01	Numerical Simulation of Flow and Combustion of Flammable Vapors Through the Inlet of a Combustion Chamber of a Water Heater	American Water Heater Company	04/04/2007 to 10/03/2007	27,822	7,472	\$35,294
		Theo G. Keith	Principal Investigator	MIME	NA	
N-119921-01	Basic Studies for the Production and Upgrading of Fischer-Tropsch Synthesis Products to Fuels	University of Kentucky Research Foundation through Selected Yet	01/17/2007 to 01/16/2008	132,916	27,166	\$160,082
		Theo G. Keith	Principal Investigator	MIME	NA	
C-109829-02	An Active Destructive Expendable Countermeasure for Aircraft Self-Protection	U.S. Department of the Navy through Orbital Research Inc.	04/01/2006 to 06/15/2007	4,165	1,835	\$6,000
		Tsun-Ming Terry Ng	Principal Investigator	MIME	NA	
C-110178-01-S1	Novel Actuators for Active Aerodynamic Control	U.S. Department of the Army through Orbital Research Inc.	01/01/2007 to 10/19/2007	3,472	1,528	\$5,000
		Tsun-Ming Terry Ng	Principal Investigator	MIME	NA	
N-110178-01	Novel Actuators for Active Aerodynamic Control	U.S. Department of the Army through Orbital Research Inc.	02/07/2007 to 04/30/2007	7,639	3,361	\$11,000
		Tsun-Ming Terry Ng	Principal Investigator	MIME	NA	
N-110259-01	Steering Guided Slender Bodies with Microactuators	U.S. Department of the Army through Orbital Research Inc.	05/15/2007 to 04/30/2008	52,083	22,917	\$75,000
		Tsun-Ming Terry Ng	Principal Investigator	MIME	22% ST	
N-119876-01	Aerodynamic Control of Pointed-Nose Slender Bodies Using Local Flow Control	U.S. Department of the Navy through Orbital Research Inc.	05/04/2007 to 11/03/2007	6,944	3,055	\$9,999
		Tsun-Ming Terry Ng	Principal Investigator	MIME	NA	
C-109415-02	Design Optimization and Control of the Hydraulic Hybrid Vehicles	U.S. Environmental Protection Agency	11/01/2005 to 10/31/2008	38,274	16,841	\$55,115
		Walter W. Olson	Principal Investigator	MIME	NA	
<b>Totals for Mechanical, Industrial, and Manufacturing Engineering, Department of</b>			<b>54</b>	<b>2,544,814</b>	<b>695,287</b>	<b>\$3,240,101</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Polymer Institute</b>						
C-109248-03	Industrial Consortium for Poly(ethylene terephthalate), PET	Ecolab	03/02/2005 to 02/28/2007	18,182	1,818	\$20,000*
		Saleh A. Jabarin	Principal Investigator	CHME	NA	
C-110629-02	Active Barrier Packaging Consortium	SK Chemicals	07/01/2006 to 06/30/2007	9,091	909	\$10,000
		Saleh A. Jabarin	Principal Investigator	POLY	NA	
N-110042-01	Research Performed for Dow Chemical Company	Dow Chemical	07/01/2005 to 06/30/2006	1,684	116	\$1,800
		Saleh A. Jabarin	Principal Investigator	POLY	NA	
N-110043-01	Research Performed for Owens-Illinois	Owens Illinois, Inc.	07/01/2006 to 06/30/2007	1,818	182	\$2,000
		Saleh A. Jabarin	Principal Investigator	POLY	NA	
N-110044-01	Research Performed for Placon Thermoformed Products	Placon Thermoformed Products	07/01/2006 to 06/30/2007	4,318	432	\$4,750
		Saleh A. Jabarin	Principal Investigator	POLY	NA	
N-110096-01	Research Performed for Pepsi Cola	Pepsi-Cola	07/01/2006 to 06/30/2007	105,195	10,520	\$115,715
		Saleh A. Jabarin	Principal Investigator	POLY	NA	
N-110098-01	Industrial Consortium for Poly(ethylene terephthalate), PET	Amcors PET Packaging	07/01/2006 to 06/30/2007	13,350	1,650	\$15,000
		Saleh A. Jabarin	Principal Investigator	POLY	NA	
N-110099-01	Research Performed for Dow Chemical Company	Dow Chemical	07/01/2006 to 06/30/2007	3,000	300	\$3,300*
		Saleh A. Jabarin	Principal Investigator	POLY	NA	
N-110100-01	Research Performed for UOP	Universal Oil Products (UOP)	07/01/2006 to 06/30/2007	1,818	182	\$2,000
		Saleh A. Jabarin	Principal Investigator	POLY	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Polymer Institute</b>						
N-110213-01	Research Performed for The Plastics Group, Inc. (Fremont Plastics)	Plastics Group, Inc. (Fremont Plastics)	07/01/2006 to 06/30/2007	7,727	773	\$8,500
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110214-01	Research Performed for Owens-Illinois	Owens Illinois, Inc.	07/01/2006 to 06/30/2007	4,636	464	\$5,100
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110215-01	Research Performed for Plastipak Packaging	Plastipak	07/01/2006 to 06/30/2007	1,455	145	\$1,600
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110216-01	Research Performed for Graham Packaging	Graham Packaging	07/01/2006 to 06/30/2007	2,318	232	\$2,550
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110217-01	Research Performed for RPF Holdings, Inc. (Rochelle Plastics)	RPF Holdings, Inc. (Rochelle Plastics)	07/01/2006 to 06/30/2007	295	30	\$325
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110218-01	Industrial Consortium for Poly(ethylene terephthalates), PET	Pepsi-Cola	07/01/2006 to 06/30/2007	13,636	1,364	\$15,000
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110219-01	Research Performed for Pepsi-Cola	Pepsi-Cola	07/01/2006 to 06/30/2007	17,730	1,970	\$19,700
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110220-01	Industrial Consortium for Poly(ethylene terephthalate), PET	SK Chemicals	07/01/2006 to 06/30/2007	13,636	1,364	\$15,000
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110275-01	Industrial Consortium for Poly(ethylene terephthalates), PET	DAK Americas	07/01/2006 to 06/30/2007	18,182	1,818	\$20,000
		Saleh A. Jabarin Principal Investigator POLY NA				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Polymer Institute</b>						
N-110276-01	Industrial Consortium for Poly(ethylene terephthalates), PET	Wellman, Inc.	07/01/2006 to 06/30/2007	18,182	1,818	\$20,000
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110277-01	Industrial Consortium for Poly(ethylene terephthalates), PET	Uhde Inventa-Fischer AG of Switzerland	07/01/2006 to 06/30/2007	18,182	1,818	\$20,000
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110278-01	Active Barrier Packaing Consortium	Wellman, Inc.	07/01/2006 to 06/30/2007	9,091	909	\$10,000
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110279-01	Industrial Consortium for Poly(ethylene terephthalates), PET	Universal Oil Products (UOP)	07/01/2006 to 06/30/2007	18,182	1,818	\$20,000
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110280-01	Research Performed for Cipco, Inc.	Cipco, Inc.	07/01/2006 to 06/30/2007	1,000	100	\$1,100
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110313-01	Research Performed for Alkafaji & Associates	Alkafaji & Associates	07/01/2006 to 06/30/2007	7,909	791	\$8,700
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110314-01	Active Barrier Packaging Consortium	Amcors PET Packaging	12/01/2006 to 12/01/2007	9,091	909	\$10,000
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110320-01	Research Performed for Sabel Plastechs	Sabel Plastechs	07/01/2006 to 06/30/2007	34,545	3,455	\$38,000
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110333-01	Industrial Consortium for Poly(ethylene terephthalates), PET	Equipolymers GmbH	07/01/2006 to 06/30/2007	13,636	1,364	\$15,000
		Saleh A. Jabarin Principal Investigator POLY NA				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Polymer Institute</b>						
N-110334-01	Active Barrier Packaging Consortium	Equipolymers GmbH	07/01/2006 to 06/30/2007	9,091	909	\$10,000
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110537-01	Research Performed for DAK Americas, Inc.	DAK Americas	12/01/1994 to 06/30/2007	1,682	168	\$1,850
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110625-01	Research Performed for Uhde-Inventa-Fischer of Switzerland	Uhde Inventa-Fischer AG of Switzerland	07/01/2006 to 06/30/2007	8,182	818	\$9,000
		Saleh A. Jabarin Principal Investigator POLY NA				
N-110626-01	Research Performed for M & G Polymers	M & G Polymers	07/01/2006 to 06/30/2007	600	60	\$660
		Saleh A. Jabarin Principal Investigator POLY NA				
N-117642-01	Research Performed for Field Manufacturing Corporation	Field Manufacturing Corporation	07/01/2006 to 06/30/2007	1,000	100	\$1,100
		Saleh A. Jabarin Principal Investigator POLY NA				
N-119922-01	Research Performed for Basell USA Inc.	Basell USA, Inc.	02/26/2007 to 06/30/2007	7,182	718	\$7,900
		Saleh A. Jabarin Principal Investigator POLY NA				
N-119923-01	Industrial Consortium for Poly(ethylene terephthalate), PET	Amcors PET Packaging	03/01/2007 to 03/01/2008	13,636	1,364	\$15,000
		Saleh A. Jabarin Principal Investigator POLY NA				
N-119925-01	Research Performed for Amcor PET Packaging	Amcors PET Packaging	07/01/2006 to 06/30/2007	6,909	691	\$7,600*
		Saleh A. Jabarin Principal Investigator POLY NA				
N-119932-01	Research Performed for S. C. Johnson & Son, Inc.	S.C. Johnson & Son, Inc.	02/28/2007 to 06/30/2007	2,727	273	\$3,000*
		Saleh A. Jabarin Principal Investigator POLY NA				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)				Proj Period Begin to	Current Year Award		
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				Funding Cycle End	Direct Cost	F&A Cost**	Total Cost
<b>Polymer Institute</b>									
N-119933-01	Research Performed for Pregis Corporation	Pregis Corporation				04/13/2007 to 06/30/2007	727	73	\$800
		Saleh A. Jabarin Principal Investigator POLY NA							
N-119934-02	Active Barrier Packaging Consortium	Pepsi-Cola				05/01/2007 to 04/30/2008	9,091	909	\$10,000
		Saleh A. Jabarin Principal Investigator POLY NA							
N-119935-01	Research Performed for BASF Corporation	BASF Corporation				07/01/2006 to 06/30/2007	445	55	\$500
		Saleh A. Jabarin Principal Investigator POLY NA							
N-119936-01	Research Performed for Pilkington North America	Pilkington North America				07/01/2006 to 06/30/2007	427	43	\$470
		Saleh A. Jabarin Principal Investigator POLY NA							
<b>Totals for Polymer Institute</b>						<b>40</b>	<b>429,588</b>	<b>43,432</b>	<b>\$473,020</b>
<b>Totals for Engineering, College of</b>						<b>164</b>	<b>5,897,274</b>	<b>1,511,362</b>	<b>\$7,408,636</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)				Proj Period Begin to	Current Year Award		
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				Funding Cycle End	Direct Cost	F&A Cost**	Total Cost
<b>Law, College of</b>									
<b>Law, College of</b>									
N-109851-01	Fatality Review Initiative	U.S. Department of Justice				01/01/2007 to 12/31/2007	137,115	60,331	\$197,446
		Gabielle Davis				Principal Investigator	LAW	NA	
	<b>Totals for Law, College of</b>					<b>1</b>	<b>137,115</b>	<b>60,331</b>	<b>\$197,446</b>
	<b>Totals for Law, College of</b>					<b>1</b>	<b>137,115</b>	<b>60,331</b>	<b>\$197,446</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Medicine, College of</b>						
<b>AHEC</b>						
C-010336-13	Model State-Supported AHEC	Division of Medicine	09/30/1994 to 08/31/2008	661,339	19,905	\$681,244
		Kathleen Vasquez Principal Investigator AHEC 50%				
R-011191-13	Women's Health Month Conferences/ Workshops	Ohio Department of Health - Federal Pass-Through Funds	11/01/1998 to 06/30/2007	7,000	0	\$7,000
		Kathleen Vasquez Principal Investigator AHEC 1%				
<b>Totals for AHEC</b>			<b>2</b>	<b>668,339</b>	<b>19,905</b>	<b>\$688,244</b>
<b>Biochemistry &amp; Cancer Biology, Department of</b>						
C-101301-02	SWI/SNF Chromatin Remodeling Enzymes in UVR Induced Melanogenesis	National Institute of Environmental Health Sciences	09/01/2005 to 07/31/2008	97,651	7,812	\$105,463
		Ivana de la Serna Principal Investigator BIOCHEM 15%				
		Bridget A Keenen Grad Research Asst BIOCHEM 40%				
		Huilin Qi Research Associate BIOCHEM 54%				
C-101302-04	Chromatin Remodeling in Microphthalmia Transcription Factor-mediated Differentiation	American Heart Association - National	09/01/2005 to 06/30/2008	59,091	5,909	\$65,000
		Ivana de la Serna Principal Investigator BIOCHEM 10%				
C-100575-04	Mechanisms for NF-kB2 Regulation of Apoptosis and Oncogenesis	American Cancer Society - National	07/01/2003 to 06/30/2008	150,000	30,000	\$180,000
		Han-Fei Ding Principal Investigator BIOCHEM 25%				
		Venkatesha Basrur Co-Investigator Med Micro & Imm 5%				
C-100839-03	The Tumor Suppression Potential of NF-kappaB2 p100	National Cancer Institute	07/11/2005 to 04/30/2009	149,813	72,360	\$222,173
		Han-Fei Ding Principal Investigator BIOCHEM 15%				
R-100147-08	Evaluation of Evaluation of Patients with Neurocardiogenic Syncope for Platelet Storage Pool Deficiency (Cole Austin Bennett)	American Society of Hematology	06/01/2000 to 08/31/2007	4,000	0	\$4,000
		William T Gunning Principal Investigator BIOCHEM 2%				
		Cole A Bennett Student Scholar BIOCHEM 25%				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award														
				Direct Cost	F&A Cost**	Total Cost												
<b>Biochemistry &amp; Cancer Biology, Department of</b>																		
T-101488-01	Biochemical Processing of Cisplatin-DNA Interstrand Cross-Links	American Cancer Society - National	09/01/2006 to 06/30/2010	128,692	25,738	\$154,430												
		<table border="1"> <tr> <td>Stephan Patrick</td> <td>Principal Investigator</td> <td>BIOCHEM</td> <td>50%</td> </tr> </table>			Stephan Patrick	Principal Investigator	BIOCHEM	50%										
Stephan Patrick	Principal Investigator	BIOCHEM	50%															
C-011064-07	Gene Regulation for Drug Targeting in AML	National Cancer Institute	12/01/1998 to 03/31/2010	181,340	73,848	\$255,188												
		<table border="1"> <tr> <td>Manohar Ratnam</td> <td>Principal Investigator</td> <td>BIOCHEM</td> <td>20%</td> </tr> <tr> <td>Robert Lee</td> <td>Co-Investigator</td> <td>Ohio State University</td> <td>5%</td> </tr> </table>			Manohar Ratnam	Principal Investigator	BIOCHEM	20%	Robert Lee	Co-Investigator	Ohio State University	5%						
Manohar Ratnam	Principal Investigator	BIOCHEM	20%															
Robert Lee	Co-Investigator	Ohio State University	5%															
C-100749-04	Regulation of a Tumor Target through Steroid Receptors	National Cancer Institute	02/01/2004 to 01/31/2009	174,939	82,221	\$257,160												
		<table border="1"> <tr> <td>Manohar Ratnam</td> <td>Principal Investigator</td> <td>BIOCHEM</td> <td>35%</td> </tr> </table>			Manohar Ratnam	Principal Investigator	BIOCHEM	35%										
Manohar Ratnam	Principal Investigator	BIOCHEM	35%															
S-011064-05-S1	Gene Regulation for Drug Targeting in AML	National Cancer Institute	12/01/1998 to 04/30/2010	1,628	787	\$2,415												
		<table border="1"> <tr> <td>Manohar Ratnam</td> <td>Principal Investigator</td> <td>BIOCHEM</td> <td>0%</td> </tr> </table>			Manohar Ratnam	Principal Investigator	BIOCHEM	0%										
Manohar Ratnam	Principal Investigator	BIOCHEM	0%															
S-011064-07-S1	Gene Regulation for Drug Targeting in AML	National Cancer Institute	05/01/2007 to 03/31/2008	20,000	9,660	\$29,660												
		<table border="1"> <tr> <td>Manohar Ratnam</td> <td>Principal Investigator</td> <td>BIOCHEM</td> <td>0%</td> </tr> <tr> <td>Robert Lee</td> <td>Co-Investigator</td> <td>Ohio State University</td> <td>0%</td> </tr> </table>			Manohar Ratnam	Principal Investigator	BIOCHEM	0%	Robert Lee	Co-Investigator	Ohio State University	0%						
Manohar Ratnam	Principal Investigator	BIOCHEM	0%															
Robert Lee	Co-Investigator	Ohio State University	0%															
C-100526-05	bHLH Transcription Factors in Prostate Cancer Malignancy	National Cancer Institute	07/11/2003 to 04/30/2008	168,776	79,325	\$248,101												
		<table border="1"> <tr> <td>Cynthia M Smas</td> <td>Principal Investigator</td> <td>BIOCHEM</td> <td>38%</td> </tr> </table>			Cynthia M Smas	Principal Investigator	BIOCHEM	38%										
Cynthia M Smas	Principal Investigator	BIOCHEM	38%															
C-101010-02	AAV Mediated Inhibition of Adenovirus	National Institute of Allergy & Infectious Diseases	07/08/2005 to 06/30/2008	33,915	0	\$33,915												
		<table border="1"> <tr> <td>Jennifer M. Timpe</td> <td>Principal Investigator</td> <td>BIOCHEM</td> <td>100%</td> </tr> </table>			Jennifer M. Timpe	Principal Investigator	BIOCHEM	100%										
Jennifer M. Timpe	Principal Investigator	BIOCHEM	100%															
C-100837-04	Regulation of Mismatch Repair	National Cancer Institute	04/01/2004 to 02/28/2009	174,939	82,221	\$257,160												
		<table border="1"> <tr> <td>Kandace J Williams</td> <td>Principal Investigator</td> <td>BIOCHEM</td> <td>33%</td> </tr> <tr> <td>John Dignam</td> <td>Co-Investigator</td> <td>BIOCHEM</td> <td>10%</td> </tr> <tr> <td>Allen G Schroering</td> <td>Technician</td> <td>BIOCHEM</td> <td>100%</td> </tr> </table>			Kandace J Williams	Principal Investigator	BIOCHEM	33%	John Dignam	Co-Investigator	BIOCHEM	10%	Allen G Schroering	Technician	BIOCHEM	100%		
Kandace J Williams	Principal Investigator	BIOCHEM	33%															
John Dignam	Co-Investigator	BIOCHEM	10%															
Allen G Schroering	Technician	BIOCHEM	100%															

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																						
				Direct Cost	F&A Cost**	Total Cost																				
<b>Biochemistry &amp; Cancer Biology, Department of</b>																										
S-100837-04-S1	Regulation of Mismatch Repair	National Cancer Institute	04/01/2004 to 02/28/2009	35,000	0	\$35,000																				
<table border="1"> <tr> <td>Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Kandace J Williams</td> <td>Principal Investigator</td> <td>BIOCHEM</td> <td>0%</td> </tr> <tr> <td>Allen G Schroering</td> <td>Technician</td> <td>BIOCHEM</td> <td>0%</td> </tr> </table>				Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				Kandace J Williams	Principal Investigator	BIOCHEM	0%	Allen G Schroering	Technician	BIOCHEM	0%											
Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)																										
Kandace J Williams	Principal Investigator	BIOCHEM	0%																							
Allen G Schroering	Technician	BIOCHEM	0%																							
<b>Totals for Department of Biochemistry and Cancer Biology</b>				<b>14</b>	<b>1,379,784</b>	<b>469,881</b>																				
<b>Family Medicine, Department of</b>																										
C-100925-03	Improving Geriatric and End-of-life Care Training	Health Resources & Services Administration	07/01/2004 to 06/30/2008	52,800	4,224	\$57,024																				
<table border="1"> <tr> <td>Paul L Schaefer</td> <td>Principal Investigator</td> <td>Fam Med</td> <td>25%</td> </tr> <tr> <td>Barbara Kopp Miller</td> <td>Prof/Medical Support</td> <td>Occup Ther</td> <td>20%</td> </tr> </table>				Paul L Schaefer	Principal Investigator	Fam Med	25%	Barbara Kopp Miller	Prof/Medical Support	Occup Ther	20%															
Paul L Schaefer	Principal Investigator	Fam Med	25%																							
Barbara Kopp Miller	Prof/Medical Support	Occup Ther	20%																							
<b>Totals for Department of Family Medicine</b>				<b>1</b>	<b>52,800</b>	<b>4,224</b>																				
<b>Med Microbiology &amp; Immunology, Department of</b>																										
C-100503-03	Conservation and Adaptation of a Regulon Across Genera	National Institute of Allergy & Infectious Diseases	07/01/2004 to 06/30/2008	255,625	40,820	\$296,445																				
<table border="1"> <tr> <td>Robert Blumenthal</td> <td>Principal Investigator</td> <td>Med Micro &amp; Imm</td> <td>13%</td> </tr> <tr> <td>Arkady Khodursky</td> <td>Co-Investigator</td> <td>University of Minnesota</td> <td>10%</td> </tr> <tr> <td>Gary Schoolnik</td> <td>Co-Investigator</td> <td>Stanford University</td> <td>4%</td> </tr> <tr> <td>Rowena Mathews</td> <td>Consultant</td> <td>University of Michigan</td> <td>0%</td> </tr> <tr> <td>Poonam Srivastava</td> <td>Student Scholar</td> <td>University of Minnesota</td> <td>100%</td> </tr> </table>				Robert Blumenthal	Principal Investigator	Med Micro & Imm	13%	Arkady Khodursky	Co-Investigator	University of Minnesota	10%	Gary Schoolnik	Co-Investigator	Stanford University	4%	Rowena Mathews	Consultant	University of Michigan	0%	Poonam Srivastava	Student Scholar	University of Minnesota	100%			
Robert Blumenthal	Principal Investigator	Med Micro & Imm	13%																							
Arkady Khodursky	Co-Investigator	University of Minnesota	10%																							
Gary Schoolnik	Co-Investigator	Stanford University	4%																							
Rowena Mathews	Consultant	University of Michigan	0%																							
Poonam Srivastava	Student Scholar	University of Minnesota	100%																							
C-101178-02	Genetic Switch Controlled by an Unusual Family of Transcription Activators	Molecular & Cellular Biosciences	08/01/2005 to 07/31/2008	94,403	45,597	\$140,000																				
<table border="1"> <tr> <td>Robert Blumenthal</td> <td>Principal Investigator</td> <td>Med Micro &amp; Imm</td> <td>18%</td> </tr> </table>				Robert Blumenthal	Principal Investigator	Med Micro & Imm	18%																			
Robert Blumenthal	Principal Investigator	Med Micro & Imm	18%																							
C-100347-05	Adherence Mechanisms of Moraxella catarrhalis	National Institute of Allergy & Infectious Diseases	12/01/2002 to 12/22/2006	117,180	55,075	\$172,255																				
<table border="1"> <tr> <td>Eric R Lafontaine</td> <td>Principal Investigator</td> <td>Med Micro &amp; Imm</td> <td>30%</td> </tr> <tr> <td>Ronald M Wooten</td> <td>Co-Investigator</td> <td>Med Micro &amp; Imm</td> <td>5%</td> </tr> </table>				Eric R Lafontaine	Principal Investigator	Med Micro & Imm	30%	Ronald M Wooten	Co-Investigator	Med Micro & Imm	5%															
Eric R Lafontaine	Principal Investigator	Med Micro & Imm	30%																							
Ronald M Wooten	Co-Investigator	Med Micro & Imm	5%																							

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																		
				Direct Cost	F&A Cost**	Total Cost																
<b>Med Microbiology &amp; Immunology, Department of</b>																						
C-100971-02	Identification of B. pseudomallei and B. mallei adhesins	National Institute of Allergy & Infectious Diseases	08/01/2005 to 12/22/2006	195,300	94,330	\$289,630																
		<table border="1"> <tr> <td>Eric R Lafontaine</td> <td>Principal Investigator</td> <td>Med Micro &amp; Imm</td> <td>30%</td> </tr> <tr> <td>Venkatesha Basrur</td> <td>Co-Investigator</td> <td>Med Micro &amp; Imm</td> <td>10%</td> </tr> <tr> <td>Donald E. Woods</td> <td>Co-Investigator</td> <td>University of Calgary</td> <td>5%</td> </tr> <tr> <td>Ronald M Wooten</td> <td>Co-Investigator</td> <td>Med Micro &amp; Imm</td> <td>30%</td> </tr> </table>			Eric R Lafontaine	Principal Investigator	Med Micro & Imm	30%	Venkatesha Basrur	Co-Investigator	Med Micro & Imm	10%	Donald E. Woods	Co-Investigator	University of Calgary	5%	Ronald M Wooten	Co-Investigator	Med Micro & Imm	30%		
Eric R Lafontaine	Principal Investigator	Med Micro & Imm	30%																			
Venkatesha Basrur	Co-Investigator	Med Micro & Imm	10%																			
Donald E. Woods	Co-Investigator	University of Calgary	5%																			
Ronald M Wooten	Co-Investigator	Med Micro & Imm	30%																			
C-101084-03	Determinants of RNA Virus Evolution	National Institute of Allergy & Infectious Diseases	06/15/2005 to 02/28/2010	266,615	88,427	\$355,042																
		<table border="1"> <tr> <td>Isabel Novella</td> <td>Principal Investigator</td> <td>Med Micro &amp; Imm</td> <td>40%</td> </tr> <tr> <td>Claus Wilke</td> <td>Co-Investigator</td> <td>University of Texas at Austin</td> <td>25%</td> </tr> </table>			Isabel Novella	Principal Investigator	Med Micro & Imm	40%	Claus Wilke	Co-Investigator	University of Texas at Austin	25%										
Isabel Novella	Principal Investigator	Med Micro & Imm	40%																			
Claus Wilke	Co-Investigator	University of Texas at Austin	25%																			
C-100877-08	Bacterial, Signaling, & Leukocyte Transcription Activation	National Institute of Allergy & Infectious Diseases	07/01/2003 to 11/30/2010	160,000	77,280	\$237,280																
		<table border="1"> <tr> <td>Zhixing K Pan</td> <td>Principal Investigator</td> <td>Med Micro &amp; Imm</td> <td>25%</td> </tr> <tr> <td>Lingyu Chen</td> <td>Co-Investigator</td> <td>Medicine</td> <td>50%</td> </tr> </table>			Zhixing K Pan	Principal Investigator	Med Micro & Imm	25%	Lingyu Chen	Co-Investigator	Medicine	50%										
Zhixing K Pan	Principal Investigator	Med Micro & Imm	25%																			
Lingyu Chen	Co-Investigator	Medicine	50%																			
C-100748-03	Alphavirus Minus Strand RNA Synthesis and Rnase L	National Institute of Allergy & Infectious Diseases	06/01/2005 to 02/28/2010	189,636	91,594	\$281,230																
		<table border="1"> <tr> <td>Dorothea Sawicki</td> <td>Principal Investigator</td> <td>Med Micro &amp; Imm</td> <td>40%</td> </tr> <tr> <td>Stanley Sawicki</td> <td>Co-Investigator</td> <td>Med Micro &amp; Imm</td> <td>100%</td> </tr> </table>			Dorothea Sawicki	Principal Investigator	Med Micro & Imm	40%	Stanley Sawicki	Co-Investigator	Med Micro & Imm	100%										
Dorothea Sawicki	Principal Investigator	Med Micro & Imm	40%																			
Stanley Sawicki	Co-Investigator	Med Micro & Imm	100%																			
N-101409-01	Secretarial Grant Account	American Society for Virology	01/20/2006 to 01/19/2009	89,911	0	\$89,911*																
		<table border="1"> <tr> <td>Dorothea Sawicki</td> <td>Principal Investigator</td> <td>Med Micro &amp; Imm</td> <td>0%</td> </tr> </table>			Dorothea Sawicki	Principal Investigator	Med Micro & Imm	0%														
Dorothea Sawicki	Principal Investigator	Med Micro & Imm	0%																			
T-101615-02	American Society for Virology Junior Scientist Travel Request	National Institute of Allergy & Infectious Diseases	04/01/2007 to 03/31/2011	30,000	0	\$30,000																
		<table border="1"> <tr> <td>Dorothea Sawicki</td> <td>Principal Investigator</td> <td>Med Micro &amp; Imm</td> <td>1%</td> </tr> </table>			Dorothea Sawicki	Principal Investigator	Med Micro & Imm	1%														
Dorothea Sawicki	Principal Investigator	Med Micro & Imm	1%																			
T-101493-02	Behavioral Dynamics of Langerhans Cells in Skin	National Institute of Arthritis & Musculoskeletal & Skin Diseases	09/15/2006 to 07/31/2011	220,000	106,260	\$326,260																
		<table border="1"> <tr> <td>Akira Takashima</td> <td>Principal Investigator</td> <td>Med Micro &amp; Imm</td> <td>31%</td> </tr> <tr> <td>Hironori Matsushima</td> <td>Grad Research Asst</td> <td>Med Micro &amp; Imm</td> <td>30%</td> </tr> <tr> <td>Rachel E Mohr</td> <td>Research Associate</td> <td>Med Micro &amp; Imm</td> <td>30%</td> </tr> </table>			Akira Takashima	Principal Investigator	Med Micro & Imm	31%	Hironori Matsushima	Grad Research Asst	Med Micro & Imm	30%	Rachel E Mohr	Research Associate	Med Micro & Imm	30%						
Akira Takashima	Principal Investigator	Med Micro & Imm	31%																			
Hironori Matsushima	Grad Research Asst	Med Micro & Imm	30%																			
Rachel E Mohr	Research Associate	Med Micro & Imm	30%																			

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Med Microbiology &amp; Immunology, Department of</b>						
T-101496-11	T Cell Dependent Terminal Maturation of Langerhans Cells	National Institute of Arthritis & Musculoskeletal & Skin Diseases	07/01/2001 to 06/30/2007	130,935	63,242	\$194,177
		Akira Takashima	Principal Investigator	Med Micro & Imm	30%	
T-101497-04	Dendritic Cell-based Biosensor System	National Institute of Allergy & Infectious Diseases	09/01/2003 to 02/28/2008	190,975	92,241	\$283,216
		Akira Takashima	Principal Investigator	Med Micro & Imm	21%	
C-100392-04	Immunologic Control of Borrelia burgdorferi in Mammalian Tissues	American Heart Association - National	07/01/2003 to 06/30/2008	59,091	5,909	\$65,000
		Ronald M Wooten	Principal Investigator	Med Micro & Imm	25%	
N-101542-03	Identification of B. Pseudomallei & B. Mallei Adhesins	National Institute of Allergy & Infectious Diseases through University of Georgia at Athens	01/01/2007 to 07/31/2007	28,186	13,613	\$41,799
		Ronald M Wooten	Principal Investigator	Med Micro & Imm	25%	
C-101319-02	Role of FcγRIIA LTL Motif in Degradation of IgG Complexes	Arthritis Foundation	09/01/2005 to 08/31/2007	69,444	5,556	\$75,000
		Randall G Worth	Principal Investigator	Med Micro & Imm	40%	
<b>Totals for Department of Medical Microbiology and Immunology</b>			<b>15</b>	<b>2,097,301</b>	<b>779,944</b>	<b>\$2,877,245</b>
<b>Medicine, Department of</b>						
C-011309-08	Prevention of Cardiovascular Disease in Diabetes Mellitus	National Heart, Lung & Blood Institute through Case Western Reserve University	09/30/1999 to 09/29/2008	32,474	15,288	\$47,762
		Basil Akpunonu	Principal Investigator	Medicine	19%	
		Patrick J Mulrow	Co-Investigator	Medicine	1%	
		Rodica Busui	Co-Investigator	University of Michigan	1%	
S-011309-07-S1	Prevention of Cardiovascular Disease in Diabetes Mellitus	National Heart, Lung & Blood Institute through Case Western Reserve University	09/30/1999 to 09/29/2008	88,312	40,652	\$128,964
		Basil Akpunonu	Principal Investigator	Medicine	0%	
S-011309-08-S1	Prevention of Cardiovascular Disease in Diabetes Mellitus	National Heart, Lung & Blood Institute through Case Western Reserve University	09/30/1999 to 09/28/2008	162,553	74,804	\$237,357

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)	Proj Period Begin to Funding Cycle End	Current Year Award																																		
					Direct Cost	F&A Cost**	Total Cost																																
<b>Medicine, Department of</b>																																							
N-100783-01	A CHF Trial Investigating Outcomes of Exercise Training (ACTION)	National Heart, Lung & Blood Institute through Duke University	<table border="1"> <tr><td>Basil Akpunonu</td><td>Principal Investigator</td><td>Medicine</td><td>0%</td></tr> <tr><td>Jennifer Gilmore</td><td>Clinical Coordinator</td><td>Medicine</td><td>100%</td></tr> <tr><td>Rebecca Bauer</td><td>Clinical Coordinator</td><td>Medicine</td><td>100%</td></tr> <tr><td>Maureen Gilmore</td><td>Clinical Coordinator</td><td>Medicine</td><td>30%</td></tr> <tr><td>Rodica Busui</td><td>Co-Investigator</td><td>University of Michigan</td><td>1%</td></tr> <tr><td>Patrick J Mulrow</td><td>Co-Investigator</td><td>Medicine</td><td>1%</td></tr> <tr><td>Lynn Godfrey</td><td>Prof/Medical Support</td><td>Medicine</td><td>100%</td></tr> <tr><td>Patricia L Ross</td><td>Prof/Medical Support</td><td>Medicine</td><td>100%</td></tr> </table>	Basil Akpunonu	Principal Investigator	Medicine	0%	Jennifer Gilmore	Clinical Coordinator	Medicine	100%	Rebecca Bauer	Clinical Coordinator	Medicine	100%	Maureen Gilmore	Clinical Coordinator	Medicine	30%	Rodica Busui	Co-Investigator	University of Michigan	1%	Patrick J Mulrow	Co-Investigator	Medicine	1%	Lynn Godfrey	Prof/Medical Support	Medicine	100%	Patricia L Ross	Prof/Medical Support	Medicine	100%	07/19/2003 to 12/14/2008	14,112	3,528	\$17,640*
Basil Akpunonu	Principal Investigator	Medicine	0%																																				
Jennifer Gilmore	Clinical Coordinator	Medicine	100%																																				
Rebecca Bauer	Clinical Coordinator	Medicine	100%																																				
Maureen Gilmore	Clinical Coordinator	Medicine	30%																																				
Rodica Busui	Co-Investigator	University of Michigan	1%																																				
Patrick J Mulrow	Co-Investigator	Medicine	1%																																				
Lynn Godfrey	Prof/Medical Support	Medicine	100%																																				
Patricia L Ross	Prof/Medical Support	Medicine	100%																																				
N-101523-01	Claudication: Exercise vs. Endoluminal Revascularization	National Heart, Lung & Blood Institute through Rhode Island Hospital	<table border="1"> <tr><td>Dalynn Badenhop</td><td>Principal Investigator</td><td>Medicine</td><td>5%</td></tr> <tr><td>Theodore Fraker</td><td>Co-Investigator</td><td>UTHSC-Provost</td><td>3%</td></tr> <tr><td>Thomas Walsh</td><td>Co-Investigator</td><td>Medicine</td><td>3%</td></tr> </table>	Dalynn Badenhop	Principal Investigator	Medicine	5%	Theodore Fraker	Co-Investigator	UTHSC-Provost	3%	Thomas Walsh	Co-Investigator	Medicine	3%	01/01/2007 to 07/31/2007	3,822	1,846	\$5,668																				
Dalynn Badenhop	Principal Investigator	Medicine	5%																																				
Theodore Fraker	Co-Investigator	UTHSC-Provost	3%																																				
Thomas Walsh	Co-Investigator	Medicine	3%																																				
R-100783-02	Effect of Exercise Training on Ventricular Function, Dyssynchrony, Resting Myocardial Perfusion and Clinical Outcomes in HF Patients: A Nuclear Ancillary Study of HF-ACTION	National Heart, Lung & Blood Institute through Duke University	<table border="1"> <tr><td>Dalynn Badenhop</td><td>Principal Investigator</td><td>Medicine</td><td>2%</td></tr> <tr><td>Dalynn Badenhop</td><td>Principal Investigator</td><td>Medicine</td><td>3%</td></tr> <tr><td>Lucy Goodenday</td><td>Co-Investigator</td><td>Medicine</td><td>2%</td></tr> <tr><td>David Dong-Oh Suh</td><td>Co-Investigator</td><td>Med-Resid Prgm</td><td>1%</td></tr> <tr><td>Thomas Walsh</td><td>Co-Investigator</td><td>Medicine</td><td>2%</td></tr> <tr><td>Samer J Khouri</td><td>Co-Investigator</td><td>Medicine</td><td>2%</td></tr> </table>	Dalynn Badenhop	Principal Investigator	Medicine	2%	Dalynn Badenhop	Principal Investigator	Medicine	3%	Lucy Goodenday	Co-Investigator	Medicine	2%	David Dong-Oh Suh	Co-Investigator	Med-Resid Prgm	1%	Thomas Walsh	Co-Investigator	Medicine	2%	Samer J Khouri	Co-Investigator	Medicine	2%	10/27/2004 to 10/26/2009	1,760	440	\$2,200*								
Dalynn Badenhop	Principal Investigator	Medicine	2%																																				
Dalynn Badenhop	Principal Investigator	Medicine	3%																																				
Lucy Goodenday	Co-Investigator	Medicine	2%																																				
David Dong-Oh Suh	Co-Investigator	Med-Resid Prgm	1%																																				
Thomas Walsh	Co-Investigator	Medicine	2%																																				
Samer J Khouri	Co-Investigator	Medicine	2%																																				
N-101072-01	Early ACS	Millennium Pharmaceuticals, Inc. and Schering Plough Corporation, through Duke University	<table border="1"> <tr><td>Riyaz Bashir</td><td>Principal Investigator</td><td>Medicine</td><td>3%</td></tr> <tr><td>Mark Burket</td><td>Co-Investigator</td><td>Medicine</td><td>2%</td></tr> <tr><td>William R Colyer</td><td>Co-Investigator</td><td>Medicine</td><td>2%</td></tr> <tr><td>Christopher Cooper</td><td>Co-Investigator</td><td>Medicine</td><td>2%</td></tr> </table>	Riyaz Bashir	Principal Investigator	Medicine	3%	Mark Burket	Co-Investigator	Medicine	2%	William R Colyer	Co-Investigator	Medicine	2%	Christopher Cooper	Co-Investigator	Medicine	2%	01/05/2005 to 01/04/2007	80	20	\$100*																
Riyaz Bashir	Principal Investigator	Medicine	3%																																				
Mark Burket	Co-Investigator	Medicine	2%																																				
William R Colyer	Co-Investigator	Medicine	2%																																				
Christopher Cooper	Co-Investigator	Medicine	2%																																				
N-101171-01	A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention/TIMI-38	Eli Lilly and Company through Quintiles, Inc.	<table border="1"> <tr><td>Mark Burket</td><td>Principal Investigator</td><td>Medicine</td><td>3%</td></tr> <tr><td>Riyaz Bashir</td><td>Co-Investigator</td><td>Medicine</td><td>2%</td></tr> <tr><td>William R Colyer</td><td>Co-Investigator</td><td>Medicine</td><td>2%</td></tr> </table>	Mark Burket	Principal Investigator	Medicine	3%	Riyaz Bashir	Co-Investigator	Medicine	2%	William R Colyer	Co-Investigator	Medicine	2%	06/28/2005 to 06/27/2008	3,704	926	\$4,630*																				
Mark Burket	Principal Investigator	Medicine	3%																																				
Riyaz Bashir	Co-Investigator	Medicine	2%																																				
William R Colyer	Co-Investigator	Medicine	2%																																				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)	Proj Period Begin to Funding Cycle End	Current Year Award		
					Direct Cost	F&A Cost**	Total Cost
<b>Medicine, Department of</b>							
N-101315-01	Zilver PTX Vascular Stent in the Above-the-Knee Femoropopliteal Artery	Cook, Inc.		09/08/2005 to 09/07/2008	10,150	2,538	\$12,688*
			Mark Burket Principal Investigator Medicine 3%				
			Riyaz Bashir Co-Investigator Medicine 2%				
			William R Colyer Co-Investigator Medicine 2%				
N-101340-01	The ViVEXX Carotid Revascularization Trial (VIVA) for High Surgical Risk Patients with Extracranial Carotid Artery Stenosis Using the Bard ViVEXX Carotid Stent and Emboshield BareWire Rapid Exchange Embolic Protection System	Bard Peripheral Vascular, Inc.		02/27/2006 to 02/26/2008	19,680	4,920	\$24,600*
			Mark Burket Principal Investigator Medicine 3%				
			Riyaz Bashir Co-Investigator Medicine 2%				
N-101387-01	CABANA: A Boston Scientific Surveillance Program	Boston Scientific Corporation		03/20/2006 to 03/19/2009	720	180	\$900*
			Mark Burket Principal Investigator Medicine 3%				
			William R Colyer Co-Investigator Medicine 2%				
			Christopher Cooper Co-Investigator Medicine 2%				
			Gretchen Tietjen Co-Preceptor Neurology 2%				
C-101269-03	RI-alpha/RIAZ on Cell Growth in Breast Cancer	National Cancer Institute		08/10/2005 to 05/31/2010	142,701	68,925	\$211,626
			Khew-Voon Chin Principal Investigator Medicine 30%				
			Maria Szkudlarek Grad Research Asst Col Grad Stds 100%				
			Qiong Wu Student Scholar Medicine 100%				
N-101042-01	D.E.S. covey Registry	Cordis Corporation		10/27/2004 to 12/31/2010	1,280	320	\$1,600*
			William R Colyer Principal Investigator Medicine 2%				
			Cathy George Clinical Coordinator Medicine 0%				
			Kelly S Jones Clinical Coordinator Medicine 2%				
			Susan R Schroeder Clinical Coordinator 51798 2%				
			Riyaz Bashir Co-Investigator Medicine 1%				
			Mark Burket Co-Investigator Medicine 1%				
			Christopher Cooper Co-Investigator Medicine 1%				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																						
				Direct Cost	F&A Cost**	Total Cost																				
<b>Medicine, Department of</b>																										
N-101061-01	Evaluation of the Fixed Combination of Torcetrapib/Atorvastatin, Administered Orally, Once Daily (QD), Compared with Atorvastatin Alone, on the Occurrence of Major Cardiovascular Events in Subjects with Coronary Heart Disease or Risk Equivalents	Pfizer, Inc. through PharmaNet	11/24/2004 to 11/23/2008	59,332	14,833	\$74,165*																				
		<table border="1"> <thead> <tr> <th colspan="4">Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)</th> </tr> </thead> <tbody> <tr> <td>William R Colyer</td> <td>Principal Investigator</td> <td>Medicine</td> <td>5%</td> </tr> <tr> <td>Mark Burket</td> <td>Co-Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>William R Colyer</td> <td>Co-Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Christopher Cooper</td> <td>Co-Investigator</td> <td>Medicine</td> <td>3%</td> </tr> </tbody> </table>			Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				William R Colyer	Principal Investigator	Medicine	5%	Mark Burket	Co-Investigator	Medicine	3%	William R Colyer	Co-Investigator	Medicine	3%	Christopher Cooper	Co-Investigator	Medicine	3%		
Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)																										
William R Colyer	Principal Investigator	Medicine	5%																							
Mark Burket	Co-Investigator	Medicine	3%																							
William R Colyer	Co-Investigator	Medicine	3%																							
Christopher Cooper	Co-Investigator	Medicine	3%																							
N-101157-01	Strategy to Reduce Atherosclerosis Development InVolving Administration of Rimonabant-The Intravascular Ultrasound Study	Sanofi-Synthelabo Research	04/29/2005 to 04/29/2008	15,896	3,974	\$19,870*																				
		<table border="1"> <tbody> <tr> <td>William R Colyer</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Riyaz Bashir</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Mark Burket</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </tbody> </table>			William R Colyer	Principal Investigator	Medicine	3%	Riyaz Bashir	Co-Investigator	Medicine	2%	Mark Burket	Co-Investigator	Medicine	2%										
William R Colyer	Principal Investigator	Medicine	3%																							
Riyaz Bashir	Co-Investigator	Medicine	2%																							
Mark Burket	Co-Investigator	Medicine	2%																							
N-101165-01	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor (HIF)-1a/VP16 in Patients with Intermittent Claudication	Genzyme Corporation	05/16/2005 to 05/15/2008	7,299	1,825	\$9,124*																				
		<table border="1"> <tbody> <tr> <td>William R Colyer</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Dalynn Badenhop</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Mark Burket</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>William R Colyer</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Christopher Cooper</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </tbody> </table>			William R Colyer	Principal Investigator	Medicine	3%	Dalynn Badenhop	Co-Investigator	Medicine	2%	Mark Burket	Co-Investigator	Medicine	2%	William R Colyer	Co-Investigator	Medicine	2%	Christopher Cooper	Co-Investigator	Medicine	2%		
William R Colyer	Principal Investigator	Medicine	3%																							
Dalynn Badenhop	Co-Investigator	Medicine	2%																							
Mark Burket	Co-Investigator	Medicine	2%																							
William R Colyer	Co-Investigator	Medicine	2%																							
Christopher Cooper	Co-Investigator	Medicine	2%																							
C-100529-04	CORAL: Clinical Coordinating Center	National Heart, Lung & Blood Institute	04/01/2004 to 03/31/2010	1,600,963	347,357	\$1,948,320																				
		<table border="1"> <tbody> <tr> <td>Christopher Cooper</td> <td>Principal Investigator</td> <td>Medicine</td> <td>35%</td> </tr> <tr> <td>Mary Ankenbrandt</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>40%</td> </tr> <tr> <td>Pamela Brewster</td> <td>Data/Clerical Support</td> <td>Medicine</td> <td>93%</td> </tr> <tr> <td>Laura Elliott</td> <td>Data/Clerical Support</td> <td>Medicine</td> <td>100%</td> </tr> <tr> <td>Holly Burtch</td> <td>Project/Lab Manager</td> <td>Medicine</td> <td>100%</td> </tr> </tbody> </table>			Christopher Cooper	Principal Investigator	Medicine	35%	Mary Ankenbrandt	Clinical Coordinator	Medicine	40%	Pamela Brewster	Data/Clerical Support	Medicine	93%	Laura Elliott	Data/Clerical Support	Medicine	100%	Holly Burtch	Project/Lab Manager	Medicine	100%		
Christopher Cooper	Principal Investigator	Medicine	35%																							
Mary Ankenbrandt	Clinical Coordinator	Medicine	40%																							
Pamela Brewster	Data/Clerical Support	Medicine	93%																							
Laura Elliott	Data/Clerical Support	Medicine	100%																							
Holly Burtch	Project/Lab Manager	Medicine	100%																							
N-100338-01	RESIST Study - Data Coordinating Center	Centocor, Inc. and Cordis Corporation	04/30/2002 to 12/31/2006	7,552	1,888	\$9,440*																				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Medicine, Department of</b>						
		<b>Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)</b>				
		Christopher Cooper Principal Investigator Medicine 5%				
		Olga Yuryevna Baker Co-Investigator University of Toledo, Health Science Campus 1%				
		Riyaz Bashir Co-Investigator Medicine 1%				
		Mark Burket Co-Investigator Medicine 1%				
		William R Colyer Co-Investigator Medicine 2%				
		Steven D Filardo Co-Investigator Medicine 2%				
		David Joseph Kennedy Co-Investigator Medicine 28%				
		David Joseph Kennedy Co-Investigator Medicine 42%				
		Ahed T Nahhas Co-Investigator Medicine 1%				
		Joseph Shapiro Co-Investigator Medicine 1%				
N-100589-01	RESIST Study - Patient Enrollment at Subinvestigators' Sites	Centocor, Inc. and Cordis Corporation	04/30/2002 to 12/31/2006	44,448	11,112	\$55,560*
		Christopher Cooper Principal Investigator Medicine 1%				
		Riyaz Bashir Co-Investigator Medicine 1%				
		Mark Burket Co-Investigator Medicine 1%				
		William R Colyer Co-Investigator Med-Resid Prgm 1%				
		Joseph Shapiro Co-Investigator Medicine 1%				
		William J Thomas Co-Investigator Medicine 1%				
N-101474-01	Pfizer Support for CORAL: Cardiovascular Outcomes for Renal Atherosclerotic Lesions	Pfizer, Inc.	09/01/2006 to 08/31/2008	800,000	0	\$800,000*
		Christopher Cooper Principal Investigator Medicine 1%				
C-100389-06	Ryan White Title III	HIV/AIDS Bureau	09/30/2001 to 03/31/2010	420,554	24,000	\$444,554
		Joan Duggan Principal Investigator Medicine 43%				
		Haig Donabedian Prof/Medical Support Medicine 15%				
		M. A. Julia Westerink Prof/Medical Support Medicine 10%				
		Ann Locher Prof/Medical Support OUTCOME MGT 20%				
N-101011-01	A Phase IIIB, Randomized, Open-label, Multi-center Study of the Safety and Efficacy of GW433908 (700mg BID) plus Ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg)	GlaxoSmithKline	06/29/2004 to 04/27/2006	8,009	2,002	\$10,011*
		Joan Duggan Principal Investigator Medicine 5%				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																																														
				Direct Cost	F&A Cost**	Total Cost																																												
<b>Medicine, Department of</b>																																																		
N-101310-01	A 96-week, Phase IV, Randomized, Double-blind, Multicenter Study of the Safety and Efficacy of EPZICOM versus Truvada Administered in Combination with Kaletra in Antiretroviral-naïve HIV-1 Infected Subjects	GlaxoSmithKline	08/12/2005 to 08/11/2008	9,554	2,388	\$11,942*																																												
		<table border="1"> <tr> <td>Joan Duggan</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Wendy E Boone</td> <td>Clinical Coordinator</td> <td>CCR</td> <td>1%</td> </tr> <tr> <td>Nicole Amadio</td> <td>Prof/Medical Support</td> <td>Medicine</td> <td>5%</td> </tr> </table>			Joan Duggan	Principal Investigator	Medicine	3%	Wendy E Boone	Clinical Coordinator	CCR	1%	Nicole Amadio	Prof/Medical Support	Medicine	5%																																		
Joan Duggan	Principal Investigator	Medicine	3%																																															
Wendy E Boone	Clinical Coordinator	CCR	1%																																															
Nicole Amadio	Prof/Medical Support	Medicine	5%																																															
N-101494-01	A Phase 3, Randomized, Open-Label Study of Lopinavir/Ritonavir Tablets 800/200 mg Once-Daily Versus 400/100 mg Twice-Daily When Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced, HIV-1 Infected Subjects	Abbott	06/09/2006 to 06/08/2008	4,355	1,089	\$5,444*																																												
		<table border="1"> <tr> <td>Joan Duggan</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Wendy E Boone</td> <td>Clinical Coordinator</td> <td>CCR</td> <td>1%</td> </tr> <tr> <td>Nicole Amadio</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>3%</td> </tr> </table>			Joan Duggan	Principal Investigator	Medicine	3%	Wendy E Boone	Clinical Coordinator	CCR	1%	Nicole Amadio	Clinical Coordinator	Medicine	3%																																		
Joan Duggan	Principal Investigator	Medicine	3%																																															
Wendy E Boone	Clinical Coordinator	CCR	1%																																															
Nicole Amadio	Clinical Coordinator	Medicine	3%																																															
N-101545-01	A Multi-center, Open-Label, Expanded Access Trial of Maraviroc	Pfizer, Inc. through ICON Clinical Research, Inc.	02/15/2007 to 02/15/2008	960	240	\$1,200*																																												
		<table border="1"> <tr> <td>Joan Duggan</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> </table>			Joan Duggan	Principal Investigator	Medicine	3%																																										
Joan Duggan	Principal Investigator	Medicine	3%																																															
N-101603-01	Study EPZ108859, Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed -Dose Combination Tablet (ABC/3TC FDC ) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 Weeks	GlaxoSmithKline	02/12/2007 to 02/11/2008	2,012	503	\$2,515*																																												
		<table border="1"> <tr> <td>Joan Duggan</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> </table>			Joan Duggan	Principal Investigator	Medicine	3%																																										
Joan Duggan	Principal Investigator	Medicine	3%																																															
R-100043-07	Multidisciplinary Comprehensive Care Center for Families Impacted by HIV	HIV/AIDS Bureau	08/01/2006 to 07/31/2011	344,221	89,498	\$433,719																																												
		<table border="1"> <tr> <td>Joan Duggan</td> <td>Principal Investigator</td> <td>Medicine</td> <td>17%</td> </tr> <tr> <td>Amy B Clark</td> <td>Data/Clerical Support</td> <td>Medicine</td> <td>100%</td> </tr> <tr> <td>Nicole Amadio</td> <td>Prof/Medical Support</td> <td>Medicine</td> <td>40%</td> </tr> <tr> <td>Susan Carter</td> <td>Prof/Medical Support</td> <td>CANCER INST-Clinical</td> <td>35%</td> </tr> <tr> <td>Christie J Clinton</td> <td>Prof/Medical Support</td> <td>Medicine</td> <td>100%</td> </tr> <tr> <td>Michelle L Coutcher</td> <td>Prof/Medical Support</td> <td>Medicine</td> <td>46%</td> </tr> <tr> <td>Barbara D Akpanudo</td> <td>Prof/Medical Support</td> <td>51655</td> <td>20%</td> </tr> <tr> <td>Mary F Dwyer</td> <td>Prof/Medical Support</td> <td>Medicine</td> <td>100%</td> </tr> <tr> <td>Terrence Horrigan</td> <td>Prof/Medical Support</td> <td>OB/GYN</td> <td>10%</td> </tr> <tr> <td>Sandra Oehrtman</td> <td>Prof/Medical Support</td> <td>Col Nursing</td> <td>31%</td> </tr> <tr> <td>Ann Locher</td> <td>Project/Lab Manager</td> <td>OUTCOME MGT</td> <td>55%</td> </tr> </table>			Joan Duggan	Principal Investigator	Medicine	17%	Amy B Clark	Data/Clerical Support	Medicine	100%	Nicole Amadio	Prof/Medical Support	Medicine	40%	Susan Carter	Prof/Medical Support	CANCER INST-Clinical	35%	Christie J Clinton	Prof/Medical Support	Medicine	100%	Michelle L Coutcher	Prof/Medical Support	Medicine	46%	Barbara D Akpanudo	Prof/Medical Support	51655	20%	Mary F Dwyer	Prof/Medical Support	Medicine	100%	Terrence Horrigan	Prof/Medical Support	OB/GYN	10%	Sandra Oehrtman	Prof/Medical Support	Col Nursing	31%	Ann Locher	Project/Lab Manager	OUTCOME MGT	55%		
Joan Duggan	Principal Investigator	Medicine	17%																																															
Amy B Clark	Data/Clerical Support	Medicine	100%																																															
Nicole Amadio	Prof/Medical Support	Medicine	40%																																															
Susan Carter	Prof/Medical Support	CANCER INST-Clinical	35%																																															
Christie J Clinton	Prof/Medical Support	Medicine	100%																																															
Michelle L Coutcher	Prof/Medical Support	Medicine	46%																																															
Barbara D Akpanudo	Prof/Medical Support	51655	20%																																															
Mary F Dwyer	Prof/Medical Support	Medicine	100%																																															
Terrence Horrigan	Prof/Medical Support	OB/GYN	10%																																															
Sandra Oehrtman	Prof/Medical Support	Col Nursing	31%																																															
Ann Locher	Project/Lab Manager	OUTCOME MGT	55%																																															

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Medicine, Department of</b>						
N-101481-01	CAREER: Investigation of Intron Cellular Roles	Molecular & Cellular Biosciences	06/15/2007 to 05/31/2011	83,356	40,260	\$123,616
		Alexei Fedorov	Principal Investigator	Medicine	58%	
N-101272-01	An Open-Label, Multicentre, Phase 3 Study Evaluating the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects with Heart Failure who will Experience an Adverse Cardiac Event	Amersham Health, Inc.	08/24/2005 to 08/23/2008	5,973	1,493	\$7,466*
		Lucy Goodenday	Principal Investigator	Medicine	3%	
		Sreedhar Billakanty	Co-Investigator	Med-Resid Prgm	2%	
		Ehab Eltahawy	Co-Investigator	Med-Resid Prgm	2%	
		Samer J Khouri	Co-Investigator	Medicine	2%	
		Daniel J Kosinski	Co-Investigator	Medicine	2%	
		Mobeen Sheikh	Co-Investigator	Med-Resid Prgm	2%	
		Jodi L Tinkel	Co-Investigator	Med-Resid Prgm	2%	
		Thomas Walsh	Co-Investigator	Medicine	2%	
		Mohammed Y Kanjwal	Co-Investigator	Medicine	2%	
		Muhammad Imran	Co-Investigator	Med-Resid Prgm	2%	
		Javier Jurado	Co-Investigator	Med-Resid Prgm	2%	
N-101550-01	A Clinical Trial - Amgen Protocol No. 20040210	Amgen, Inc.	03/14/2007 to 03/13/2008	9,995	2,499	\$12,494*
		Lorie Gottwald	Principal Investigator	Medicine	3%	
		Suzanne M Dade	Clinical Coordinator	Medicine	3%	
N-101081-01	A Multi-center, Randomized, Open-label Phase 3 Study to Compare the Safety and Efficacy of Intravenous Doripenem with that of Intravenous Imipenem in Ventilator-associated Pneumonia	Peninsula Pharmaceuticals, Inc.	12/01/2004 to 11/30/2007	20,400	5,100	\$25,500*
		Jeffrey Hammersley	Principal Investigator	Medicine	5%	
		John F Blust	Clinical Coordinator	Medicine	5%	
		Andrew P Fox	Clinical Coordinator	Medicine	1%	
		Ragheb Assaly	Co-Investigator	Medicine	1%	
		Dan Olson	Co-Investigator	Medicine	1%	
		James Willey	Co-Investigator	Medicine	1%	
		Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	1%	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																																		
				Direct Cost	F&A Cost**	Total Cost																																
<b>Medicine, Department of</b>																																						
N-101086-01	A Randomized, Double-blind, Parallel Group, 52-week Study to Compare the Effect of Cluticasone Propionate/ Salmeterol DISKUS Combination Product 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects	GlaxoSmithKline	10/25/2004 to 03/28/2008	16,979	4,245	\$21,223*																																
		<table border="1"> <tr> <td>Jeffrey Hammersley</td> <td>Principal Investigator</td> <td>Medicine</td> <td>5%</td> </tr> <tr> <td>Carol Albright</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>65%</td> </tr> <tr> <td>John F Blust</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>10%</td> </tr> <tr> <td>Ragheb Assaly</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Dan Olson</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>James Willey</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Youngsook Yoon-Krawczyk</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Carol Albright</td> <td>Prof/Medical Support</td> <td>Medicine</td> <td>2%</td> </tr> </table>					Jeffrey Hammersley	Principal Investigator	Medicine	5%	Carol Albright	Clinical Coordinator	Medicine	65%	John F Blust	Clinical Coordinator	Medicine	10%	Ragheb Assaly	Co-Investigator	Medicine	1%	Dan Olson	Co-Investigator	Medicine	1%	James Willey	Co-Investigator	Medicine	1%	Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	1%	Carol Albright	Prof/Medical Support	Medicine	2%
Jeffrey Hammersley	Principal Investigator	Medicine	5%																																			
Carol Albright	Clinical Coordinator	Medicine	65%																																			
John F Blust	Clinical Coordinator	Medicine	10%																																			
Ragheb Assaly	Co-Investigator	Medicine	1%																																			
Dan Olson	Co-Investigator	Medicine	1%																																			
James Willey	Co-Investigator	Medicine	1%																																			
Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	1%																																			
Carol Albright	Prof/Medical Support	Medicine	2%																																			
N-101110-01	A 12-Month Double-Blind Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort	AstraZeneca, L.P.	03/14/2005 to 03/13/2008	29,240	7,310	\$36,550*																																
		<table border="1"> <tr> <td>Jeffrey Hammersley</td> <td>Principal Investigator</td> <td>Medicine</td> <td>5%</td> </tr> <tr> <td>Ragheb Assaly</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Dawn-Alita Hernandez</td> <td>Co-Investigator</td> <td>Med-Resid Prgm</td> <td>2%</td> </tr> <tr> <td>Dan Olson</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Ahmad Saltagi</td> <td>Co-Investigator</td> <td>Med-Resid Prgm</td> <td>2%</td> </tr> <tr> <td>James Willey</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Youngsook Yoon-Krawczyk</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </table>					Jeffrey Hammersley	Principal Investigator	Medicine	5%	Ragheb Assaly	Co-Investigator	Medicine	2%	Dawn-Alita Hernandez	Co-Investigator	Med-Resid Prgm	2%	Dan Olson	Co-Investigator	Medicine	2%	Ahmad Saltagi	Co-Investigator	Med-Resid Prgm	2%	James Willey	Co-Investigator	Medicine	2%	Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	2%				
Jeffrey Hammersley	Principal Investigator	Medicine	5%																																			
Ragheb Assaly	Co-Investigator	Medicine	2%																																			
Dawn-Alita Hernandez	Co-Investigator	Med-Resid Prgm	2%																																			
Dan Olson	Co-Investigator	Medicine	2%																																			
Ahmad Saltagi	Co-Investigator	Med-Resid Prgm	2%																																			
James Willey	Co-Investigator	Medicine	2%																																			
Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	2%																																			
N-100955-01	Novartis Protocol No. CCIB002I2301	Novartis	01/01/2004 to 06/01/2009	17,559	4,390	\$21,949*																																
		<table border="1"> <tr> <td>Srini K Hejeebu</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Joan M Bick</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>48%</td> </tr> <tr> <td>Jennifer Gilmore</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>24%</td> </tr> <tr> <td>Maureen Gilmore</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>10%</td> </tr> <tr> <td>Cletus U Iwuagwu</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </table>					Srini K Hejeebu	Principal Investigator	Medicine	3%	Joan M Bick	Clinical Coordinator	Medicine	48%	Jennifer Gilmore	Clinical Coordinator	Medicine	24%	Maureen Gilmore	Clinical Coordinator	Medicine	10%	Cletus U Iwuagwu	Co-Investigator	Medicine	2%												
Srini K Hejeebu	Principal Investigator	Medicine	3%																																			
Joan M Bick	Clinical Coordinator	Medicine	48%																																			
Jennifer Gilmore	Clinical Coordinator	Medicine	24%																																			
Maureen Gilmore	Clinical Coordinator	Medicine	10%																																			
Cletus U Iwuagwu	Co-Investigator	Medicine	2%																																			
N-101048-01	Clinical Investigation of Rasagaline	Eisai Medical Research Inc. through PRA International	10/11/2004 to 10/10/2007	3,905	976	\$4,881*																																
		<table border="1"> <tr> <td>Cletus U Iwuagwu</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Maureen Gilmore</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>10%</td> </tr> <tr> <td>Srini K Hejeebu</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Barbara Hicks</td> <td>Co-Investigator</td> <td>Col Nursing</td> <td>2%</td> </tr> <tr> <td>Anand Mutgi</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Victoria Steiner</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </table>					Cletus U Iwuagwu	Principal Investigator	Medicine	3%	Maureen Gilmore	Clinical Coordinator	Medicine	10%	Srini K Hejeebu	Co-Investigator	Medicine	2%	Barbara Hicks	Co-Investigator	Col Nursing	2%	Anand Mutgi	Co-Investigator	Medicine	2%	Victoria Steiner	Co-Investigator	Medicine	2%								
Cletus U Iwuagwu	Principal Investigator	Medicine	3%																																			
Maureen Gilmore	Clinical Coordinator	Medicine	10%																																			
Srini K Hejeebu	Co-Investigator	Medicine	2%																																			
Barbara Hicks	Co-Investigator	Col Nursing	2%																																			
Anand Mutgi	Co-Investigator	Medicine	2%																																			
Victoria Steiner	Co-Investigator	Medicine	2%																																			

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																										
				Direct Cost	F&A Cost**	Total Cost																								
<b>Medicine, Department of</b>																														
N-101090-01	REMIND - Review of Management Strategies in Dementia Study	Janssen Pharmaceutica, Inc.	11/18/2004 to 11/17/2007	960	240	\$1,200*																								
		<table border="1"> <tr> <td>Cletus U Iwuagwu</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Maureen Gilmore</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Barbara Hicks</td> <td>Co-Investigator</td> <td>Col Nursing</td> <td>2%</td> </tr> <tr> <td>Victoria Steiner</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </table>			Cletus U Iwuagwu	Principal Investigator	Medicine	3%	Maureen Gilmore	Clinical Coordinator	Medicine	3%	Barbara Hicks	Co-Investigator	Col Nursing	2%	Victoria Steiner	Co-Investigator	Medicine	2%										
Cletus U Iwuagwu	Principal Investigator	Medicine	3%																											
Maureen Gilmore	Clinical Coordinator	Medicine	3%																											
Barbara Hicks	Co-Investigator	Col Nursing	2%																											
Victoria Steiner	Co-Investigator	Medicine	2%																											
N-101133-01	Phase II/III Multi-center, Randomized, Double-blind Placebo-controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive Function in Subjects with Mild to Moderate Dementia of the Alzheimer's Type	Myriad through PPD Development, LLC	04/06/2005 to 04/05/2008	24,976	6,244	\$31,221*																								
		<table border="1"> <tr> <td>Cletus U Iwuagwu</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Maureen Gilmore</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Kimberly Myers</td> <td>Clinical Coordinator</td> <td>Med Clinic</td> <td>2%</td> </tr> <tr> <td>Srini K Hejeebu</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Barbara Hicks</td> <td>Co-Investigator</td> <td>Col Nursing</td> <td>2%</td> </tr> <tr> <td>Victoria Steiner</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </table>			Cletus U Iwuagwu	Principal Investigator	Medicine	3%	Maureen Gilmore	Clinical Coordinator	Medicine	2%	Kimberly Myers	Clinical Coordinator	Med Clinic	2%	Srini K Hejeebu	Co-Investigator	Medicine	2%	Barbara Hicks	Co-Investigator	Col Nursing	2%	Victoria Steiner	Co-Investigator	Medicine	2%		
Cletus U Iwuagwu	Principal Investigator	Medicine	3%																											
Maureen Gilmore	Clinical Coordinator	Medicine	2%																											
Kimberly Myers	Clinical Coordinator	Med Clinic	2%																											
Srini K Hejeebu	Co-Investigator	Medicine	2%																											
Barbara Hicks	Co-Investigator	Col Nursing	2%																											
Victoria Steiner	Co-Investigator	Medicine	2%																											
N-101535-01	Open Label Study of the Effect of Daily Treatment with MPC-7879 in Subjects with Dementia of the Alzheimer's Type	Myriad through PPD Development, LLC	12/20/2006 to 12/19/2008	2,400	600	\$3,000*																								
		<table border="1"> <tr> <td>Cletus U Iwuagwu</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Srini K Hejeebu</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> </table>			Cletus U Iwuagwu	Principal Investigator	Medicine	3%	Srini K Hejeebu	Co-Investigator	Medicine	1%																		
Cletus U Iwuagwu	Principal Investigator	Medicine	3%																											
Srini K Hejeebu	Co-Investigator	Medicine	1%																											
C-100870-02	Long Term Bosentan Open Label Extension of the RAPIDS-2 Study in Systemic Sclerosis Patients with Ischemic Digital Ulcers	Actelion Clinical Operations, Inc.	10/22/2003 to 08/03/2008	4,714	1,178	\$5,892*																								
		<table border="1"> <tr> <td>M Bashar Kahaleh</td> <td>Principal Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Carol Albright</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>13%</td> </tr> </table>			M Bashar Kahaleh	Principal Investigator	Medicine	1%	Carol Albright	Clinical Coordinator	Medicine	13%																		
M Bashar Kahaleh	Principal Investigator	Medicine	1%																											
Carol Albright	Clinical Coordinator	Medicine	13%																											
N-101115-01	Randomized Open-label Phase II/III Multicenter Study of High-dose Immunosuppressive Therapy of Irradiation, Cyclophosphamide, ATGAM & Autologous Transplantation c/Auto-CD34+ HPC vs IV Pulse Cyclophosphamide for Treatment of Severe Systemic Sclerosis( SCOT)	National Institute of Allergy & Infectious Diseases through Duke University	09/27/2005 to 09/21/2012	10,000	2,500	\$12,500*																								
		<table border="1"> <tr> <td>M Bashar Kahaleh</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> </table>			M Bashar Kahaleh	Principal Investigator	Medicine	3%																						
M Bashar Kahaleh	Principal Investigator	Medicine	3%																											
N-101329-01	Phase III "In-life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Prevention of Raynaud's Phenomenon	MediQuest Therapeutics, Inc.	10/10/2005 to 08/15/2006	14,280	3,570	\$17,850*																								
		<table border="1"> <tr> <td>M Bashar Kahaleh</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> </table>			M Bashar Kahaleh	Principal Investigator	Medicine	3%																						
M Bashar Kahaleh	Principal Investigator	Medicine	3%																											

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Medicine, Department of</b>						
N-101446-01	Open Label Study of a Topical Gel Formulation of Nitroglycerin MQX-503	MediQuest Therapeutics, Inc.	05/01/2006 to 05/17/2008	3,300	825	\$4,125*
		M Bashar Kahaleh	Principal Investigator	Medicine	3%	
N-101578-01	Investigation of the Role of Vasopressin in Scleroderma	Ferring Research Limited	05/01/2007 to 04/30/2008	36,606	9,151	\$45,757
		M Bashar Kahaleh	Principal Investigator	Medicine	2%	
		Yongqing Wang	Co-Investigator	Medicine	40%	
N-100913-01	Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Idraparinux (SanOrg34006) with Adjusted-dose Oral Vitamin-K Antagonists in the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation	Sanofi-Synthelabo Research through Quintiles, Inc.	02/10/2004 to 02/09/2006	6,664	1,666	\$8,330*
		Mohammed Y Kanjwal	Principal Investigator	Medicine	3%	
N-101256-01	Study No. 1VIT04004	Luitpold Pharmaceuticals, Inc.	01/31/2006 to 08/23/2007	6,400	1,600	\$8,000*
		Dinkar Kaw	Principal Investigator	Medicine	3%	
N-101466-01	Multicenter Trial of the Orqis Medical CRS System for the Enhanced Treatment of CHF Unresponsive to Medical Therapy (MOMENTUM)	Orqis Medical Corporation	08/24/2006 to 08/23/2008	10,600	2,650	\$13,250*
		Samer J Khouri	Principal Investigator	Medicine	1%	
		Mark Burket	Co-Investigator	Medicine	1%	
		William R Colyer	Co-Investigator	Medicine	1%	
		Samer J Khouri	Co-Investigator	Medicine	1%	
		Utpal Pandya	Co-Investigator	Medicine	1%	
N-101392-01	Ouabain-activated Signaling in Sodium Handling in Renal Proximal Tubule	American Heart Association-Ohio Valley Affiliate	07/01/2006 to 06/30/2008	55,000	5,500	\$60,500
		Jiang Liu	Principal Investigator	Medicine	75%	
N-101051-01	The National LymphoCare Study: An Observational Study of Treatment, Outcomes and Prognosis in Patients with Follicular Non-Hodgkin's Lymphoma	Genentech, Inc. Center Affiliation: Cancer Center	09/29/2004 to 12/31/2014	1,400	350	\$1,750*
		Iman E Mohamed	Principal Investigator	Medicine	1%	
		Sarah J Lyons	Clinical Coordinator	Cancer Inst	5%	
		Roland Skeel	Co-Investigator	Medicine	1%	
		Rekha Chaudhary	Co-Investigator	Medicine	5%	
		Salvatore Veltri	Co-Investigator	Medicine	5%	
		Beth Fields	Data/Clerical Support	Cancer Inst	5%	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																													
				Direct Cost	F&A Cost**	Total Cost																											
<b>Medicine, Department of</b>																																	
N-101074-01	RegistHER: An Observational Cohort Study of Patients with HER2-Positive Metastatic Breast Cancer	Genentech, Inc. Center Affiliation: Cancer Center	09/29/2004 to 12/31/2008	600	150	\$750*																											
		<table border="1"> <tr> <td>Iman E Mohamed</td> <td>Principal Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Sarah J Lyons</td> <td>Co-Investigator</td> <td>Cancer Inst</td> <td>10%</td> </tr> </table>	Iman E Mohamed	Principal Investigator	Medicine	2%	Sarah J Lyons	Co-Investigator	Cancer Inst	10%																							
Iman E Mohamed	Principal Investigator	Medicine	2%																														
Sarah J Lyons	Co-Investigator	Cancer Inst	10%																														
N-101421-01	A Phase II Open Label Single-arm Study of E7389 in Patients with Locally Advanced or Metastatic Breast Cancer, Previously Treated with Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for their Disease	Eisai Medical Research Inc. through PRA International Center Affiliation: Cancer Center	07/10/2006 to 07/09/2007	11,920	2,980	\$14,900*																											
		<table border="1"> <tr> <td>Iman E Mohamed</td> <td>Principal Investigator</td> <td>Medicine</td> <td>5%</td> </tr> <tr> <td>Sarah J Lyons</td> <td>Clinical Coordinator</td> <td>Cancer Inst</td> <td>15%</td> </tr> </table>	Iman E Mohamed	Principal Investigator	Medicine	5%	Sarah J Lyons	Clinical Coordinator	Cancer Inst	15%																							
Iman E Mohamed	Principal Investigator	Medicine	5%																														
Sarah J Lyons	Clinical Coordinator	Cancer Inst	15%																														
N-101453-01	It's Not Just About Women: When Men Get Breast Cancer	Northwest Ohio Affiliate of the Susan G. Komen Breast Cancer Foundation	07/01/2006 to 06/30/2008	5,000	0	\$5,000																											
		<table border="1"> <tr> <td>Iman E Mohamed</td> <td>Principal Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Ashley Elizabeth Dixon</td> <td>Co-Principal Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Laura Anne Boomer</td> <td>Co-Principal Investigator</td> <td>University of Toledo, Health Science Campus</td> <td>1%</td> </tr> </table>	Iman E Mohamed	Principal Investigator	Medicine	1%	Ashley Elizabeth Dixon	Co-Principal Investigator	Medicine	1%	Laura Anne Boomer	Co-Principal Investigator	University of Toledo, Health Science Campus	1%																			
Iman E Mohamed	Principal Investigator	Medicine	1%																														
Ashley Elizabeth Dixon	Co-Principal Investigator	Medicine	1%																														
Laura Anne Boomer	Co-Principal Investigator	University of Toledo, Health Science Campus	1%																														
N-100820-01	A Multicenter, International Randomized, Open-label, Assessor-blind, Non-inferiority Study of the Efficacy & Safety of Subcutaneous SanOrg 34006 with Combination of Heparin & Vitamin K Antagonist in the Treatment of Acute Pulmonary Embolism (VanGogh-PE)	Sanofi-Synthelabo Research	12/08/2003 to 06/17/2006	2,160	540	\$2,700*																											
		<table border="1"> <tr> <td>Dan Olson</td> <td>Principal Investigator</td> <td>Medicine</td> <td>5%</td> </tr> </table>	Dan Olson	Principal Investigator	Medicine	5%																											
Dan Olson	Principal Investigator	Medicine	5%																														
N-101350-01	A Pivotal, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis	Takeda Pharmaceuticals North America, Inc. through PPD Development, LLC	07/20/2006 to 02/01/2007	3,600	900	\$4,500*																											
		<table border="1"> <tr> <td>Dan Olson</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>John F Blust</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Andrew P Fox</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Ragheb Assaly</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>James Willey</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Youngsook Yoon-Krawczyk</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Jeffrey Hammersley</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </table>	Dan Olson	Principal Investigator	Medicine	3%	John F Blust	Clinical Coordinator	Medicine	2%	Andrew P Fox	Clinical Coordinator	Medicine	3%	Ragheb Assaly	Co-Investigator	Medicine	2%	James Willey	Co-Investigator	Medicine	2%	Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	2%	Jeffrey Hammersley	Co-Investigator	Medicine	2%			
Dan Olson	Principal Investigator	Medicine	3%																														
John F Blust	Clinical Coordinator	Medicine	2%																														
Andrew P Fox	Clinical Coordinator	Medicine	3%																														
Ragheb Assaly	Co-Investigator	Medicine	2%																														
James Willey	Co-Investigator	Medicine	2%																														
Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	2%																														
Jeffrey Hammersley	Co-Investigator	Medicine	2%																														

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																														
				Direct Cost	F&A Cost**	Total Cost																												
<b>Medicine, Department of</b>																																		
N-101356-01	A Controlled, Randomized, Single-Blind, Multi-Center Pivotal Clinical Study Using Angiotech CVC to Prevent Bacterial Colonization on Short-Term Central Venous Catheters	Angiotech Pharmaceuticals, Inc.	05/25/2006 to 05/24/2008	67,521	16,880	\$84,401*																												
		<table border="1"> <tr> <td>Dan Olson</td> <td>Principal Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>John F Blust</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Andrew P Fox</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Ragheb Assaly</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Jeffrey Hammersley</td> <td>Co-Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>James Willey</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Youngsook Yoon-Krawczyk</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </table>					Dan Olson	Principal Investigator	Medicine	2%	John F Blust	Clinical Coordinator	Medicine	2%	Andrew P Fox	Clinical Coordinator	Medicine	3%	Ragheb Assaly	Co-Investigator	Medicine	2%	Jeffrey Hammersley	Co-Investigator	Medicine	3%	James Willey	Co-Investigator	Medicine	2%	Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	2%
Dan Olson	Principal Investigator	Medicine	2%																															
John F Blust	Clinical Coordinator	Medicine	2%																															
Andrew P Fox	Clinical Coordinator	Medicine	3%																															
Ragheb Assaly	Co-Investigator	Medicine	2%																															
Jeffrey Hammersley	Co-Investigator	Medicine	3%																															
James Willey	Co-Investigator	Medicine	2%																															
Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	2%																															
N-101426-01	Effect of Roflumilast on Exacerbation Rate in Patients with COPD	Altana Pharma AG	07/06/2006 to 07/05/2008	25,080	6,270	\$31,350*																												
		<table border="1"> <tr> <td>Dan Olson</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Andrew P Fox</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>John F Blust</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Jeffrey Hammersley</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Ragheb Assaly</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Youngsook Yoon-Krawczyk</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>James Willey</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </table>					Dan Olson	Principal Investigator	Medicine	3%	Andrew P Fox	Clinical Coordinator	Medicine	2%	John F Blust	Clinical Coordinator	Medicine	3%	Jeffrey Hammersley	Co-Investigator	Medicine	2%	Ragheb Assaly	Co-Investigator	Medicine	2%	Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	2%	James Willey	Co-Investigator	Medicine	2%
Dan Olson	Principal Investigator	Medicine	3%																															
Andrew P Fox	Clinical Coordinator	Medicine	2%																															
John F Blust	Clinical Coordinator	Medicine	3%																															
Jeffrey Hammersley	Co-Investigator	Medicine	2%																															
Ragheb Assaly	Co-Investigator	Medicine	2%																															
Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	2%																															
James Willey	Co-Investigator	Medicine	2%																															
N-101458-01	A Phase IIIb Multicenter, Randomized, Double-blind, Placebo-controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with Advair 500/50 bid	Genentech, Inc.	07/03/2006 to 12/01/2008	7,455	1,864	\$9,319*																												
		<table border="1"> <tr> <td>Dan Olson</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>John F Blust</td> <td>Clinical Coordinator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Jeffrey Hammersley</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Ragheb Assaly</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Youngsook Yoon-Krawczyk</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>James Willey</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </table>					Dan Olson	Principal Investigator	Medicine	3%	John F Blust	Clinical Coordinator	Medicine	3%	Jeffrey Hammersley	Co-Investigator	Medicine	2%	Ragheb Assaly	Co-Investigator	Medicine	2%	Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	2%	James Willey	Co-Investigator	Medicine	2%				
Dan Olson	Principal Investigator	Medicine	3%																															
John F Blust	Clinical Coordinator	Medicine	3%																															
Jeffrey Hammersley	Co-Investigator	Medicine	2%																															
Ragheb Assaly	Co-Investigator	Medicine	2%																															
Youngsook Yoon-Krawczyk	Co-Investigator	Medicine	2%																															
James Willey	Co-Investigator	Medicine	2%																															
N-101334-01	Effect of Sirolimus on Cyst Regression in Renal Transplant Recipients with Polycystic Kidney Disease	Wyeth Pharmaceuticals	09/06/2006 to 09/05/2008	32,000	8,000	\$40,000*																												
		<table border="1"> <tr> <td>Shobha Ratnam</td> <td>Principal Investigator</td> <td>Medicine</td> <td>3%</td> </tr> <tr> <td>Michael Rees</td> <td>Co-Investigator</td> <td>Urology</td> <td>1%</td> </tr> <tr> <td>Haitham M Elsamaloty</td> <td>Co-Investigator</td> <td>Radiology</td> <td>1%</td> </tr> <tr> <td>Sadik Khuder</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> </table>					Shobha Ratnam	Principal Investigator	Medicine	3%	Michael Rees	Co-Investigator	Urology	1%	Haitham M Elsamaloty	Co-Investigator	Radiology	1%	Sadik Khuder	Co-Investigator	Medicine	1%												
Shobha Ratnam	Principal Investigator	Medicine	3%																															
Michael Rees	Co-Investigator	Urology	1%																															
Haitham M Elsamaloty	Co-Investigator	Radiology	1%																															
Sadik Khuder	Co-Investigator	Medicine	1%																															
N-100540-01	RESIST Study - Core Serology/Urine Markers Lab	Centocor, Inc. and Cordis Corporation	04/30/2002 to 12/31/2006	12,000	3,000	\$15,000*																												

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)	Proj Period Begin to Funding Cycle End	Current Year Award																														
					Direct Cost	F&A Cost**	Total Cost																												
<b>Medicine, Department of</b>																																			
N-100983-01	A Clinical Trial - Amgen Protocol No. 20030232	Amgen, Inc.	Center Affiliation: Cancer Center	01/30/2004 to 01/29/2006	2,000	500	\$2,500*																												
<table border="1"> <tr> <td>Joseph Shapiro</td> <td>Principal Investigator</td> <td>Medicine</td> <td>5%</td> </tr> <tr> <td>Mark Burket</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>William R Colyer</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Christopher Cooper</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Steven D Filardo</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>William J Thomas</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>David Joseph Kennedy</td> <td>Grad Research Asst</td> <td>Medicine</td> <td>28%</td> </tr> </table>								Joseph Shapiro	Principal Investigator	Medicine	5%	Mark Burket	Co-Investigator	Medicine	1%	William R Colyer	Co-Investigator	Medicine	1%	Christopher Cooper	Co-Investigator	Medicine	1%	Steven D Filardo	Co-Investigator	Medicine	1%	William J Thomas	Co-Investigator	Medicine	1%	David Joseph Kennedy	Grad Research Asst	Medicine	28%
Joseph Shapiro	Principal Investigator	Medicine	5%																																
Mark Burket	Co-Investigator	Medicine	1%																																
William R Colyer	Co-Investigator	Medicine	1%																																
Christopher Cooper	Co-Investigator	Medicine	1%																																
Steven D Filardo	Co-Investigator	Medicine	1%																																
William J Thomas	Co-Investigator	Medicine	1%																																
David Joseph Kennedy	Grad Research Asst	Medicine	28%																																
N-101637-01	Information Needs of Caregivers of Persons with Dementia	Center for Community Based Care		06/01/2007 to 01/31/2009	989	0	\$989																												
<table border="1"> <tr> <td>Roland Skeel</td> <td>Principal Investigator</td> <td>Medicine</td> <td>5%</td> </tr> </table>								Roland Skeel	Principal Investigator	Medicine	5%																								
Roland Skeel	Principal Investigator	Medicine	5%																																
R-010998-06-A2	Elderly Immune Response to Pneumococcal Polysaccharide	National Institute on Aging		09/01/2006 to 08/31/2011	205,000	95,054	\$300,054																												
<table border="1"> <tr> <td>Victoria Steiner</td> <td>Principal Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>Linda Pierce</td> <td>Co-Investigator</td> <td>Col Nursing</td> <td>2%</td> </tr> <tr> <td>Diane Salvador</td> <td>Co-Investigator</td> <td>Col Nursing</td> <td>2%</td> </tr> <tr> <td>Michelle Marie Young</td> <td>Grad Research Asst</td> <td>Col Grad Stds</td> <td>2%</td> </tr> </table>								Victoria Steiner	Principal Investigator	Medicine	2%	Linda Pierce	Co-Investigator	Col Nursing	2%	Diane Salvador	Co-Investigator	Col Nursing	2%	Michelle Marie Young	Grad Research Asst	Col Grad Stds	2%												
Victoria Steiner	Principal Investigator	Medicine	2%																																
Linda Pierce	Co-Investigator	Col Nursing	2%																																
Diane Salvador	Co-Investigator	Col Nursing	2%																																
Michelle Marie Young	Grad Research Asst	Col Grad Stds	2%																																
<table border="1"> <tr> <td>M. A. Julia Westerink</td> <td>Principal Investigator</td> <td>Medicine</td> <td>30%</td> </tr> <tr> <td>Cuixia Tian</td> <td>Co-Investigator</td> <td>Vanderbilt University</td> <td>20%</td> </tr> <tr> <td>Sadik Khuder</td> <td>Co-Investigator</td> <td>Medicine</td> <td>3%</td> </tr> </table>								M. A. Julia Westerink	Principal Investigator	Medicine	30%	Cuixia Tian	Co-Investigator	Vanderbilt University	20%	Sadik Khuder	Co-Investigator	Medicine	3%																
M. A. Julia Westerink	Principal Investigator	Medicine	30%																																
Cuixia Tian	Co-Investigator	Vanderbilt University	20%																																
Sadik Khuder	Co-Investigator	Medicine	3%																																
<b>Totals for Department of Medicine</b>				<b>61</b>	<b>4,546,534</b>	<b>953,581</b>	<b>\$5,500,115</b>																												
<b>Neurology, Department of</b>																																			
N-101251-01	A MultiCenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of SPM 927 (600 mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without Secondary Generalization	Schwarz Biosciences, Inc.		06/06/2005 to 06/05/2006	2,806	701	\$3,507*																												
<table border="1"> <tr> <td>Imran Ali</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>								Imran Ali	Principal Investigator	Neurology	5%																								
Imran Ali	Principal Investigator	Neurology	5%																																

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																		
				Direct Cost	F&A Cost**	Total Cost																
<b>Neurology, Department of</b>																						
N-101316-01	An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine when Switching Patients with Epilepsy on LAMICTAL Immediate Release to Extended Release Formulation and Vice Versa	GlaxoSmithKline	08/04/2005 to 07/09/2007	8,797	2,199	\$10,996*																
		<table border="1"> <tr> <td>Imran Ali</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Andrea Korsnack</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Lazar J Greenfield</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>			Imran Ali	Principal Investigator	Neurology	5%	Andrea Korsnack	Clinical Coordinator	Neurology	5%	Lazar J Greenfield	Co-Investigator	Neurology	5%						
Imran Ali	Principal Investigator	Neurology	5%																			
Andrea Korsnack	Clinical Coordinator	Neurology	5%																			
Lazar J Greenfield	Co-Investigator	Neurology	5%																			
N-101332-01	A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Phase 3 Study to Determine the Efficacy and Safety of Tetigabine used as Adjunctive Thereapy in Refractory Epilepsy Patients with Partial-onset Seizures	Valeant Research & Development through Quintiles, Inc.	01/26/2006 to 01/25/2008	8,677	2,169	\$10,846*																
		<table border="1"> <tr> <td>Imran Ali</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Andrea Korsnack</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>10%</td> </tr> <tr> <td>Lazar J Greenfield</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>			Imran Ali	Principal Investigator	Neurology	5%	Andrea Korsnack	Clinical Coordinator	Neurology	10%	Lazar J Greenfield	Co-Investigator	Neurology	5%						
Imran Ali	Principal Investigator	Neurology	5%																			
Andrea Korsnack	Clinical Coordinator	Neurology	10%																			
Lazar J Greenfield	Co-Investigator	Neurology	5%																			
N-101346-01	An Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral SPM927 in Patients with Partial Seizures	Schwarz Biosciences, Inc.	10/25/2005 to 10/24/2008	9,277	2,319	\$11,596*																
		<table border="1"> <tr> <td>Imran Ali</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Andrea Korsnack</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Lazar J Greenfield</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>			Imran Ali	Principal Investigator	Neurology	5%	Andrea Korsnack	Clinical Coordinator	Neurology	5%	Lazar J Greenfield	Co-Investigator	Neurology	5%						
Imran Ali	Principal Investigator	Neurology	5%																			
Andrea Korsnack	Clinical Coordinator	Neurology	5%																			
Lazar J Greenfield	Co-Investigator	Neurology	5%																			
N-101443-01	A Multi-center, Open-label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients with Partial-onset Seizures (Extension of Study VRX-RET-E22-301)	Valeant Pharmaceuticals, North America through Quintiles, Inc.	04/11/2006 to 04/10/2008	6,400	1,600	\$8,000*																
		<table border="1"> <tr> <td>Imran Ali</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>			Imran Ali	Principal Investigator	Neurology	5%														
Imran Ali	Principal Investigator	Neurology	5%																			
N-101480-01	A Double-blind, Placebo-controlled, Parallel-group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures	Eisai Medical Research Inc.	09/07/2006 to 09/06/2008	9,201	2,300	\$11,501*																
		<table border="1"> <tr> <td>Imran Ali</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Kimberly A Cole</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Kimberly M Wilson</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Lazar J Greenfield</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>			Imran Ali	Principal Investigator	Neurology	5%	Kimberly A Cole	Clinical Coordinator	Neurology	5%	Kimberly M Wilson	Clinical Coordinator	Neurology	5%	Lazar J Greenfield	Co-Investigator	Neurology	5%		
Imran Ali	Principal Investigator	Neurology	5%																			
Kimberly A Cole	Clinical Coordinator	Neurology	5%																			
Kimberly M Wilson	Clinical Coordinator	Neurology	5%																			
Lazar J Greenfield	Co-Investigator	Neurology	5%																			
C-011251-08	Parkinson Disease Collaboration Study of Genetic Linkage, 'PROGENI'	National Institute of Neurological Disorders and Stroke through University of Rochester	09/01/1998 to 01/31/2007	1,500	375	\$1,875*																
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>			Lawrence Elmer	Principal Investigator	Neurology	5%														
Lawrence Elmer	Principal Investigator	Neurology	5%																			
C-101367-02	Study of Antidepressants in Parkinson's Disease (SAD PD)	National Institute of Neurological Disorders and Stroke through University of Rochester	05/01/2005 to 04/30/2007	2,854	714	\$3,568*																
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>1%</td> </tr> <tr> <td>Colleen Taylor</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>50%</td> </tr> <tr> <td>Julia L. Spears</td> <td>Prof/Medical Support</td> <td>Neurology</td> <td>5%</td> </tr> </table>			Lawrence Elmer	Principal Investigator	Neurology	1%	Colleen Taylor	Clinical Coordinator	Neurology	50%	Julia L. Spears	Prof/Medical Support	Neurology	5%						
Lawrence Elmer	Principal Investigator	Neurology	1%																			
Colleen Taylor	Clinical Coordinator	Neurology	50%																			
Julia L. Spears	Prof/Medical Support	Neurology	5%																			

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																					
				Direct Cost	F&A Cost**	Total Cost																			
<b>Neurology, Department of</b>																									
C-101367-03	Study of Antidepressants in Parkinson's Disease (SAD PD)	National Institute of Neurological Disorders and Stroke through University of Rochester	05/01/2005 to 04/30/2008	5,653	1,413	\$7,067*																			
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>1%</td> </tr> <tr> <td>Colleen Taylor</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>50%</td> </tr> <tr> <td>Julia L Spears</td> <td>Prof/Medical Support</td> <td>Neurology</td> <td>5%</td> </tr> </table>	Lawrence Elmer	Principal Investigator	Neurology	1%	Colleen Taylor	Clinical Coordinator	Neurology	50%	Julia L Spears	Prof/Medical Support	Neurology	5%											
Lawrence Elmer	Principal Investigator	Neurology	1%																						
Colleen Taylor	Clinical Coordinator	Neurology	50%																						
Julia L Spears	Prof/Medical Support	Neurology	5%																						
N-100410-01	An Active Extension of the PRESTO Study	Teva Neuroscience, Inc.	09/01/2001 to 05/19/2007	27,719	6,930	\$34,649*																			
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Stephanie Wilson</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>91%</td> </tr> <tr> <td>Melanie Langlois</td> <td>Co-Investigator</td> <td>Neurology</td> <td>100%</td> </tr> <tr> <td>Lorie Gottwald</td> <td>Prof/Medical Support</td> <td>Medicine</td> <td>1%</td> </tr> </table>	Lawrence Elmer	Principal Investigator	Neurology	5%	Stephanie Wilson	Clinical Coordinator	Neurology	91%	Melanie Langlois	Co-Investigator	Neurology	100%	Lorie Gottwald	Prof/Medical Support	Medicine	1%							
Lawrence Elmer	Principal Investigator	Neurology	5%																						
Stephanie Wilson	Clinical Coordinator	Neurology	91%																						
Melanie Langlois	Co-Investigator	Neurology	100%																						
Lorie Gottwald	Prof/Medical Support	Medicine	1%																						
N-100472-01	A Multi-center, Multi-national, Phase III, Randomized, Double-blind, Placebo Controlled Trial of the Efficacy and Safety of the Rotigotine CDS Patch in Subjects with Early Stage, Idiopathic Parkinson's Disease	Schwarz Biosciences, Inc. through CroMedica Inc.	01/16/2002 to 09/15/2008	10,702	2,675	\$13,377*																			
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Melanie Langlois</td> <td>Co-Investigator</td> <td>Neurology</td> <td>0%</td> </tr> </table>	Lawrence Elmer	Principal Investigator	Neurology	5%	Melanie Langlois	Co-Investigator	Neurology	0%															
Lawrence Elmer	Principal Investigator	Neurology	5%																						
Melanie Langlois	Co-Investigator	Neurology	0%																						
N-100534-01	Multi-center, Multi-national, Phase III, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial of the Efficacy and Safety of Rotigotine CDS Patch in Subjects with Advanced Stage, Idiopathic Parkinson's Who are not Controlled on Levodopa	Schwarz Biosciences, Inc. through CroMedica Inc.	01/23/2002 to 12/17/2008	15,157	3,789	\$18,946*																			
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Melanie Langlois</td> <td>Research Associate</td> <td>Neurology</td> <td>0%</td> </tr> </table>	Lawrence Elmer	Principal Investigator	Neurology	5%	Melanie Langlois	Research Associate	Neurology	0%															
Lawrence Elmer	Principal Investigator	Neurology	5%																						
Melanie Langlois	Research Associate	Neurology	0%																						
N-100948-01	An Open-label Extension Study with REQUIP (Ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169	GlaxoSmithKline through Quintiles, Inc.	04/14/2004 to 04/13/2008	1,136	284	\$1,420*																			
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Julia L Spears</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>10%</td> </tr> <tr> <td>Kathy A Davis</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>3%</td> </tr> <tr> <td>Colleen Taylor</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>3%</td> </tr> <tr> <td>Stephanie Wilson</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>10%</td> </tr> </table>	Lawrence Elmer	Principal Investigator	Neurology	5%	Julia L Spears	Clinical Coordinator	Neurology	10%	Kathy A Davis	Clinical Coordinator	Neurology	3%	Colleen Taylor	Clinical Coordinator	Neurology	3%	Stephanie Wilson	Clinical Coordinator	Neurology	10%			
Lawrence Elmer	Principal Investigator	Neurology	5%																						
Julia L Spears	Clinical Coordinator	Neurology	10%																						
Kathy A Davis	Clinical Coordinator	Neurology	3%																						
Colleen Taylor	Clinical Coordinator	Neurology	3%																						
Stephanie Wilson	Clinical Coordinator	Neurology	10%																						
N-101116-01	A Long-term, Multi-center, Open-label, Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy	Kyowa Pharmaceuticals through PharmaNet	12/17/2004 to 11/12/2007	16,032	4,008	\$20,040*																			
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Kimberly A Cole</td> <td>Co-Investigator</td> <td>Neurology</td> <td>3%</td> </tr> </table>	Lawrence Elmer	Principal Investigator	Neurology	5%	Kimberly A Cole	Co-Investigator	Neurology	3%															
Lawrence Elmer	Principal Investigator	Neurology	5%																						
Kimberly A Cole	Co-Investigator	Neurology	3%																						

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																		
				Direct Cost	F&A Cost**	Total Cost																
<b>Neurology, Department of</b>																						
N-101312-01	An Open-Label, Multicenter, Multinational Phase III Follow-up Study to Investigate the Long-term Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients with Parkinson's Disease Suffering from Treatment-associated Dyskinesia (PADDY -O)	Merck KGaA through Monitoring Force USA, Inc.	08/08/2005 to 08/07/2007	37,648	9,412	\$47,060*																
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Kathy A Davis</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>0%</td> </tr> </table>					Lawrence Elmer	Principal Investigator	Neurology	5%	Kathy A Davis	Clinical Coordinator	Neurology	0%								
Lawrence Elmer	Principal Investigator	Neurology	5%																			
Kathy A Davis	Clinical Coordinator	Neurology	0%																			
N-101354-01	A Multicenter, Double-blind, Randomized Start, Placebo-controlled, Parallel-group Study to Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects	Teva Neuroscience, Inc.	11/21/2005 to 11/20/2008	13,801	3,450	\$17,251*																
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Kathy A Davis</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>10%</td> </tr> <tr> <td>Colleen Taylor</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>20%</td> </tr> <tr> <td>Julia L. Spears</td> <td>Project/Lab Manager</td> <td>Neurology</td> <td>5%</td> </tr> </table>					Lawrence Elmer	Principal Investigator	Neurology	5%	Kathy A Davis	Clinical Coordinator	Neurology	10%	Colleen Taylor	Clinical Coordinator	Neurology	20%	Julia L. Spears	Project/Lab Manager	Neurology	5%
Lawrence Elmer	Principal Investigator	Neurology	5%																			
Kathy A Davis	Clinical Coordinator	Neurology	10%																			
Colleen Taylor	Clinical Coordinator	Neurology	20%																			
Julia L. Spears	Project/Lab Manager	Neurology	5%																			
N-101420-01	An Open Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) in Subjects with Parkinson's Disease who have Recently Completed One Year of Treatment with Istradefylline	Kyowa Pharmaceuticals through PharmaNet	05/17/2006 to 05/16/2008	11,280	2,820	\$14,100*																
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>1%</td> </tr> </table>					Lawrence Elmer	Principal Investigator	Neurology	1%												
Lawrence Elmer	Principal Investigator	Neurology	1%																			
N-101439-01	A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLC308 Monotherapy in the Treatment of Patients with Early Stage Parkinson's Disease	Solvay Pharmaceuticals, Inc.	04/01/2006 to 11/12/2008	8,137	2,034	\$10,171*																
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Kathy A Davis</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>25%</td> </tr> <tr> <td>Julia L. Spears</td> <td>Project/Lab Manager</td> <td>Neurology</td> <td>5%</td> </tr> </table>					Lawrence Elmer	Principal Investigator	Neurology	5%	Kathy A Davis	Clinical Coordinator	Neurology	25%	Julia L. Spears	Project/Lab Manager	Neurology	5%				
Lawrence Elmer	Principal Investigator	Neurology	5%																			
Kathy A Davis	Clinical Coordinator	Neurology	25%																			
Julia L. Spears	Project/Lab Manager	Neurology	5%																			
N-101462-01	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations	Eisai Medical Research Inc. through Quintiles, Inc.	09/01/2006 to 08/31/2008	32,430	8,107	\$40,537*																
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>1%</td> </tr> <tr> <td>Kimberly A Cole</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> </table>					Lawrence Elmer	Principal Investigator	Neurology	1%	Kimberly A Cole	Clinical Coordinator	Neurology	5%								
Lawrence Elmer	Principal Investigator	Neurology	1%																			
Kimberly A Cole	Clinical Coordinator	Neurology	5%																			
N-101563-01	A Multi-Center, Open Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.	Eisai Medical Research Inc.	03/28/2007 to 03/27/2008	10,210	2,553	\$12,763*																
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>1%</td> </tr> <tr> <td>Mary E Scott</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Julia L. Spears</td> <td>Project/Lab Manager</td> <td>Neurology</td> <td>5%</td> </tr> </table>					Lawrence Elmer	Principal Investigator	Neurology	1%	Mary E Scott	Clinical Coordinator	Neurology	5%	Julia L. Spears	Project/Lab Manager	Neurology	5%				
Lawrence Elmer	Principal Investigator	Neurology	1%																			
Mary E Scott	Clinical Coordinator	Neurology	5%																			
Julia L. Spears	Project/Lab Manager	Neurology	5%																			

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																																		
				Direct Cost	F&A Cost**	Total Cost																																
<b>Neurology, Department of</b>																																						
N-101596-01	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients with Parkinson's Disease Experiencing Motor Fluctuations	Solvay Pharmaceuticals, Inc. through Quintiles, Inc.	05/03/2007 to 05/02/2008	9,600	2,400	\$12,000*																																
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>1%</td> </tr> <tr> <td>Kathy A Davis</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Julia L Spears</td> <td>Project/Lab Manager</td> <td>Neurology</td> <td>5%</td> </tr> </table>					Lawrence Elmer	Principal Investigator	Neurology	1%	Kathy A Davis	Clinical Coordinator	Neurology	5%	Julia L Spears	Project/Lab Manager	Neurology	5%																				
Lawrence Elmer	Principal Investigator	Neurology	1%																																			
Kathy A Davis	Clinical Coordinator	Neurology	5%																																			
Julia L Spears	Project/Lab Manager	Neurology	5%																																			
R-100996-02	A Double-blind, Placebo-controlled, Multi-center, Multi-national Phase III Trial to Evaluate the Safety and Efficacy of Sarozotan HCl 1 mg b.i.d. in Patients with Parkinson's Disease Suffering from Treatment-associated Dyskinesias ( PADDY 2)	Merck KGaA through Monitoring Force USA, Inc.	09/01/2004 to 05/31/2007	16,640	4,160	\$20,800*																																
		<table border="1"> <tr> <td>Lawrence Elmer</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>					Lawrence Elmer	Principal Investigator	Neurology	5%																												
Lawrence Elmer	Principal Investigator	Neurology	5%																																			
C-100898-02	Post-Hypoxic Regulation of GABA-A Receptor Function	National Institute of Neurological Disorders and Stroke	01/01/2006 to 12/31/2010	174,780	84,419	\$259,199																																
		<table border="1"> <tr> <td>Lazar J Greenfield</td> <td>Principal Investigator</td> <td>Neurology</td> <td>25%</td> </tr> <tr> <td>Marthe Howard</td> <td>Co-Investigator</td> <td>Neurosci</td> <td>5%</td> </tr> <tr> <td>David Giovannucci</td> <td>Consultant</td> <td>Neurosci</td> <td>0%</td> </tr> <tr> <td>Elizabeth Tietz</td> <td>Consultant</td> <td>Phys-Pharm</td> <td>0%</td> </tr> </table>					Lazar J Greenfield	Principal Investigator	Neurology	25%	Marthe Howard	Co-Investigator	Neurosci	5%	David Giovannucci	Consultant	Neurosci	0%	Elizabeth Tietz	Consultant	Phys-Pharm	0%																
Lazar J Greenfield	Principal Investigator	Neurology	25%																																			
Marthe Howard	Co-Investigator	Neurosci	5%																																			
David Giovannucci	Consultant	Neurosci	0%																																			
Elizabeth Tietz	Consultant	Phys-Pharm	0%																																			
N-100994-01	A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis ( CombiRx-Phase III)	National Institute of Neurological Disorders and Stroke through Mount Sinai School of Medicine - New York City	08/01/2004 to 07/31/2009	16,560	4,140	\$20,700*																																
		<table border="1"> <tr> <td>Boyd Koffman</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Andrea Korsnack</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Noor Pirzada</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>					Boyd Koffman	Principal Investigator	Neurology	5%	Andrea Korsnack	Clinical Coordinator	Neurology	5%	Noor Pirzada	Co-Investigator	Neurology	5%																				
Boyd Koffman	Principal Investigator	Neurology	5%																																			
Andrea Korsnack	Clinical Coordinator	Neurology	5%																																			
Noor Pirzada	Co-Investigator	Neurology	5%																																			
N-101508-01	Novartis Protocol No. CFTY720D2309	Novartis	02/26/2007 to 02/25/2008	20,000	5,000	\$24,999*																																
		<table border="1"> <tr> <td>Boyd Koffman</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Kimberly A Cole</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Kimberly M Wilson</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>30%</td> </tr> <tr> <td>Vicki A Ramsey-Williams</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Noor Pirzada</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Andrea Korsnack</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Faizan Hafeez</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Mark Ramirez</td> <td>Co-Investigator</td> <td>Neurology-Resid Prgm</td> <td>5%</td> </tr> </table>					Boyd Koffman	Principal Investigator	Neurology	5%	Kimberly A Cole	Clinical Coordinator	Neurology	5%	Kimberly M Wilson	Clinical Coordinator	Neurology	30%	Vicki A Ramsey-Williams	Co-Investigator	Neurology	5%	Noor Pirzada	Co-Investigator	Neurology	5%	Andrea Korsnack	Co-Investigator	Neurology	5%	Faizan Hafeez	Co-Investigator	Neurology	5%	Mark Ramirez	Co-Investigator	Neurology-Resid Prgm	5%
Boyd Koffman	Principal Investigator	Neurology	5%																																			
Kimberly A Cole	Clinical Coordinator	Neurology	5%																																			
Kimberly M Wilson	Clinical Coordinator	Neurology	30%																																			
Vicki A Ramsey-Williams	Co-Investigator	Neurology	5%																																			
Noor Pirzada	Co-Investigator	Neurology	5%																																			
Andrea Korsnack	Co-Investigator	Neurology	5%																																			
Faizan Hafeez	Co-Investigator	Neurology	5%																																			
Mark Ramirez	Co-Investigator	Neurology-Resid Prgm	5%																																			

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																		
				Direct Cost	F&A Cost**	Total Cost																
<b>Neurology, Department of</b>																						
C-100719-03	Race, Psychiatric Comorbidity and Headache Disorders	National Institute of Neurological Disorders and Stroke through Ohio University	09/01/2003 to 07/31/2007	2,891	1,359	\$4,250																
		<table border="1"> <tr> <td>Gretchen Tietjen</td> <td>Principal Investigator</td> <td>Neurology</td> <td>3%</td> </tr> <tr> <td>Christine Utley</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>10%</td> </tr> <tr> <td>Jody Hamilton</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>10%</td> </tr> </table>			Gretchen Tietjen	Principal Investigator	Neurology	3%	Christine Utley	Clinical Coordinator	Neurology	10%	Jody Hamilton	Clinical Coordinator	Neurology	10%						
Gretchen Tietjen	Principal Investigator	Neurology	3%																			
Christine Utley	Clinical Coordinator	Neurology	10%																			
Jody Hamilton	Clinical Coordinator	Neurology	10%																			
N-100773-01	Safety and Efficacy of the STARFlex Septal Closure System vs Best Medical Therapy in Patients with a Stroke and/or Transient Ischemic Attack Due to a Presumed Paradoxical Embolism through a Patient Foramen Ovale (CLOSURE 1)	NMT Medical, Inc.	07/18/2003 to 05/19/2008	16,000	4,000	\$20,000*																
		<table border="1"> <tr> <td>Gretchen Tietjen</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>William R Colyer</td> <td>Co-Investigator</td> <td>Medicine</td> <td>5%</td> </tr> <tr> <td>Faizan Hafeez</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>William J Thomas</td> <td>Co-Investigator</td> <td>Medicine</td> <td>5%</td> </tr> </table>			Gretchen Tietjen	Principal Investigator	Neurology	5%	William R Colyer	Co-Investigator	Medicine	5%	Faizan Hafeez	Co-Investigator	Neurology	5%	William J Thomas	Co-Investigator	Medicine	5%		
Gretchen Tietjen	Principal Investigator	Neurology	5%																			
William R Colyer	Co-Investigator	Medicine	5%																			
Faizan Hafeez	Co-Investigator	Neurology	5%																			
William J Thomas	Co-Investigator	Medicine	5%																			
N-100875-01	PRoFESS - Prevention Regimen for Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel + Aspirin, with and without Micardis	Boehringer Ingelheim Pharmaceuticals, Inc.	03/26/2004 to 12/17/2008	3,674	919	\$4,593*																
		<table border="1"> <tr> <td>Gretchen Tietjen</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Andrea Korsnack</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Faizan Hafeez</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>			Gretchen Tietjen	Principal Investigator	Neurology	5%	Andrea Korsnack	Clinical Coordinator	Neurology	5%	Faizan Hafeez	Co-Investigator	Neurology	5%						
Gretchen Tietjen	Principal Investigator	Neurology	5%																			
Andrea Korsnack	Clinical Coordinator	Neurology	5%																			
Faizan Hafeez	Co-Investigator	Neurology	5%																			
N-101361-01	vWF as a Marker for Endothelial Dysfunction in Female Migraineurs	GlaxoSmithKline	11/01/2005 to 10/31/2008	69,089	17,272	\$86,361*																
		<table border="1"> <tr> <td>Gretchen Tietjen</td> <td>Principal Investigator</td> <td>Neurology</td> <td>10%</td> </tr> <tr> <td>Christine Utley</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>10%</td> </tr> <tr> <td>Bina Joe</td> <td>Co-Investigator</td> <td>Phys-Pharm</td> <td>10%</td> </tr> </table>			Gretchen Tietjen	Principal Investigator	Neurology	10%	Christine Utley	Clinical Coordinator	Neurology	10%	Bina Joe	Co-Investigator	Phys-Pharm	10%						
Gretchen Tietjen	Principal Investigator	Neurology	10%																			
Christine Utley	Clinical Coordinator	Neurology	10%																			
Bina Joe	Co-Investigator	Phys-Pharm	10%																			
N-101408-03	Insulin Resistance Intervention after Stroke (IRIS) Trial	National Institute of Neurological Disorders and Stroke through Yale University	07/01/2006 to 06/30/2009	5,593	1,454	\$7,047*																
		<table border="1"> <tr> <td>Gretchen Tietjen</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Andrea Korsnack</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Faizan Hafeez</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>			Gretchen Tietjen	Principal Investigator	Neurology	5%	Andrea Korsnack	Clinical Coordinator	Neurology	5%	Faizan Hafeez	Co-Investigator	Neurology	5%						
Gretchen Tietjen	Principal Investigator	Neurology	5%																			
Andrea Korsnack	Clinical Coordinator	Neurology	5%																			
Faizan Hafeez	Co-Investigator	Neurology	5%																			
N-101445-01	Double-blind, Single-migraine Attack, Placebo-controlled, Parallel-group Multi-center Study to Evaluate the Efficacy and Tolerability of TreximaTM (Sumatriptan Succinate/naproxen Sodium) Tablets vs Placebo when Administered During Mild Pain Phase of Menstrual Migraine in Women with Dysmenorrhea	GlaxoSmithKline	03/24/2006 to 03/23/2007	5,979	1,495	\$7,474*																
		<table border="1"> <tr> <td>Gretchen Tietjen</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Jody Hamilton</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Christine Utley</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Faizan Hafeez</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>			Gretchen Tietjen	Principal Investigator	Neurology	5%	Jody Hamilton	Clinical Coordinator	Neurology	5%	Christine Utley	Clinical Coordinator	Neurology	5%	Faizan Hafeez	Co-Investigator	Neurology	5%		
Gretchen Tietjen	Principal Investigator	Neurology	5%																			
Jody Hamilton	Clinical Coordinator	Neurology	5%																			
Christine Utley	Clinical Coordinator	Neurology	5%																			
Faizan Hafeez	Co-Investigator	Neurology	5%																			

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																		
				Direct Cost	F&A Cost**	Total Cost																
<b>Neurology, Department of</b>																						
N-101473-01	Adherence Evaluation After Ischemic Stroke Longitudinal Registry (AVAIL)	Bristol-Myers Squibb/Sanofi-Synthelabo Pharmaceuticals Partnership through Duke University	08/01/2006 to 07/18/2008	584	146	\$730*																
		<table border="1"> <tr> <td>Gretchen Tietjen</td> <td>Principal Investigator</td> <td>Neurology</td> <td>1%</td> </tr> <tr> <td>Andrea Korsnack</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>Faizan Hafeez</td> <td>Co-Investigator</td> <td>Neurology</td> <td>1%</td> </tr> </table>			Gretchen Tietjen	Principal Investigator	Neurology	1%	Andrea Korsnack	Clinical Coordinator	Neurology	5%	Faizan Hafeez	Co-Investigator	Neurology	1%						
Gretchen Tietjen	Principal Investigator	Neurology	1%																			
Andrea Korsnack	Clinical Coordinator	Neurology	5%																			
Faizan Hafeez	Co-Investigator	Neurology	1%																			
N-101515-01	A Study of Combination Product ( Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Eletriptan (Study 2 of 2) TRX106573	GlaxoSmithKline	11/13/2006 to 09/12/2008	15,478	3,869	\$19,347*																
		<table border="1"> <tr> <td>Gretchen Tietjen</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5%</td> </tr> </table>			Gretchen Tietjen	Principal Investigator	Neurology	5%														
Gretchen Tietjen	Principal Investigator	Neurology	5%																			
N-119919-01	Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension	Minster Research Ltd	10/31/2007 to 10/30/2008	2,940	735	\$3,675*																
		<table border="1"> <tr> <td>Gretchen Tietjen</td> <td>Principal Investigator</td> <td>Neurology</td> <td>5% CY</td> </tr> <tr> <td>Jody Hamilton</td> <td>Clinical Coordinator</td> <td>Neurology</td> <td>5% CY</td> </tr> <tr> <td>Faizan Hafeez</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5% CY</td> </tr> <tr> <td>Christine Utley</td> <td>Prof/Medical Support</td> <td>Neurology</td> <td>5% CY</td> </tr> </table>			Gretchen Tietjen	Principal Investigator	Neurology	5% CY	Jody Hamilton	Clinical Coordinator	Neurology	5% CY	Faizan Hafeez	Co-Investigator	Neurology	5% CY	Christine Utley	Prof/Medical Support	Neurology	5% CY		
Gretchen Tietjen	Principal Investigator	Neurology	5% CY																			
Jody Hamilton	Clinical Coordinator	Neurology	5% CY																			
Faizan Hafeez	Co-Investigator	Neurology	5% CY																			
Christine Utley	Prof/Medical Support	Neurology	5% CY																			
<b>Totals for Department of Neurology</b>			<b>34</b>	<b>599,223</b>	<b>191,222</b>	<b>\$790,445</b>																
<b>Neurosciences, Department of</b>																						
C-101364-02	Calcium Influx Mechanisms in Neuroendocrine & Carcinoid Tumor Cells	Raymond and Beverly Sackler Foundation	05/15/2006 to 04/30/2009	165,840	0	\$165,840																
		<table border="1"> <tr> <td>David Giovannucci</td> <td>Principal Investigator</td> <td>Neurosci</td> <td>35%</td> </tr> </table>			David Giovannucci	Principal Investigator	Neurosci	35%														
David Giovannucci	Principal Investigator	Neurosci	35%																			
C-100841-02	Mechanisms of Enteric Nervous System Development	National Institute of Diabetes, Digestive & Kidney Diseases	08/01/2005 to 07/31/2010	200,183	96,688	\$296,871																
		<table border="1"> <tr> <td>Marthe Howard</td> <td>Principal Investigator</td> <td>Neurosci</td> <td>40%</td> </tr> </table>			Marthe Howard	Principal Investigator	Neurosci	40%														
Marthe Howard	Principal Investigator	Neurosci	40%																			
R-100004-06-A1	Mechanisms of Sympathetic Neuron Development	National Institute of Neurological Disorders and Stroke	07/01/2000 to 12/31/2010	229,873	94,533	\$324,406																
		<table border="1"> <tr> <td>Marthe Howard</td> <td>Principal Investigator</td> <td>Neurosci</td> <td>35%</td> </tr> </table>			Marthe Howard	Principal Investigator	Neurosci	35%														
Marthe Howard	Principal Investigator	Neurosci	35%																			
N-101403-01	Altering Gene Expression and Function at Single Neuronal Nicotinic Synapses	National Institute on Drug Abuse	09/30/2006 to 08/31/2008	100,000	48,300	\$148,300																
		<table border="1"> <tr> <td>Joseph Margiotta</td> <td>Principal Investigator</td> <td>Neurosci</td> <td>30%</td> </tr> <tr> <td>Selwyn S Jayakar</td> <td>Grad Research Asst</td> <td>Neurosci</td> <td>50%</td> </tr> </table>			Joseph Margiotta	Principal Investigator	Neurosci	30%	Selwyn S Jayakar	Grad Research Asst	Neurosci	50%										
Joseph Margiotta	Principal Investigator	Neurosci	30%																			
Selwyn S Jayakar	Grad Research Asst	Neurosci	50%																			

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)				Proj Period Begin to Funding Cycle End		Current Year Award																		
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				Direct Cost	F&A Cost**	Total Cost																		
<b>Neurosciences, Department of</b>																										
N-100882-20-A2	Thalamocortical Boundary Markers and the Influence of Serotonin	National Institute of Neurological Disorders and Stroke through Washington University in St. Louis				05/05/2006 to 12/31/2010		184,022	88,883	272,905																
		<table border="1"> <tr> <td>Richard Mooney</td> <td>Principal Investigator</td> <td>Neurosci</td> <td>30%</td> </tr> <tr> <td>Nicolas Chiaia</td> <td>Co-Investigator</td> <td>Neurosci</td> <td>30%</td> </tr> <tr> <td>Richard Lane</td> <td>Co-Investigator</td> <td>Neurosci</td> <td>30%</td> </tr> </table>				Richard Mooney	Principal Investigator	Neurosci	30%	Nicolas Chiaia	Co-Investigator	Neurosci	30%	Richard Lane	Co-Investigator	Neurosci	30%									
Richard Mooney	Principal Investigator	Neurosci	30%																							
Nicolas Chiaia	Co-Investigator	Neurosci	30%																							
Richard Lane	Co-Investigator	Neurosci	30%																							
<b>Totals for Department of Neurosciences</b>						<b>5</b>	<b>879,918</b>	<b>328,404</b>	<b>1,208,322</b>																	
<b>Obstetrics &amp; Gynecology, Department of</b>																										
N-100685-01	A Double-blind, Placebo-controlled, Multi-center Clinical Trial of Intravenous Ovarex MAb-B43.13 as Post-chemotherapy Consolidation for Epithelial Carcinoma of Ovarian, Tubal or Peritoneal Origin	Unither Pharmaceuticals, Inc. Center		Center Affiliation: Cancer Center		03/13/2003 to 12/17/2008		6,480	1,620	8,100*																
		<table border="1"> <tr> <td>Stephen J Andrews</td> <td>Principal Investigator</td> <td>OB/GYN</td> <td>5%</td> </tr> <tr> <td>James Fanning</td> <td>Co-Investigator</td> <td>OB/GYN</td> <td>2%</td> </tr> <tr> <td>Angela Kueck</td> <td>Prof/Medical Support</td> <td>OB/GYN</td> <td>15%</td> </tr> </table>				Stephen J Andrews	Principal Investigator	OB/GYN	5%	James Fanning	Co-Investigator	OB/GYN	2%	Angela Kueck	Prof/Medical Support	OB/GYN	15%									
Stephen J Andrews	Principal Investigator	OB/GYN	5%																							
James Fanning	Co-Investigator	OB/GYN	2%																							
Angela Kueck	Prof/Medical Support	OB/GYN	15%																							
N-101138-01	A Double-Blind, Randomized, Multicenter Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (SB-497115-GR)	GlaxoSmithKline		Center Affiliation: Cancer Center		03/02/2005 to 05/25/2007		59,687	14,922	74,609*																
		<table border="1"> <tr> <td>Stephen J Andrews</td> <td>Principal Investigator</td> <td>OB/GYN</td> <td>3%</td> </tr> <tr> <td>Iman E Mohamed</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Paul R Walker</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Roland Skeel</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> </table>				Stephen J Andrews	Principal Investigator	OB/GYN	3%	Iman E Mohamed	Co-Investigator	Medicine	1%	Paul R Walker	Co-Investigator	Medicine	1%	Roland Skeel	Co-Investigator	Medicine	1%					
Stephen J Andrews	Principal Investigator	OB/GYN	3%																							
Iman E Mohamed	Co-Investigator	Medicine	1%																							
Paul R Walker	Co-Investigator	Medicine	1%																							
Roland Skeel	Co-Investigator	Medicine	1%																							
N-101245-01	An Open-label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL/CAELYX and YONDELIS with DOXIL/CAELYX Alone in Subjects with Advanced Relapsed Ovarian Cancer	Johnson & Johnson Pharmaceutical Services, LLC				Center Affiliation: Cancer Center		06/17/2005 to 04/30/2009		52,000	13,000	65,000*														
		<table border="1"> <tr> <td>Stephen J Andrews</td> <td>Principal Investigator</td> <td>OB/GYN</td> <td>2%</td> </tr> <tr> <td>Sarah J Lyons</td> <td>Clinical Coordinator</td> <td>Cancer Inst</td> <td>20%</td> </tr> </table>				Stephen J Andrews	Principal Investigator	OB/GYN	2%	Sarah J Lyons	Clinical Coordinator	Cancer Inst	20%													
Stephen J Andrews	Principal Investigator	OB/GYN	2%																							
Sarah J Lyons	Clinical Coordinator	Cancer Inst	20%																							
N-101411-01	Multicenter, Randomized, Open-label, Parallel-arm, 2-stage Study of AVE0005 ( VEGF Trap) Administered Intravenously Every 2 Weeks in Patients w/Platinum-and Taxane-resistant, plus Topotecan-and/or Liposomal Doxorubicin-resistant, Advanced Ovarian Cancer	Sanofi-Aventis Group		Center Affiliation: Cancer Center		11/06/2006 to 11/05/2008		4,800	1,200	6,000*																
		<table border="1"> <tr> <td>Stephen J Andrews</td> <td>Principal Investigator</td> <td>OB/GYN</td> <td>5%</td> </tr> <tr> <td>Sarah J Lyons</td> <td>Co-Investigator</td> <td>Cancer Inst</td> <td>10%</td> </tr> <tr> <td>Angela Kueck</td> <td>Co-Investigator</td> <td>OB/GYN</td> <td>2%</td> </tr> </table>				Stephen J Andrews	Principal Investigator	OB/GYN	5%	Sarah J Lyons	Co-Investigator	Cancer Inst	10%	Angela Kueck	Co-Investigator	OB/GYN	2%									
Stephen J Andrews	Principal Investigator	OB/GYN	5%																							
Sarah J Lyons	Co-Investigator	Cancer Inst	10%																							
Angela Kueck	Co-Investigator	OB/GYN	2%																							

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																					
				Direct Cost	F&A Cost**	Total Cost																			
<b>Obstetrics &amp; Gynecology, Department of</b>																									
N-101128-01	A 12-Month Open-Label, Multicenter Study to Evaluate the Safety of a 1.3g Oral Dose of a New Modified-Release Tranexamic Acid Formulation	Xanodyne Pharmaceutical Inc.	12/13/2004 to 12/12/2008	45,145	11,286	\$56,431*																			
		<table border="1"> <tr> <td>Terrence Horrigan</td> <td>Principal Investigator</td> <td>OB/GYN</td> <td>1%</td> </tr> <tr> <td>Peggy Fitzgerald</td> <td>Clinical Coordinator</td> <td>OB/GYN</td> <td>50%</td> </tr> <tr> <td>Judith Lamp</td> <td>Co-Investigator</td> <td>Col Nursing</td> <td>1%</td> </tr> <tr> <td>Thomas Mehelas</td> <td>Co-Investigator</td> <td>Surgery</td> <td>2%</td> </tr> <tr> <td>Lynda Wolf</td> <td>Co-Investigator</td> <td>OB/GYN</td> <td>1%</td> </tr> </table>	Terrence Horrigan	Principal Investigator	OB/GYN	1%	Peggy Fitzgerald	Clinical Coordinator	OB/GYN	50%	Judith Lamp	Co-Investigator	Col Nursing	1%	Thomas Mehelas	Co-Investigator	Surgery	2%	Lynda Wolf	Co-Investigator	OB/GYN	1%			
Terrence Horrigan	Principal Investigator	OB/GYN	1%																						
Peggy Fitzgerald	Clinical Coordinator	OB/GYN	50%																						
Judith Lamp	Co-Investigator	Col Nursing	1%																						
Thomas Mehelas	Co-Investigator	Surgery	2%																						
Lynda Wolf	Co-Investigator	OB/GYN	1%																						
N-101378-01	A Double-blind, Randomized, Placebo- and Active Controlled Efficacy and Safety of Bazedoxifene/Conjugated Estrogens Combinations for Treatment of Moderate to Severe Vulvar/Vaginal Atrophy in Postmenopausal Women	Wyeth Pharmaceuticals	03/21/2006 to 03/20/2008	20,552	5,138	\$25,691*																			
		<table border="1"> <tr> <td>Terrence Horrigan</td> <td>Principal Investigator</td> <td>OB/GYN</td> <td>5%</td> </tr> <tr> <td>Peggy Fitzgerald</td> <td>Clinical Coordinator</td> <td>OB/GYN</td> <td>5%</td> </tr> <tr> <td>Sybille K Gendaszek</td> <td>Co-Investigator</td> <td>OP CLINIC-OB-GYN</td> <td>8%</td> </tr> </table>	Terrence Horrigan	Principal Investigator	OB/GYN	5%	Peggy Fitzgerald	Clinical Coordinator	OB/GYN	5%	Sybille K Gendaszek	Co-Investigator	OP CLINIC-OB-GYN	8%											
Terrence Horrigan	Principal Investigator	OB/GYN	5%																						
Peggy Fitzgerald	Clinical Coordinator	OB/GYN	5%																						
Sybille K Gendaszek	Co-Investigator	OP CLINIC-OB-GYN	8%																						
<b>Totals for Department of Obstetrics and Gynecology</b>			<b>6</b>	<b>188,664</b>	<b>47,166</b>	<b>\$235,830</b>																			
<b>Orthopaedic Surgery, Department of</b>																									
N-101528-01	A Retrospective Study of the Use of INFUSE Bone Graft in Clinical Practice	Medtronic Sofamor Danet USA, Inc,	11/30/2006 to 11/29/2008	3,600	900	\$4,500*																			
		<table border="1"> <tr> <td>Ashok Biyani</td> <td>Principal Investigator</td> <td>Ortho Surg</td> <td>10%</td> </tr> <tr> <td>Wendy E Boone</td> <td>Clinical Coordinator</td> <td>CCR</td> <td>3%</td> </tr> <tr> <td>Zeshan Muhammad Chaudhry</td> <td>Research Associate</td> <td>CCR</td> <td>5%</td> </tr> </table>	Ashok Biyani	Principal Investigator	Ortho Surg	10%	Wendy E Boone	Clinical Coordinator	CCR	3%	Zeshan Muhammad Chaudhry	Research Associate	CCR	5%											
Ashok Biyani	Principal Investigator	Ortho Surg	10%																						
Wendy E Boone	Clinical Coordinator	CCR	3%																						
Zeshan Muhammad Chaudhry	Research Associate	CCR	5%																						
N-101495-01	Ascension PIP Follow-up Study	Ascension Orthopedics, Inc.	10/01/2006 to 09/30/2009	560	140	\$700*																			
		<table border="1"> <tr> <td>Martin Skie</td> <td>Principal Investigator</td> <td>Ortho Surg</td> <td>3%</td> </tr> </table>	Martin Skie	Principal Investigator	Ortho Surg	3%																			
Martin Skie	Principal Investigator	Ortho Surg	3%																						
<b>Totals for Department of Orthopaedic Surgery</b>			<b>2</b>	<b>4,160</b>	<b>1,040</b>	<b>\$5,200</b>																			
<b>Orthopedics</b>																									
N-120009-01	Biomechanical Analysis Comparing Three C1-2 Transarticular Screw Salvaging Fixation Techniques	Synthes Spine Co	06/30/2007 to 06/29/2008	24,000	6,000	\$30,000																			
		<table border="1"> <tr> <td>Hossein Elgafy</td> <td>Principal Investigator</td> <td>Ortho Surg</td> <td>5%</td> </tr> <tr> <td>Vijay K Goel</td> <td>Co-Investigator</td> <td>Ortho Surg</td> <td>5%</td> </tr> </table>	Hossein Elgafy	Principal Investigator	Ortho Surg	5%	Vijay K Goel	Co-Investigator	Ortho Surg	5%															
Hossein Elgafy	Principal Investigator	Ortho Surg	5%																						
Vijay K Goel	Co-Investigator	Ortho Surg	5%																						
<b>Totals for Department of Orthopedics</b>			<b>1</b>	<b>24,000</b>	<b>6,000</b>	<b>\$30,000</b>																			

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Pediatrics, Department of</b>						
C-010845-07	Genetic Epidemiology of Lung Cancer: Gene ID in High Risk Families	National Cancer Institute through University of Cincinnati	09/01/2006 to 08/31/2010	14,776	7,137	\$21,913
		Colette Gaba	Principal Investigator	Pediatrics	33%	
N-100438-01	Genentech National Cooperative Growth Study (NCGS) Post Marketing Surveillance Program for Nutropin Depot, Nutropin AQ and Protropin	Genentech, Inc.	05/01/2002 to 12/31/2008	1,380	345	\$1,725*
		James Horner	Principal Investigator	Pediatrics	1%	
C-010085-28	Regional Comprehensive Genetic Services	Ohio Department of Health - Federal Pass-Through Funds	10/01/1979 to 06/30/2007	170,000	0	\$170,000
		David Krol	Principal Investigator	Pediatrics	7%	
		Beatrice French	Co-Investigator	Pediatrics	64%	
		Colette Gaba	Co-Investigator	Pediatrics	44%	
		Thaddeus Kurczynski	Prof/Medical Support	Children's Hospital & Medical Center of Akron	7%	
S-010085-28-S1	Regional Comprehensive Genetic Services	Ohio Department of Health - Federal Pass-Through Funds	10/01/1979 to 06/30/2007	49,500	0	\$49,500
		David Krol	Principal Investigator	Pediatrics	0%	
		Thaddeus Kurczynski	Prof/Medical Support	Children's Hospital & Medical Center of Akron	0%	
N-101030-01	An Epidemiologic Study of Xolair (Ornalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)	Genentech, Inc.	11/08/2004 to 06/30/2006	3,038	760	\$3,798*
		Lois Nelson	Principal Investigator	Pediatrics	3%	
R-101054-03	Reach Out and Read	Ohio Department of Jobs and Family Services	07/03/2006 to 06/30/2007	45,455	4,545	\$50,000
		Valarie S Ruiz	Principal Investigator	Pediatrics	5%	
		Lori R Legendre	Co-Investigator	Pediatrics	36%	
S-101054-03-S1	Reach Out and Read	Ohio Department of Jobs and Family Services	07/03/2006 to 06/30/2007	12,054	1,205	\$13,259
		Valarie S Ruiz	Principal Investigator	Pediatrics	5%	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																						
				Direct Cost	F&A Cost**	Total Cost																				
<b>Pediatrics, Department of</b>																										
C-010099-20	Hospital-Based Regional Child Find Grant Program	Ohio Department of Health - Federal Pass-Through Funds	04/01/1988 to 09/30/2007	32,000	0	\$32,000																				
		<table border="1"> <tr> <td>Randall Schlievert</td> <td>Principal Investigator</td> <td>Pediatrics</td> <td>5%</td> </tr> <tr> <td>Rachel Collin</td> <td>Co-Investigator</td> <td>Pediatrics</td> <td>50%</td> </tr> </table>			Randall Schlievert	Principal Investigator	Pediatrics	5%	Rachel Collin	Co-Investigator	Pediatrics	50%														
Randall Schlievert	Principal Investigator	Pediatrics	5%																							
Rachel Collin	Co-Investigator	Pediatrics	50%																							
C-101166-03	Hospital-Based Regional Child Find Grant Program	Mercy Children's Hospital	10/01/2004 to 09/30/2007	12,214	0	\$12,214																				
		<table border="1"> <tr> <td>Randall Schlievert</td> <td>Principal Investigator</td> <td>Pediatrics</td> <td>5%</td> </tr> <tr> <td>Rachel Collin</td> <td>Co-Investigator</td> <td>Pediatrics</td> <td>19%</td> </tr> </table>			Randall Schlievert	Principal Investigator	Pediatrics	5%	Rachel Collin	Co-Investigator	Pediatrics	19%														
Randall Schlievert	Principal Investigator	Pediatrics	5%																							
Rachel Collin	Co-Investigator	Pediatrics	19%																							
N-101486-01	Regional Child Find	Lucas County Family Council - Federal Pass-Through Funds through Board of County (Lucas) Commissioners	10/01/2006 to 06/30/2007	15,000	0	\$15,000																				
		<table border="1"> <tr> <td>Randall Schlievert</td> <td>Principal Investigator</td> <td>Pediatrics</td> <td>5%</td> </tr> <tr> <td>Rachel Collin</td> <td>Clinical Coordinator</td> <td>Pediatrics</td> <td>31%</td> </tr> </table>			Randall Schlievert	Principal Investigator	Pediatrics	5%	Rachel Collin	Clinical Coordinator	Pediatrics	31%														
Randall Schlievert	Principal Investigator	Pediatrics	5%																							
Rachel Collin	Clinical Coordinator	Pediatrics	31%																							
N-119840-01	Project DOCC (Delivery of Chronic Care)	Ohio Developmental Disabilities Council - Federal Pass-through through Toledo Hospital	01/01/2007 to 12/31/2007	800	200	\$1,000																				
		<table border="1"> <tr> <td>Randall Schlievert</td> <td>Principal Investigator</td> <td>Pediatrics</td> <td>1%</td> </tr> </table>			Randall Schlievert	Principal Investigator	Pediatrics	1%																		
Randall Schlievert	Principal Investigator	Pediatrics	1%																							
<b>Totals for Department of Pediatrics</b>			<b>11</b>	<b>356,217</b>	<b>14,192</b>	<b>\$370,409</b>																				
<b>Phys Pharm Met/Cardio Science, Department of</b>																										
C-010087-20	Control Mechanisms of Cardiac Proteins & Enzymes	National Heart, Lung & Blood Institute	07/01/1986 to 02/28/2009	1,015,475	354,701	\$1,370,176																				
		<table border="1"> <tr> <td>Amir Askari</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>30%</td> </tr> <tr> <td>Lijun Liu</td> <td>Co-Investigator</td> <td>Phys-Pharm</td> <td>100%</td> </tr> <tr> <td>Nikolai Modyanov</td> <td>Co-Investigator</td> <td>Phys-Pharm</td> <td>40%</td> </tr> <tr> <td>Sandrine Pierre</td> <td>Co-Investigator</td> <td>Phys-Pharm</td> <td>54%</td> </tr> <tr> <td>Zi-Jian Xie</td> <td>Co-Investigator</td> <td>Phys-Pharm</td> <td>25%</td> </tr> </table>			Amir Askari	Principal Investigator	Phys-Pharm	30%	Lijun Liu	Co-Investigator	Phys-Pharm	100%	Nikolai Modyanov	Co-Investigator	Phys-Pharm	40%	Sandrine Pierre	Co-Investigator	Phys-Pharm	54%	Zi-Jian Xie	Co-Investigator	Phys-Pharm	25%		
Amir Askari	Principal Investigator	Phys-Pharm	30%																							
Lijun Liu	Co-Investigator	Phys-Pharm	100%																							
Nikolai Modyanov	Co-Investigator	Phys-Pharm	40%																							
Sandrine Pierre	Co-Investigator	Phys-Pharm	54%																							
Zi-Jian Xie	Co-Investigator	Phys-Pharm	25%																							
C-010310-30	Biochemistry and Genetics of Hypertension	National Heart, Lung & Blood Institute	06/01/1986 to 11/30/2008	421,688	198,193	\$619,881																				
		<table border="1"> <tr> <td>Bina Joe</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>30%</td> </tr> </table>			Bina Joe	Principal Investigator	Phys-Pharm	30%																		
Bina Joe	Principal Investigator	Phys-Pharm	30%																							
C-100722-04	Functional Genomic Dissection of Rat Blood Pressure QTL	National Heart, Lung & Blood Institute	07/01/2004 to 05/31/2008	284,051	55,618	\$339,669																				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)	Proj Period Begin to Funding Cycle End	Current Year Award																		
					Direct Cost	F&A Cost**	Total Cost																
<b>Phys Pharm Met/Cardio Science, Department of</b>																							
C-010991-07	Ceacam and Insulin Action	National Institute of Diabetes, Digestive & Kidney Diseases	<table border="1"> <tr> <td>Bina Joe</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>34%</td> </tr> <tr> <td>Norman Lee</td> <td>Co-Investigator</td> <td>George Washington University</td> <td>15%</td> </tr> </table>	Bina Joe	Principal Investigator	Phys-Pharm	34%	Norman Lee	Co-Investigator	George Washington University	15%	03/01/2000 to 02/28/2009	208,600	100,754	\$309,354								
Bina Joe	Principal Investigator	Phys-Pharm	34%																				
Norman Lee	Co-Investigator	George Washington University	15%																				
R-101255-02	Dietary and Genetic Risk Factors in Obesity and Diabetes	U.S. Department of Agriculture through University of Toledo, Main Campus	<table border="1"> <tr> <td>Sonia Najjar</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>14%</td> </tr> <tr> <td>Ana Maria Oyarce</td> <td>Co-Investigator</td> <td>Phys-Pharm</td> <td>10%</td> </tr> </table>	Sonia Najjar	Principal Investigator	Phys-Pharm	14%	Ana Maria Oyarce	Co-Investigator	Phys-Pharm	10%	09/01/2005 to 08/31/2007	166,989	63,011	\$230,000								
Sonia Najjar	Principal Investigator	Phys-Pharm	14%																				
Ana Maria Oyarce	Co-Investigator	Phys-Pharm	10%																				
C-100917-11	Physiological Significance of Na, K-pump Diversity	National Center for Research Resources through Texas Tech University	<table border="1"> <tr> <td>Sonia Najjar</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>10%</td> </tr> <tr> <td>Abraham Lee</td> <td>Co-Investigator</td> <td>Physical Ther</td> <td>10%</td> </tr> <tr> <td>Ana Maria Oyarce</td> <td>Co-Investigator</td> <td>Phys-Pharm</td> <td>15%</td> </tr> <tr> <td>William Sodeman</td> <td>Prof/Medical Support</td> <td>Medicine</td> <td>0%</td> </tr> </table>	Sonia Najjar	Principal Investigator	Phys-Pharm	10%	Abraham Lee	Co-Investigator	Physical Ther	10%	Ana Maria Oyarce	Co-Investigator	Phys-Pharm	15%	William Sodeman	Prof/Medical Support	Medicine	0%	09/26/2005 to 06/30/2007	37,574	18,148	\$55,722
Sonia Najjar	Principal Investigator	Phys-Pharm	10%																				
Abraham Lee	Co-Investigator	Physical Ther	10%																				
Ana Maria Oyarce	Co-Investigator	Phys-Pharm	15%																				
William Sodeman	Prof/Medical Support	Medicine	0%																				
C-101230-02	Characterizing the RAD51D E233G High-Risk Breast Cancer Allele	Ohio Cancer Research Associates	<table border="1"> <tr> <td>Sandrine Pierre</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>20%</td> </tr> <tr> <td>Zi-Jian Xie</td> <td>Consultant</td> <td>Phys-Pharm</td> <td>5%</td> </tr> </table>	Sandrine Pierre	Principal Investigator	Phys-Pharm	20%	Zi-Jian Xie	Consultant	Phys-Pharm	5%	07/01/2005 to 06/30/2008	22,727	2,273	\$25,000								
Sandrine Pierre	Principal Investigator	Phys-Pharm	20%																				
Zi-Jian Xie	Consultant	Phys-Pharm	5%																				
C-100995-02	TPR Proteins in Steroid Receptor Signaling and Physiology	National Institute of Diabetes, Digestive & Kidney Diseases	<table border="1"> <tr> <td>Douglas L Pittman</td> <td>Principal Investigator</td> <td>University of South Carolina</td> <td>1%</td> </tr> <tr> <td>Randall Ruch</td> <td>Co-Principal Investigator</td> <td>BIOCHEM</td> <td>5%</td> </tr> <tr> <td>Aditi A Nadkarni</td> <td>Grad Research Asst</td> <td>Phys-Pharm</td> <td>100%</td> </tr> </table>	Douglas L Pittman	Principal Investigator	University of South Carolina	1%	Randall Ruch	Co-Principal Investigator	BIOCHEM	5%	Aditi A Nadkarni	Grad Research Asst	Phys-Pharm	100%	08/01/2005 to 06/30/2010	191,266	56,640	\$247,906				
Douglas L Pittman	Principal Investigator	University of South Carolina	1%																				
Randall Ruch	Co-Principal Investigator	BIOCHEM	5%																				
Aditi A Nadkarni	Grad Research Asst	Phys-Pharm	100%																				
C-101192-02	Role of FKBP52 in Androgen Signaling and Hypospadias	National Institute of Diabetes, Digestive & Kidney Diseases through Indiana University	<table border="1"> <tr> <td>Edwin Sanchez</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>25%</td> </tr> </table> <table border="1"> <tr> <td>Edwin Sanchez</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>15%</td> </tr> <tr> <td>Sumudra Periyasamy</td> <td>Co-Investigator</td> <td>Phys-Pharm</td> <td>30%</td> </tr> </table>	Edwin Sanchez	Principal Investigator	Phys-Pharm	25%	Edwin Sanchez	Principal Investigator	Phys-Pharm	15%	Sumudra Periyasamy	Co-Investigator	Phys-Pharm	30%	02/01/2006 to 12/31/2007	53,945	26,055	\$80,000				
Edwin Sanchez	Principal Investigator	Phys-Pharm	25%																				
Edwin Sanchez	Principal Investigator	Phys-Pharm	15%																				
Sumudra Periyasamy	Co-Investigator	Phys-Pharm	30%																				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award													
				Direct Cost	F&A Cost**	Total Cost											
<b>Phys Pharm Met/Cardio Science, Department of</b>																	
N-101192-01-A1	Role of FKBP52 in Androgen Signaling and Hypospadias	National Institute of Diabetes, Digestive & Kidney Diseases through Indiana University	02/01/2006 to 12/31/2006	57,145	27,601	\$84,746											
		<table border="1"> <tr> <td>Edwin Sanchez</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>15%</td> </tr> <tr> <td>Sumudra Periyasamy</td> <td>Co-Investigator</td> <td>Phys-Pharm</td> <td>30%</td> </tr> </table>	Edwin Sanchez	Principal Investigator	Phys-Pharm	15%	Sumudra Periyasamy	Co-Investigator	Phys-Pharm	30%							
Edwin Sanchez	Principal Investigator	Phys-Pharm	15%														
Sumudra Periyasamy	Co-Investigator	Phys-Pharm	30%														
C-100889-03	Benzodiazepine-induced Glutamate Receptor Plasticity	National Institute on Drug Abuse	04/01/2005 to 03/31/2010	189,636	77,988	\$267,624											
		<table border="1"> <tr> <td>Elizabeth Tietz</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>40%</td> </tr> <tr> <td>Lazar J Greenfield</td> <td>Co-Investigator</td> <td>Neurology</td> <td>5%</td> </tr> <tr> <td>William T Gunning</td> <td>Co-Investigator</td> <td>BIOCHEM</td> <td>2%</td> </tr> </table>	Elizabeth Tietz	Principal Investigator	Phys-Pharm	40%	Lazar J Greenfield	Co-Investigator	Neurology	5%	William T Gunning	Co-Investigator	BIOCHEM	2%			
Elizabeth Tietz	Principal Investigator	Phys-Pharm	40%														
Lazar J Greenfield	Co-Investigator	Neurology	5%														
William T Gunning	Co-Investigator	BIOCHEM	2%														
N-101555-01	Receptor Dependent Regulation of Calcium Permeable TRPC1 and TRPC3 Cation Channels in Human Coronary Artery Endothelium	American Heart Association - National	04/01/2007 to 03/28/2011	59,091	5,909	\$65,000											
		<table border="1"> <tr> <td>Guillermo Vazquez</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>55%</td> </tr> </table>	Guillermo Vazquez	Principal Investigator	Phys-Pharm	55%											
Guillermo Vazquez	Principal Investigator	Phys-Pharm	55%														
C-101321-02	Mechanism Of Temperature-Dependent Export of DeltaF508 CFTR	Cystic Fibrosis Foundation	04/01/2006 to 03/31/2008	90,000	7,200	\$97,200											
		<table border="1"> <tr> <td>Xiaodong Wang</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>30%</td> </tr> </table>	Xiaodong Wang	Principal Investigator	Phys-Pharm	30%											
Xiaodong Wang	Principal Investigator	Phys-Pharm	30%														
N-101479-01	Immunophilins Regulate the Export of Ion Channels from the Endoplasmic Reticulum	American Heart Association - National	01/01/2007 to 12/31/2010	59,091	5,909	\$65,000											
		<table border="1"> <tr> <td>Xiaodong Wang</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>20%</td> </tr> </table>	Xiaodong Wang	Principal Investigator	Phys-Pharm	20%											
Xiaodong Wang	Principal Investigator	Phys-Pharm	20%														
C-100186-05	The Role of ROS and Na/K-ATPase in Uremic Cardiomyopathy	National Heart, Lung & Blood Institute	07/25/2002 to 06/30/2008	170,888	80,317	\$251,205											
		<table border="1"> <tr> <td>Zi-Jian Xie</td> <td>Principal Investigator</td> <td>Phys-Pharm</td> <td>30%</td> </tr> <tr> <td>Joseph Shapiro</td> <td>Co-Investigator</td> <td>Medicine</td> <td>10%</td> </tr> </table>	Zi-Jian Xie	Principal Investigator	Phys-Pharm	30%	Joseph Shapiro	Co-Investigator	Medicine	10%							
Zi-Jian Xie	Principal Investigator	Phys-Pharm	30%														
Joseph Shapiro	Co-Investigator	Medicine	10%														
<b>Totals for Department of Physiology, Pharmacology, Metabolism, and Cardiovascular Science</b>			<b>15</b>	<b>3,028,166</b>	<b>1,080,317</b>	<b>\$4,108,483</b>											
<b>Psychiatry, Department of</b>																	
C-101317-02	Child and Adolescent Public Psychiatry Residency/Traineeship Program	Ohio Department of Mental Health	07/01/2005 to 06/30/2007	28,571	1,429	\$30,000											

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Psychiatry, Department of</b>						
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				
		Mary K Smith Principal Investigator Psychiatry 1%				
		Mary-Jo Swartzberg Data/Clerical Support Psychiatry 33%				
		Dianne M Adams Data/Clerical Support Psychiatry 12%				
		John W Edinger Prof/Medical Support Psychiatry 1%				
		Michele Knox Prof/Medical Support Psychiatry 1%				
		Theodor B Rais Prof/Medical Support Psychiatry 1%				
		Joel Zrull Prof/Medical Support Psychiatry 1%				
R-010532-12	Public Psychiatry Residency/Traineeship	Ohio Department of Mental Health	07/01/1995 to 06/30/2007	69,552	3,478	\$73,030
		Mary K Smith Principal Investigator Psychiatry 20%				
<b>Totals for Department of Psychiatry</b>			<b>2</b>	<b>98,123</b>	<b>4,907</b>	<b>\$103,030</b>
<b>Public Hlth/Homeland Security, Department of</b>						
C-100252-07	Project EXCITE: Environmental Health Science Explorations through Cross-Disciplinary and Investigative Team Experiences	National Institute of Environmental Health Sciences through Bowling Green State University	09/15/2000 to 08/31/2008	3,989	319	\$4,308
		Michael Bisesi Principal Investigator Pub Hlth/Hmlnd Sec 3%				
C-101313-02	Occupational Health Training Grant	National Institute for Occupational Safety and Health	07/01/2001 to 06/30/2009	84,582	2,610	\$87,192
		Michael Bisesi Principal Investigator Pub Hlth/Hmlnd Sec 70%				
		Farhang Akbar-Khanzadeh Co-Investigator Pub Hlth/Hmlnd Sec 70%				
		Michael Dennis Co-Investigator Radiology 5%				
		Brian Harrington Co-Investigator Pub Hlth/Hmlnd Sec 20%				
		Hailu Kassa Co-Investigator Pub Hlth/Hmlnd Sec 5%				
		Charles Keil Co-Investigator Pub Hlth/Hmlnd Sec 5%				
		Sadik Khuder Co-Investigator Medicine 30%				
		Sheryl Milz Co-Investigator Pub Hlth/Hmlnd Sec 50%				
C-101325-02	Public Health Workforce Scholarship Program	Ohio Department of Health - Federal Pass-Through Funds through Ohio State University Research Foundation	04/22/2005 to 08/31/2010	67,500	5,400	\$72,900
		Michael Bisesi Principal Investigator Pub Hlth/Hmlnd Sec 1%				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																			
				Direct Cost	F&A Cost**	Total Cost																	
<b>Public Hlth/Homeland Security, Department of</b>																							
N-101565-01	Professional Services to Perform Facets Towards the Development and Execution of a Functional Biological Exercise for the Northwest Ohio Regional Medical Response System 2007	City of Toledo	02/01/2007 to 08/01/2008	57,644	11,356	\$69,000																	
		<table border="1"> <tr> <td>Michael Bisesi</td> <td>Principal Investigator</td> <td>Pub Hlth/Hmlnd Sec</td> <td>3%</td> </tr> <tr> <td>Farhang Akbar-Khanzadeh</td> <td>Co-Investigator</td> <td>Pub Hlth/Hmlnd Sec</td> <td>1%</td> </tr> <tr> <td>Christopher Bork</td> <td>Co-Investigator</td> <td>Pub Hlth/Hmlnd Sec</td> <td>3%</td> </tr> <tr> <td>Brian Harrington</td> <td>Co-Investigator</td> <td>Pub Hlth/Hmlnd Sec</td> <td>1%</td> </tr> </table>			Michael Bisesi	Principal Investigator	Pub Hlth/Hmlnd Sec	3%	Farhang Akbar-Khanzadeh	Co-Investigator	Pub Hlth/Hmlnd Sec	1%	Christopher Bork	Co-Investigator	Pub Hlth/Hmlnd Sec	3%	Brian Harrington	Co-Investigator	Pub Hlth/Hmlnd Sec	1%			
Michael Bisesi	Principal Investigator	Pub Hlth/Hmlnd Sec	3%																				
Farhang Akbar-Khanzadeh	Co-Investigator	Pub Hlth/Hmlnd Sec	1%																				
Christopher Bork	Co-Investigator	Pub Hlth/Hmlnd Sec	3%																				
Brian Harrington	Co-Investigator	Pub Hlth/Hmlnd Sec	1%																				
<b>Totals for Department of Public Health/Homeland Security</b>			<b>4</b>	<b>213,715</b>	<b>19,685</b>	<b>\$233,400</b>																	
<b>Radiation Oncology, Department of</b>																							
N-100901-01	Phase V Registry Trial	Proxima Therapeutics through American Society of Breast Surgeons, Inc. Center Affiliation: Cancer Center	01/01/2004 to 12/31/2006	20	5	\$25*																	
		<table border="1"> <tr> <td>John Feldmeier</td> <td>Principal Investigator</td> <td>Rad Oncol</td> <td>10%</td> </tr> <tr> <td>Sarah J Lyons</td> <td>Co-Investigator</td> <td>Cancer Inst</td> <td>15%</td> </tr> <tr> <td>Edgar Staren</td> <td>Co-Investigator</td> <td>Surgery</td> <td>10%</td> </tr> </table>			John Feldmeier	Principal Investigator	Rad Oncol	10%	Sarah J Lyons	Co-Investigator	Cancer Inst	15%	Edgar Staren	Co-Investigator	Surgery	10%							
John Feldmeier	Principal Investigator	Rad Oncol	10%																				
Sarah J Lyons	Co-Investigator	Cancer Inst	15%																				
Edgar Staren	Co-Investigator	Surgery	10%																				
N-101412-01	Toledo Community Clinical Oncology Program (TCCOP)	National Cancer Institute through Toledo Community Hospital Oncology Program	06/01/2006 to 05/31/2007	2,160	540	\$2,700*																	
		<table border="1"> <tr> <td>John Feldmeier</td> <td>Principal Investigator</td> <td>Rad Oncol</td> <td>5%</td> </tr> <tr> <td>Sarah J Lyons</td> <td>Clinical Coordinator</td> <td>Cancer Inst</td> <td>10%</td> </tr> <tr> <td>Wendy E Boone</td> <td>Clinical Coordinator</td> <td>CCR</td> <td>2%</td> </tr> </table>			John Feldmeier	Principal Investigator	Rad Oncol	5%	Sarah J Lyons	Clinical Coordinator	Cancer Inst	10%	Wendy E Boone	Clinical Coordinator	CCR	2%							
John Feldmeier	Principal Investigator	Rad Oncol	5%																				
Sarah J Lyons	Clinical Coordinator	Cancer Inst	10%																				
Wendy E Boone	Clinical Coordinator	CCR	2%																				
<b>Totals for Department of Radiation Oncology</b>			<b>2</b>	<b>2,180</b>	<b>545</b>	<b>\$2,725</b>																	
<b>Radiology, Department of</b>																							
N-101263-01	Multi-centre, Randomized, Double-blind, Parallel Group, Phase IV Study to Compare Renal Effects of Non-ionic Iso-osmolar Contrast Medium with a Non-ionic Low Osmolar Contrast Medium in Subjects with Impaired Renal Function and Diabetes	GE Healthcare	06/16/2005 to 06/15/2008	8,900	2,225	\$11,125*																	
		<table border="1"> <tr> <td>Haitham M Elsamaloty</td> <td>Principal Investigator</td> <td>Radiology</td> <td>3%</td> </tr> <tr> <td>Mark Burket</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> <tr> <td>William R Colyer</td> <td>Co-Investigator</td> <td>Medicine</td> <td>2%</td> </tr> </table>			Haitham M Elsamaloty	Principal Investigator	Radiology	3%	Mark Burket	Co-Investigator	Medicine	2%	William R Colyer	Co-Investigator	Medicine	2%							
Haitham M Elsamaloty	Principal Investigator	Radiology	3%																				
Mark Burket	Co-Investigator	Medicine	2%																				
William R Colyer	Co-Investigator	Medicine	2%																				
<b>Totals for Department of Radiology</b>			<b>1</b>	<b>8,900</b>	<b>2,225</b>	<b>\$11,125</b>																	
<b>Surgery, Department of</b>																							

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Surgery, Department of</b>						
N-101225-01	A Non-randomized, Prospective Study of IVC Filter Retrieval Out to 12 Weeks without Interim Filter Manipulation Utilizing the Gunther Tulip Vena Cava Filter	Cook, Inc.	05/11/2005 to 05/10/2007	100	25	\$125*
		Jihad T Abbas	Principal Investigator	Surgery	10%	
		Khaled Khechen	Clinical Coordinator	Surgery	2%	
		Munier M Nazzal	Co-Investigator	Surgery	10%	
		Colleen Taylor	Co-Investigator	Surgery	5%	
N-101551-01	A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects who Fail the Combination	Amgen, Inc.	04/09/2007 to 04/08/2008	1,600	400	\$2,000*
		Prabir Chaudhuri	Principal Investigator	Surgery	2%	
		Sarah J Lyons	Clinical Coordinator	Cancer Inst	10%	
		Iman E Mohamed	Co-Investigator	Medicine	4%	
		Rekha Chaudhary	Co-Investigator	Medicine	4%	
		Salvatore Veltri	Co-Investigator	Medicine	1%	
C-100704-02-W4	Altered Gene Expression in Human Colon Polyp Cells Treated with Selected Chemopreventive Agents-Work Assignment #4	National Cancer Institute	06/01/2005 to 05/31/2008	171,869	0	\$171,869
		Keith Crist	Principal Investigator	Surgery	0%	
C-100704-02-W5	Effect of Chemopreventive Agents on the Development of BCC and SCC in the Ptch +/- Hairless Mouse-Work Assignment #5	National Cancer Institute	09/01/2005 to 07/31/2008	0	0	\$0
		Keith Crist	Principal Investigator	Surgery	0%	
C-100704-03-W1	Preclinical in vitro and in vivo Screening Assays - Work Assignment #1 - Contract Administration and Management	National Cancer Institute	04/30/2004 to 04/29/2009	28,510	13,400	\$41,910
		Keith Crist	Principal Investigator	Surgery	25%	
C-100704-04-W1	Preclinical in vitro and in vivo Screening Assays - Work Assignment #1 - Contract Administration and Management	National Cancer Institute	04/30/2004 to 04/29/2009	29,566	13,896	\$43,462
		Keith Crist	Principal Investigator	Surgery	25%	
N-100704-01-W7	Preclinical In Vitro and In Vivo Screening Assays for Cancer Preventative Agent Development Work Assignment #7	National Cancer Institute	09/01/2006 to 10/31/2008	366,584	11,750	\$378,334
		Keith Crist	Principal Investigator	Surgery	0%	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Surgery, Department of</b>						
N-100704-01-W8	Mechanism-Based In Vitro Screening of Chemopreventive Agents for the Inhibition/ Reversal of the Tumorigenic Phenotype in ERa-Negative Human Mammary Epithelial Cells - Work Assignment #8	National Cancer Institute	11/01/2006 to 10/31/2008	448,386	11,750	\$460,136
		Keith Crist	Principal Investigator	Surgery	0%	
N-101088-01	Carotid Revascularization Endarterectomy vs. Stenting	National Institute of Neurological Disorders and Stroke through University of Medicine & Dentistry of New Jersey	01/03/2005 to 01/02/2009	10,500	2,625	\$13,125*
		Munier M Nazzal	Principal Investigator	Surgery	20%	
		Marilyn Ritter	Clinical Coordinator	Surgery	50%	
		Faizan Hafeez	Co-Investigator	Neurology	10%	
N-101373-01	Phase 3, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects with Acute Peripheral Arterial Occlusion (NAPA -3)	Nuvelo, Inc.	03/02/2006 to 03/01/2011	20,900	5,225	\$26,125*
		Munier M Nazzal	Principal Investigator	Surgery	2%	
		Marilyn Ritter	Clinical Coordinator	Surgery	15%	
		Jihad T Abbas	Co-Investigator	Surgery	1%	
		Khaled Khechen	Research Associate	Surgery	5%	
N-101492-01	A Double-blind, Placebo Controlled, Randomized Dose Response Trial to Investigate the Efficacy of Juvista in the Improvement of Scar Appearance When Applied to the Approximated Wound Margins Following Bilateral Varicose Vein Removal	Chiltern International Inc. and Renovo Limited	11/01/2006 to 11/02/2006	1,800	450	\$2,250*
		Munier M Nazzal	Principal Investigator	Surgery	0%	
		Marilyn Ritter	Clinical Coordinator	Surgery	0%	
		Jihad T Abbas	Co-Investigator	Surgery	0%	
N-101544-01	A Prospective, Randomized, Multi-Center, Two Arm Study to Evaluate the Safety and Effectiveness of the Vascular Sealant System Compared with Gelfoam/Thrombin for Control of Anastomosis Suture Line Bleeding in Patients	Confluent Surgical, Inc.	02/01/2007 to 07/31/2008	1,200	300	\$1,500*
		Munier M Nazzal	Principal Investigator	Surgery	25%	
		Anne E Knepper	Clinical Coordinator	Surgery	35%	
		Jihad T Abbas	Co-Investigator	Surgery	25%	
N-101324-01	The Evaluation of the Safety and Effectiveness of the SprayGel Abdominal Adhesion Barrier System in Reducing Post -Operative Adhesion Formation to Serosal Tissue Following Major Open Abdominal Surgery	Confluent Surgical, Inc.	09/02/2005 to 09/01/2006	3,426	856	\$4,282*
		Anthony Senagore	Principal Investigator	Surgery	1%	
<b>Totals for Department of Surgery</b>			<b>13</b>	<b>1,084,441</b>	<b>60,677</b>	<b>\$1,145,118</b>
<b>Urology, Department of</b>						

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award																																																		
				Direct Cost	F&A Cost**	Total Cost																																																
<b>Urology, Department of</b>																																																						
N-101529-01	Expression of Large Amounts of Genetically Engineered LOX and PAI-1	American Diagnostica, Inc.	01/03/2007 to 07/02/2008	20,000	5,000	\$25,000																																																
		<table border="1"> <tr> <td>Jerzy Jankun</td> <td>Principal Investigator</td> <td>Urology</td> <td>5%</td> </tr> <tr> <td>Ewa Skrzypczak-Jankun</td> <td>Co-Investigator</td> <td>Urology</td> <td>5%</td> </tr> </table>		Jerzy Jankun	Principal Investigator	Urology	5%	Ewa Skrzypczak-Jankun	Co-Investigator	Urology	5%																																											
Jerzy Jankun	Principal Investigator	Urology	5%																																																			
Ewa Skrzypczak-Jankun	Co-Investigator	Urology	5%																																																			
C-100763-02	Innate Cellular Lectin-Mediated Binding of Xenoantigens	National Institute of Diabetes, Digestive & Kidney Diseases	09/09/2005 to 08/31/2010	197,741	73,978	\$271,719																																																
		<table border="1"> <tr> <td>Michael Rees</td> <td>Principal Investigator</td> <td>Urology</td> <td>35%</td> </tr> <tr> <td>Mauro Sandrin</td> <td>Co-Investigator</td> <td>Austin Research Institute</td> <td>5%</td> </tr> <tr> <td>David Aminoff</td> <td>Co-Investigator</td> <td>University of Michigan</td> <td>5%</td> </tr> <tr> <td>Parastoo Azadi</td> <td>Co-Investigator</td> <td>University of Georgia at Athens</td> <td>5%</td> </tr> <tr> <td>Venkatesha Basrur</td> <td>Co-Investigator</td> <td>Med Micro &amp; Imm</td> <td>5%</td> </tr> <tr> <td>John Dignam</td> <td>Co-Investigator</td> <td>BIOCHEM</td> <td>5%</td> </tr> <tr> <td>Peter Friend</td> <td>Co-Investigator</td> <td>University of Oxford</td> <td>5%</td> </tr> </table>		Michael Rees	Principal Investigator	Urology	35%	Mauro Sandrin	Co-Investigator	Austin Research Institute	5%	David Aminoff	Co-Investigator	University of Michigan	5%	Parastoo Azadi	Co-Investigator	University of Georgia at Athens	5%	Venkatesha Basrur	Co-Investigator	Med Micro & Imm	5%	John Dignam	Co-Investigator	BIOCHEM	5%	Peter Friend	Co-Investigator	University of Oxford	5%																							
Michael Rees	Principal Investigator	Urology	35%																																																			
Mauro Sandrin	Co-Investigator	Austin Research Institute	5%																																																			
David Aminoff	Co-Investigator	University of Michigan	5%																																																			
Parastoo Azadi	Co-Investigator	University of Georgia at Athens	5%																																																			
Venkatesha Basrur	Co-Investigator	Med Micro & Imm	5%																																																			
John Dignam	Co-Investigator	BIOCHEM	5%																																																			
Peter Friend	Co-Investigator	University of Oxford	5%																																																			
C-101233-02	Transplantation Research	Medical University of Ohio at Toledo Foundation	02/01/2005 to 01/31/2009	64,000	0	\$64,000*																																																
		<table border="1"> <tr> <td>Michael Rees</td> <td>Principal Investigator</td> <td>Urology</td> <td>1%</td> </tr> </table>		Michael Rees	Principal Investigator	Urology	1%																																															
Michael Rees	Principal Investigator	Urology	1%																																																			
N-100765-01	Protocol No. FTY 720 0125	Novartis	06/17/2003 to 02/28/2007	39,347	9,837	\$49,184*																																																
		<table border="1"> <tr> <td>Michael Rees</td> <td>Principal Investigator</td> <td>Urology</td> <td>5%</td> </tr> <tr> <td>Amy L Miller</td> <td>Clinical Coordinator</td> <td>51747</td> <td>0%</td> </tr> <tr> <td>Susan E Schwartz</td> <td>Clinical Coordinator</td> <td>51747</td> <td>10%</td> </tr> <tr> <td>Lisa Twining</td> <td>Clinical Coordinator</td> <td>Urology</td> <td>50%</td> </tr> <tr> <td>George Adam</td> <td>Co-Investigator</td> <td>Urology-Resid Prgm</td> <td>1%</td> </tr> <tr> <td>Mirza Baig</td> <td>Co-Investigator</td> <td>Urology-Resid Prgm</td> <td>5%</td> </tr> <tr> <td>Dinkar Kaw</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>James B Kay</td> <td>Co-Investigator</td> <td>Urology-Resid Prgm</td> <td>5%</td> </tr> <tr> <td>Dennis Liu</td> <td>Co-Investigator</td> <td>Urology-Resid Prgm</td> <td>1%</td> </tr> <tr> <td>Deepak Malhotra</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Panduranga S Rao</td> <td>Co-Investigator</td> <td>Medicine</td> <td>1%</td> </tr> <tr> <td>Steven Selman</td> <td>Co-Investigator</td> <td>Urology</td> <td>1%</td> </tr> </table>		Michael Rees	Principal Investigator	Urology	5%	Amy L Miller	Clinical Coordinator	51747	0%	Susan E Schwartz	Clinical Coordinator	51747	10%	Lisa Twining	Clinical Coordinator	Urology	50%	George Adam	Co-Investigator	Urology-Resid Prgm	1%	Mirza Baig	Co-Investigator	Urology-Resid Prgm	5%	Dinkar Kaw	Co-Investigator	Medicine	1%	James B Kay	Co-Investigator	Urology-Resid Prgm	5%	Dennis Liu	Co-Investigator	Urology-Resid Prgm	1%	Deepak Malhotra	Co-Investigator	Medicine	1%	Panduranga S Rao	Co-Investigator	Medicine	1%	Steven Selman	Co-Investigator	Urology	1%			
Michael Rees	Principal Investigator	Urology	5%																																																			
Amy L Miller	Clinical Coordinator	51747	0%																																																			
Susan E Schwartz	Clinical Coordinator	51747	10%																																																			
Lisa Twining	Clinical Coordinator	Urology	50%																																																			
George Adam	Co-Investigator	Urology-Resid Prgm	1%																																																			
Mirza Baig	Co-Investigator	Urology-Resid Prgm	5%																																																			
Dinkar Kaw	Co-Investigator	Medicine	1%																																																			
James B Kay	Co-Investigator	Urology-Resid Prgm	5%																																																			
Dennis Liu	Co-Investigator	Urology-Resid Prgm	1%																																																			
Deepak Malhotra	Co-Investigator	Medicine	1%																																																			
Panduranga S Rao	Co-Investigator	Medicine	1%																																																			
Steven Selman	Co-Investigator	Urology	1%																																																			

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)		Proj Period Begin to Funding Cycle End	Current Year Award		
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)			Direct Cost	F&A Cost**	Total Cost
<b>Urology, Department of</b>							
N-101444-01	Optimizing Paired Donation	Ohio Department of Health		07/01/2006 to 06/30/2007	100,000	0	\$100,000
		Michael Rees Principal Investigator Urology		5%			
N-101543-01	Replacement of Intestinal Mucosa with Urothelium in Pig Augmented Bladders Using Intravesical Photodynamic Therapy with 5-Aminolaevulinic Acid (ALA)	F.M. Douglass Foundation		01/01/2007 to 12/31/2008	50,000	0	\$50,000
		Steven Selman Principal Investigator Urology		3%			
		Kenneth Kropp Co-Investigator Urology		3%			
		Ranko Micionovic Prof/Medical Support Urology-Resid Prgm		25%			
		Rickie Keck Research Associate Urology		25%			
<b>Totals for Department of Urology</b>				<b>6</b>	<b>471,088</b>	<b>88,815</b>	<b>\$559,903</b>
<b>Totals for Medicine, College of</b>				<b>195</b>	<b>15,703,554</b>	<b>4,072,730</b>	<b>\$19,776,284</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)				Proj Period Begin to	Current Year Award		
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				Funding Cycle End	Direct Cost	F&A Cost**	Total Cost
<b>Nursing, College of</b>									
<b>Nursing, College of</b>									
R-100121-07	Nursing Traineeships Answers Nursing Shortages	Bureau of Health Professions				07/01/2000 to 06/30/2007	27,008	0	\$27,008
		Jeri Milstead	Principal Investigator	Col Nursing	4%				
<b>Totals for Nursing, College of</b>						<b>1</b>	<b>27,008</b>	<b>0</b>	<b>\$27,008</b>
<b>Totals for Nursing, College of</b>						<b>1</b>	<b>27,008</b>	<b>0</b>	<b>\$27,008</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Pharmacy, College of</b>						
<b>Center for Drug Design and Development</b>						
C-108292-04	Determine Natural Product Induction in Legumes and the Pharmacologic Consequences in Human Model Systems	U.S. Department of Agriculture	06/01/2003 to 07/31/2008	393,205	39,321	\$432,526
		Paul Erhardt	Principal Investigator	CDDD	NA	
N-119954-01	A Partnership for Pharmaceutical and Economic Development of Wild Lebanese Plants	U.S. Department of Agriculture	09/15/2004 to 12/31/2007	156,986	10,503	\$167,489
		Paul Erhardt	Principal Investigator	CDDD	10%	
<b>Totals for Center for Drug Design and Development</b>			<b>2</b>	<b>550,191</b>	<b>49,824</b>	<b>\$600,015</b>
<b>Pharmacology, Department of</b>						
C-110182-02	Mechanosensory Role of Endothelial Cilia in Polycystic Kidney	National Heart, Lung & Blood Institute	12/02/2006 to 04/30/2008	169,925	49,133	\$219,058
		Surya M Nauli	Principal Investigator	PHAR	NA	
N-110182-01	Mechanosensory Role of Endothelial Cilia in Polycystic Kidney Disease	National Heart, Lung & Blood Institute	12/02/2006 to 04/30/2008	117,400	51,656	\$169,056
		Surya M Nauli	Principal Investigator	PHAR	NA	
N-109631-01	Development Toxicology of Compounds	Global Lifesciences	10/01/2005 to 05/07/2008	6,250	2,750	\$9,000
		Frederick E Williams	Principal Investigator	PHAR	NA	
<b>Totals for Pharmacology, Department of</b>			<b>3</b>	<b>293,575</b>	<b>103,539</b>	<b>\$397,114</b>
<b>Pharmacy Practice, Department of</b>						
N-110211-01	Evaluation of Efflux Pumps in Multidrug-Resistant Pseudomonas Aeruginosa	Society of Infectious Diseases Pharmacists	10/01/2005 to 12/31/2006	10,000	0	\$10,000
		Steven J. Martin	Principal Investigator	PRAC	NA	
N-109682-01	Pharmacokinetic Analysis of Boosted Atazanavir When Administered Simultaneously with and 2 Hours Prior to Omeprazole in Healthy Volunteers	American Association of Colleges of Pharmacy	01/01/2006 to 01/01/2008	10,000	0	\$10,000
		Eric G Sahloff	Principal Investigator	PRAC	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award										
				Direct Cost	F&A Cost**	Total Cost								
<b>Pharmacy Practice, Department of</b>														
N-110221-01	Community Molecular Fingerprinting to Identify the Spatial Origins of Microbial Contamination in Van Wert County, Ohio	Van Wert Soil & Water Conservation District	11/15/2006 to 12/31/2006	3,478	522	\$4,000								
		<table border="1"> <tr> <td>Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>William Von Sigler</td> <td>Principal Investigator</td> <td>ENVS</td> <td>1% AY</td> </tr> </table>			Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				William Von Sigler	Principal Investigator	ENVS	1% AY		
Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)														
William Von Sigler	Principal Investigator	ENVS	1% AY											
<b>Totals for Pharmacy Practice, Department of</b>			<b>3</b>	<b>23,478</b>	<b>522</b>	<b>\$24,000</b>								
<b>Totals for Pharmacy, College of</b>			<b>8</b>	<b>867,244</b>	<b>153,885</b>	<b>\$1,021,129</b>								

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>The College of Health and Human Services</b>						
<b>Administration, College of Health and Human Services</b>						
N-110003-01	Tech Prep Urban Network Grant	Ohio Department of Education	07/01/2006 to 06/30/2007	95,238	4,762	\$100,000
		Nancy A. Pietras	Principal Investigator	AHHS	NA	
N-110073-01	A High School Anatomy and Physiology Course of Study	Ohio Department of Education	07/01/2006 to 06/30/2007	33,333	1,667	\$35,000
		Nancy A. Pietras	Principal Investigator	AHHS	NA	
R-107299-07	High Schools That Work Regional Office	Ohio Department of Education through Lucas County Educational Service Center	07/01/2002 to 06/30/2007	138,095	6,905	\$145,000
		Nancy A. Pietras	Principal Investigator	AHHS	NA	
S-105164-09-S1	Tech Prep Federal Base	U.S. Department of Education through Ohio Department of Education	07/01/1998 to 06/30/2007	1,221	61	\$1,282
		Nancy A. Pietras	Principal Investigator	AHHS	NA	
S-107299-07-S1	High Schools That Work Regional Office	Ohio Department of Education through Lucas County Educational Service Center	07/01/2002 to 06/30/2007	772	39	\$811
		Nancy A. Pietras	Principal Investigator	AHHS	NA	
S-109917-01-S1	Strengthen linkage between Tech Prep and GEARUP Lighthouse	Ohio Board of Regents	07/01/2006 to 06/30/2007	10,000	0	\$10,000
		Nancy A. Pietras	Principal Investigator	AHHS	NA	
<b>Totals for Administration, College of Health and Human Services</b>			<b>6</b>	<b>278,659</b>	<b>13,434</b>	<b>\$292,093</b>
<b>Criminal Justice</b>						
N-109854-01	Evaluation of KIF Offender Reentry Project	Legal Aid of Northwest Ohio through Key Initiative Focus	01/01/2006 to 12/31/2006	7,263	726	\$7,989
		Morris Jenkins	Principal Investigator	CRMJ	NA	
N-109968-01	Evaluation of Family Ties Project	Urban Minority Alcoholism and Drug Abuse Outreach Program	08/01/2006 to 05/15/2007	13,757	1,376	\$15,133
		Morris Jenkins	Principal Investigator	CRMJ	NA	

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Criminal Justice</b>						
R-109457-02	Batterer Intervention Research	Ohio Criminal Justice System	05/01/2005 to 12/31/2008	68,646	11,354	\$80,000
		Lois A. Ventura	Principal Investigator	CRMJ	NA	
<b>Totals for Criminal Justice</b>			<b>3</b>	<b>89,666</b>	<b>13,456</b>	<b>\$103,122</b>
<b>Health Professions</b>						
N-109804-01	Development of Technical Content Standards in the Health Science Career Field	Ohio Department of Education	07/01/2006 to 06/30/2007	60,185	4,815	\$65,000
		Suzanne Wambold	Principal Investigator	HPRF	NA	
<b>Totals for Health Professions</b>			<b>1</b>	<b>60,185</b>	<b>4,815</b>	<b>\$65,000</b>
<b>Kinesiology, Department of</b>						
N-109704-01	The Effects of Rehabilitation on Proximal Joint Neuromuscular Control in Subjects with Chronic Ankle Instability	Ohio Athletic Trainers' Association	05/06/2006 to 04/30/2007	1,000	0	\$1,000
		Phillip Alexander Gribble	Principal Investigator	KNLS	NA	
N-110089-01	The Effects of Hand Placement on Muscle Activation During an Upper Extremity Closed Kinetic Chain Exercises	National Athletic Trainers' Association	01/10/2007 to 06/30/2008	873	0	\$873
		Phillip Alexander Gribble	Principal Investigator	KNLS	NA	
N-110223-01	CD18-Mediated Skeletal Muscle Hypertrophy	American College of Sports Medicine Foundation	07/01/2007 to 06/30/2008	5,000	0	\$5,000
		Francis Xavier Pizza	Principal Investigator	KNLS	NA	
R-109332-02	Effect of Blood Flow Pattern on Endothelial Damage	National Heart, Lung & Blood Institute	05/08/2006 to 05/07/2007	46,413	0	\$46,413
		Barry William Scheuermann	Principal Investigator	KNLS	NA	
<b>Totals for Kinesiology, Department of</b>			<b>4</b>	<b>53,286</b>	<b>0</b>	<b>\$53,286</b>
<b>Public Health and Rehabilitative Services</b>						

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
C-108849-03	Internship Agreement Between the University of Toledo and The Board of Lucas County Commissioners	Lucas County Commissioners	06/01/2004 to 05/31/2008	38,854	3,885	\$42,739
		Debra J Boardley Principal Investigator PHRS NA				
N-117644-01	External Agency Research Doctoral Assistantship	Polly Fox Academy	05/04/2007 to 05/04/2008	16,646	1,665	\$18,311
		Joseph A. Dake Principal Investigator PHRS NA				
N-110155-01	External Agency Research Doctoral Assistantships	Abstinence the Better Choice, Inc.	01/08/2007 to 08/03/2007	10,393	1,039	\$11,432
		Timothy Ray Jordan Principal Investigator PHRS NA				
N-119963-01	National Youth Sports Program	Robert J. Stransky Foundation	06/10/2007 to 07/08/2007	29,000	0	\$29,000
		Ruth Kucharewski Principal Investigator PHRS 100% AY				
R-104938-11	Support of National Youth Sports Program	Lucas County Board of Commissioners	06/06/2004 to 07/13/2006	2,273	227	\$2,500
		Ruth Kucharewski Principal Investigator PHRS NA				
R-109554-02	Journal Editorship	American School Health Association	05/16/2005 to 08/03/2007	2,727	273	\$3,000
		James H. Price Principal Investigator PHRS NA				
R-109514-02	Internship Agreement	Hospital Council of Northwest Ohio	08/22/2005 to 05/05/2007	5,099	510	\$5,609
		Stephen M. Roberts Principal Investigator PHRS NA				
S-109514-02-S1	Internship Agreement	Hospital Council of Northwest Ohio	08/22/2005 to 05/05/2007	5,197	520	\$5,717
		Stephen M. Roberts Principal Investigator PHRS NA				
S-109514-02-S2	Internship Agreement	Hospital Council of Northwest Ohio	08/22/2005 to 05/05/2007	5,197	520	\$5,717
		Stephen M. Roberts Principal Investigator PHRS 2% AY				
<b>Totals for Health and Rehabilitative Services</b>			<b>9</b>	<b>115,386</b>	<b>8,639</b>	<b>\$124,025</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s) Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Totals for The College of Health and Human Services</b>			<b>23</b>	<b>597,182</b>	<b>40,344</b>	<b>\$637,526</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award						
				Direct Cost	F&A Cost**	Total Cost				
<b>Undergraduate and Graduate Education</b>										
<b>Graduate School</b>										
N-119961-01	STARS 2007	Ohio Board of Regents through Miami University (Ohio)	07/01/2006 to 06/30/2008	3,600	0	\$3,600				
		<table border="1"> <tr> <td>Jamilah Jones</td> <td>Principal Investigator</td> <td>GRAD</td> <td>14% CY</td> </tr> </table>			Jamilah Jones	Principal Investigator	GRAD	14% CY		
Jamilah Jones	Principal Investigator	GRAD	14% CY							
N-119994-01	OBR Innovation Incentive	Ohio Board of Regents	07/01/2006 to 06/30/2008	110,828	0	\$110,828				
		<table border="1"> <tr> <td>Constantine E. Theodosiou</td> <td>Principal Investigator</td> <td>PHYS</td> <td>2% CY</td> </tr> </table>			Constantine E. Theodosiou	Principal Investigator	PHYS	2% CY		
Constantine E. Theodosiou	Principal Investigator	PHYS	2% CY							
<b>Totals for Graduate School</b>			<b>2</b>	<b>114,428</b>	<b>0</b>	<b>\$114,428</b>				
<b>Totals for Undergraduate and Graduate Education</b>			<b>2</b>	<b>114,428</b>	<b>0</b>	<b>\$114,428</b>				

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>University Administration</b>						
<b>Administration, Academic Affairs</b>						
R-119967-21	OBR Research Incentive	Ohio Board of Regents	05/01/1986 to 06/30/2007	582,249	0	582,249
		Rosemary Haggett	Principal Investigator	University of Toledo, Main Campus	NA	
<b>Totals for Administration, Academic Affairs</b>			<b>1</b>	<b>582,249</b>	<b>0</b>	<b>582,249</b>
<b>Administration, University Office of Research</b>						
R-108632-04	Support of Agricultural Research of Mutual Interest	U.S. Department of Agriculture	10/01/2003 to 09/30/2007	47,900	4,790	52,690
		Frank Calzonetti	Principal Investigator	AUOR	2%	
R-108632-05	Support of Agricultural Research of Mutual Interest	U.S. Department of Agriculture	10/01/2003 to 09/30/2007	9,000	900	9,900
		Frank Calzonetti	Principal Investigator	AUOR	2%	
<b>Totals for Administration, University Office of Research</b>			<b>2</b>	<b>56,900</b>	<b>5,690</b>	<b>62,590</b>
<b>Administration, VP Undergraduate Studies</b>						
N-110258-01	NIST-Summer Undergraduate Research Fellowship for Darnell Ray	National Institute of Standards and Technology	05/01/2007 to 09/30/2007	7,400	0	7,400
		Thomas J. Kvale	Principal Investigator	AVUG	NA	
<b>Totals for Administration, VP Undergraduate Studies</b>			<b>1</b>	<b>7,400</b>	<b>0</b>	<b>7,400</b>
<b>Intermodal Transportation Institute</b>						
N-119952-01	Independent Technical Review of the Great Lakes and St. Lawrence Seaway Transportation Rate Analysis	U.S. Army Corps of Engineers	04/23/2007 to 07/13/2007	6,720	2,957	9,677
		Mark A. Vonderembse	Principal Investigator	INTI	23% CY	
<b>Totals for Intermodal Transportation Institute</b>			<b>1</b>	<b>6,720</b>	<b>2,957</b>	<b>9,677</b>
<b>Safety &amp; Health, Office</b>						

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award														
				Direct Cost	F&A Cost**	Total Cost												
<b>Safety &amp; Health, Office</b>																		
N-101007-01	First Spending Plan Hospital Funding	Health Resources & Services Administration through Hospital Council of Northwest Ohio	04/15/2004 to 08/31/2007	29,034	0	\$29,034*												
<table border="1"> <tr> <td>Gary Jankowski</td> <td>Principal Investigator</td> <td>Safety &amp; Hlth</td> <td>5%</td> </tr> <tr> <td>Michael Valigosky</td> <td>Co-Investigator</td> <td>Safety &amp; Hlth</td> <td>5%</td> </tr> </table>			Gary Jankowski	Principal Investigator	Safety & Hlth	5%	Michael Valigosky	Co-Investigator	Safety & Hlth	5%								
Gary Jankowski	Principal Investigator	Safety & Hlth	5%															
Michael Valigosky	Co-Investigator	Safety & Hlth	5%															
<b>Totals for Safety &amp; Health, Office</b>			<b>1</b>	<b>29,034</b>	<b>0</b>	<b>\$29,034</b>												
<b>SrVP Med Aff/Dean Coll Medicin</b>																		
R-010323-21	OBR Research Incentive	Ohio Board of Regents	05/01/1986 to 06/30/2007	538,889	0	\$538,889												
<table border="1"> <tr> <td>Jeffrey Gold</td> <td>Principal Investigator</td> <td>UTHSC-Provost</td> <td>0%</td> </tr> </table>			Jeffrey Gold	Principal Investigator	UTHSC-Provost	0%												
Jeffrey Gold	Principal Investigator	UTHSC-Provost	0%															
<b>Totals for SrVP Medical Affairs/Dean College of Medicine</b>			<b>1</b>	<b>538,889</b>	<b>0</b>	<b>\$538,889</b>												
<b>Student Svcs</b>																		
R-010184-12	Scholarships for Disadvantaged Students	Health Resources & Services Administration	07/01/2005 to 06/30/2007	31,404	0	\$31,404												
<table border="1"> <tr> <td>Kathryn Coy</td> <td>Principal Investigator</td> <td>UTHSC-Std Svcs</td> <td>1%</td> </tr> </table>			Kathryn Coy	Principal Investigator	UTHSC-Std Svcs	1%												
Kathryn Coy	Principal Investigator	UTHSC-Std Svcs	1%															
<b>Totals for Student Services</b>			<b>1</b>	<b>31,404</b>	<b>0</b>	<b>\$31,404</b>												
<b>Urban Affairs Center</b>																		
C-109916-02	Economic Development Research Collaborative	Ohio Board of Regents	07/01/2005 to 06/30/2007	139,777	0	\$139,777												
<table border="1"> <tr> <td>Neil Reid</td> <td>Principal Investigator</td> <td>URB</td> <td>25% CY</td> </tr> </table>			Neil Reid	Principal Investigator	URB	25% CY												
Neil Reid	Principal Investigator	URB	25% CY															
N-109838-01	Toledo Community Food Assessment and Planning Project	U.S. Department of Agriculture through Toledo Area Ministries	10/01/2006 to 09/30/2007	3,374	371	\$3,746*												
<table border="1"> <tr> <td>Neil Reid</td> <td>Principal Investigator</td> <td>URB</td> <td>2% CY</td> </tr> <tr> <td>Barbara Kingman Chesney</td> <td>Co-Investigator</td> <td>SOCI</td> <td>5% CY</td> </tr> <tr> <td>Paula Suzanne Ross</td> <td>Research Associate</td> <td>URB</td> <td>19% CY</td> </tr> </table>			Neil Reid	Principal Investigator	URB	2% CY	Barbara Kingman Chesney	Co-Investigator	SOCI	5% CY	Paula Suzanne Ross	Research Associate	URB	19% CY				
Neil Reid	Principal Investigator	URB	2% CY															
Barbara Kingman Chesney	Co-Investigator	SOCI	5% CY															
Paula Suzanne Ross	Research Associate	URB	19% CY															
N-109872-01	Community Technology Needs: Revisiting CATNeT: A Proposal for Partial Operating Support and a Year Long Community Planning Process	Stranahan Foundation	07/01/2006 to 06/30/2007	16,500	0	\$16,500												
<table border="1"> <tr> <td>Neil Reid</td> <td>Principal Investigator</td> <td>URB</td> <td>NA</td> </tr> </table>			Neil Reid	Principal Investigator	URB	NA												
Neil Reid	Principal Investigator	URB	NA															

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>Urban Affairs Center</b>						
N-109945-01	Proposal to Conduct an Analysis of Projected Impacts of Sylvania Township-City of Toledo Merger	Sylvania Area Community Improvement Corporation	07/01/2006 to 12/31/2006	14,693	1,469	\$16,162
		Neil Reid	Principal Investigator	URB	NA	
N-119957-01	Comprehensive Analysis of the Financial Impacts of a Potential merger Between Washington Township and Centerville City	City of Centerville, Ohio	05/02/2007 to 12/31/2007	40,823	4,082	\$44,905
		Neil Reid	Principal Investigator	GEOG	3% CY	
		Sue A. Wuest	Co-Investigator	URB	4% CY	
		Hugh F. Hinton	Co-Investigator	POLS	20% AY	
R-109882-02	Urban Affairs Center 2007 Program Plan	Ohio Board of Regents	07/01/2005 to 06/30/2007	160,500	0	\$160,500
		Neil Reid	Principal Investigator	URB	100% CY	
S-108831-01-S2	Greenhouse Nurseries, Ohio Research Grant	U.S. Department of Agriculture through Ohio State University Research Foundation	10/01/2004 to 09/14/2008	2,400	600	\$3,000
		Neil Reid	Principal Investigator	URB	NA	
<b>Totals for Urban Affairs Center</b>			<b>7</b>	<b>378,067</b>	<b>6,522</b>	<b>\$384,590</b>
<b>Totals for University Administration</b>			<b>15</b>	<b>1,630,663</b>	<b>15,169</b>	<b>\$1,645,833</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
<b>UT Medical Center</b>						
<b>Outcome Management</b>						
R-010737-12	University of Toledo Health Science Campus HIV Testing Program	Centers for Disease Control and Prevention and Ohio Department of Health, through Lucas County Regional Health District	01/01/2006 to 12/31/2007	24,125	0	\$24,125
		Ann Locher Principal Investigator OUTCOME MGT 6%				
		Susan Carter Clinical Coordinator Cancer Inst 15%				
		Judy Didion Prof/Medical Support OUTCOME MGT 3%				
R-101281-02	Support Group for Children	Children Affected by AIDS Foundation	01/01/2006 to 12/31/2007	5,948	892	\$6,840
		Ann Locher Principal Investigator OUTCOME MGT 1%				
R-101303-02	Healthy Relationships through Existing Support Groups Project	Centers for Disease Control and Prevention and Ohio Department of Health, through Lucas County Regional Health District	01/01/2006 to 12/31/2007	12,500	0	\$12,500
		Ann Locher Principal Investigator OUTCOME MGT 1%				
		Michelle L Coutcher Prof/Medical Support OUTCOME MGT 20%				
R-101307-02	HIV Prevention in Medical Care Settings	Centers for Disease Control and Prevention and Ohio Department of Health, through Lucas County Regional Health District	01/01/2006 to 12/31/2007	11,368	1,132	\$12,500
		Ann Locher Principal Investigator OUTCOME MGT 1%				
		Michelle L Coutcher Prof/Medical Support OUTCOME MGT 25%				
<b>Totals for Outcome Management</b>			<b>4</b>	<b>53,941</b>	<b>2,024</b>	<b>\$55,965</b>
<b>Totals for UT Medical Center</b>			<b>4</b>	<b>53,941</b>	<b>2,024</b>	<b>\$55,965</b>

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.

Proposal #	Public Title	Agency Name(s)	Proj Period Begin to Funding Cycle End	Current Year Award		
				Direct Cost	F&A Cost**	Total Cost
		Key Personnel: (Name, Project Role, Department/Institution, Committed Effort, Appt.)				
<b>Grand Totals for Fiscal Year</b>			<b>544</b>	<b>53,879,012</b>	<b>9,332,723</b>	<b>\$63,211,734</b>

<b>Appointment Type Key</b> AY - Academic Year CY - Calendar Year ST - Summer Term
---

\* Reported by Cash Received

\*\* Facilities and Administrative Cost

\*\*\*Beginning in FY07, awards are reported in the fiscal year when the funds are available.